<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11679499</article-id><article-id pub-id-type="pmcid-ver">PMC11679499.1</article-id><article-id pub-id-type="pmcaid">11679499</article-id><article-id pub-id-type="pmcaiid">11679499</article-id><article-id pub-id-type="pmid">39772007</article-id><article-id pub-id-type="doi">10.3390/vaccines12121345</article-id><article-id pub-id-type="publisher-id">vaccines-12-01345</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hsiung</surname><given-names initials="KC">Kuei-Ching</given-names></name><xref rid="af1-vaccines-12-01345" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chiang</surname><given-names initials="HJ">Huan-Jung</given-names></name><xref rid="af1-vaccines-12-01345" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01345" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reinig</surname><given-names initials="S">Sebastian</given-names></name><xref rid="af1-vaccines-12-01345" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shih</surname><given-names initials="SR">Shin-Ru</given-names></name><xref rid="af1-vaccines-12-01345" ref-type="aff">1</xref><xref rid="af3-vaccines-12-01345" ref-type="aff">3</xref><xref rid="af4-vaccines-12-01345" ref-type="aff">4</xref><xref rid="af5-vaccines-12-01345" ref-type="aff">5</xref><xref rid="c1-vaccines-12-01345" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Strych</surname><given-names initials="U">Ulrich</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01345"><label>1</label>Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan; <email>kchsiung@gap.cgu.edu.tw</email> (K.-C.H.); <email>chianghuanjung@gmail.com</email> (H.-J.C.); <email>plinigdererste@mail.de</email> (S.R.)</aff><aff id="af2-vaccines-12-01345"><label>2</label>Graduate Institute of Biomedical Science, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan</aff><aff id="af3-vaccines-12-01345"><label>3</label>Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan</aff><aff id="af4-vaccines-12-01345"><label>4</label>Department of Medical Biotechnology &amp; Laboratory Science, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan</aff><aff id="af5-vaccines-12-01345"><label>5</label>Research Center for Chinese Herbal Medicine, Research Center for Food &amp; Cosmetic Safety, Graduate Institute of Health Industry Technology, College of Human Ecology, Chang Gung University of Science &amp; Technology, Taoyuan 33303, Taiwan</aff><author-notes><corresp id="c1-vaccines-12-01345"><label>*</label>Correspondence: <email>srshih@mail.cgu.edu.tw</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">477868</issue-id><elocation-id>1345</elocation-id><history><date date-type="received"><day>29</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>24</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-09 10:25:37.670"><day>09</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-12-01345.pdf"/><abstract><p>The development of vaccines against RNA viruses has undergone a rapid evolution in recent years, particularly driven by the COVID-19 pandemic. This review examines the key roles that RNA viruses, with their high mutation rates and zoonotic potential, play in fostering vaccine innovation. We also discuss both traditional and modern vaccine platforms and the impact of new technologies, such as artificial intelligence, on optimizing immunization strategies. This review evaluates various vaccine platforms, ranging from traditional approaches (inactivated and live-attenuated vaccines) to modern technologies (subunit vaccines, viral and bacterial vectors, nucleic acid vaccines such as mRNA and DNA, and phage-like particle vaccines). To illustrate these platforms&#8217; practical applications, we present case studies of vaccines developed for RNA viruses such as SARS-CoV-2, influenza, Zika, and dengue. Additionally, we assess the role of artificial intelligence in predicting viral mutations and enhancing vaccine design. The case studies underscore the successful application of RNA-based vaccines, particularly in the fight against COVID-19, which has saved millions of lives. Current clinical trials for influenza, Zika, and dengue vaccines continue to show promise, highlighting the growing efficacy and adaptability of these platforms. Furthermore, artificial intelligence is driving improvements in vaccine candidate optimization and providing predictive models for viral evolution, enhancing our ability to respond to future outbreaks. Advances in vaccine technology, such as the success of mRNA vaccines against SARS-CoV-2, highlight the potential of nucleic acid platforms in combating RNA viruses. Ongoing trials for influenza, Zika, and dengue demonstrate platform adaptability, while artificial intelligence enhances vaccine design by predicting viral mutations. Integrating these innovations with the One Health approach, which unites human, animal, and environmental health, is essential for strengthening global preparedness against future RNA virus threats.</p></abstract><kwd-group><kwd>RNA virus</kwd><kwd>vaccine platform</kwd><kwd>RNA virus vaccines</kwd><kwd>SARS-CoV-2</kwd><kwd>influenza virus</kwd><kwd>enterovirus</kwd><kwd>dengue virus</kwd><kwd>Zika virus</kwd><kwd>immune response</kwd></kwd-group><funding-group><award-group><funding-source>Chang Gung Memorial Hospital</funding-source><award-id>CORPD1J0061-63</award-id></award-group><award-group><funding-source>Research Center for Emerging Viral Infections from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan</funding-source></award-group><funding-statement>This research was funded by Chang Gung Memorial Hospital (grant number: CORPD1J0061-63) and the Research Center for Emerging Viral Infections from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01345"><title>1. Introduction</title><p>RNA viruses have profoundly impacted both global health and regional and global economies; they account for 44% of all emerging contagious diseases [<xref rid="B1-vaccines-12-01345" ref-type="bibr">1</xref>]. Although all possess RNA as the genetic material, RNA viruses constitute a diverse group of pathogens that are very different in their biological characteristics and cause distinct clinical manifestations. Humans have long been in a constant battle against these life-threatening foes [<xref rid="B2-vaccines-12-01345" ref-type="bibr">2</xref>] since the first documented outbreak of measles [<xref rid="B3-vaccines-12-01345" ref-type="bibr">3</xref>]. The emergence and re-emergence of RNA viruses have led to widespread morbidity, mortality, and economic disruption. In the past century, highly pathogenic RNA viruses have caused devastating outbreaks, including the 1918 influenza pandemic, severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in 2003, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019. Other significant outbreaks include the Zika virus epidemic from 2015 to 2016, dengue fever with its first report in 1635 [<xref rid="B4-vaccines-12-01345" ref-type="bibr">4</xref>], enterovirus outbreaks since 2014, and the Nipah virus outbreak in 2023. Despite advances in vaccine development, the onset of the COVID-19 pandemic in 2019, caused by SARS-CoV-2, is estimated to have resulted in over 7 million deaths and economic losses exceeding USD 10 trillion [<xref rid="B5-vaccines-12-01345" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-12-01345" ref-type="bibr">6</xref>]. Similarly, even with the availability of seasonal influenza vaccines, influenza viruses continue to cause significant levels of morbidity and mortality each year [<xref rid="B7-vaccines-12-01345" ref-type="bibr">7</xref>]. Nonetheless, vaccination remains one of the most effective approaches to preventing viral infections and reducing viral transmission [<xref rid="B8-vaccines-12-01345" ref-type="bibr">8</xref>]. Vaccines are designed to stimulate the hosts&#8217; immune responses against pathogens, thereby providing both individual and herd immunity [<xref rid="B9-vaccines-12-01345" ref-type="bibr">9</xref>]. Given the high genetic variability of RNA viruses, developing vaccines against these viruses and platforms for rapid and flexible vaccine production has become a major challenge. However, innovative developments in vaccine technology, including viral vectors, mRNA vaccines, and novel adjuvants, have demonstrated promise in addressing these difficulties. Compared with DNA viruses, RNA viruses have mutation rates that are hundreds of times higher and are thus characterized by more rapid rates of evolution and host adaptation, which often contribute to the emergence of epidemics or pandemics [<xref rid="B10-vaccines-12-01345" ref-type="bibr">10</xref>]. The emergence of new variants or viruses accordingly presents considerable challenges for effective vaccine development. However, therapeutic interventions or treatments for some virus-induced diseases remain costly or unavailable [<xref rid="B11-vaccines-12-01345" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-01345" ref-type="bibr">12</xref>], underscoring the persistent unmet medical need for vaccination and the importance of future vaccine development. According to the World Health Organization, global vaccination programs have saved at least 150 million lives over the past 50 years, thereby highlighting the vital role vaccination plays in public health and the prevention of emerging viral diseases [<xref rid="B13-vaccines-12-01345" ref-type="bibr">13</xref>].</p><p>In this review, we provide a comprehensive overview of current strategies and advances in the development of vaccines against RNA viruses, along with the immune responses they elicit. We cover both traditional and modern vaccine platforms, highlighting their advantages and limitations, and present case studies of RNA virus vaccines based on the characteristics and epidemiological impact of major RNA viruses and the immune responses that these infections trigger. Additionally, we examine technological advances and emerging strategies, including universal and personalized vaccines and the One Health approach. By addressing these essential topics, we hope to inform researchers, healthcare professionals, and policymakers regarding the current state and future prospects of RNA virus vaccines, thereby contributing to global efforts to control and prevent RNA virus-associated diseases.</p></sec><sec id="sec2-vaccines-12-01345"><title>2. Immunity Induced by Viral Infections and Vaccinations</title><p>While many vaccine candidates are under investigation, the fundamental principle remains to safely elicit a robust immune response that mimics the protection achieved through natural infection. To this end, it is essential to explore both how body responds to RNA virus during natural infection and how vaccination can replicate these immune responses, providing long-lasting immunity without causing disease.</p><sec id="sec2dot1-vaccines-12-01345"><title>2.1. Innate Immune Response to Viral Infections</title><p>Innate immunity, which serves as the first line of defense against viruses, involves an immediate response that contributes to preventing infection. As primary mediators in this response, when stimulated by viral RNA, pattern recognition receptors, such as Toll-like receptors (TLRs) and retinoic acid-inducible gene I-like receptors, initiate downstream signaling pathways that lead to the production of type-1 interferons (IFNs) and inflammatory cytokines [<xref rid="B14-vaccines-12-01345" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-12-01345" ref-type="bibr">15</xref>]. Type 1 IFNs play an important role in establishing an antiviral response by inducing the expression of interferon-simulated genes, including those involved in apoptosis, immune modulation, cell attraction and adhesion, and antiviral detection, which collectively contribute to an inhibition of viral replication and spread [<xref rid="B16-vaccines-12-01345" ref-type="bibr">16</xref>]. These responses are complemented by the activity of inflammatory cytokines, such as interleukins (ILs) and tumor-necrosis factors, that contribute to recruiting immune cells, including macrophages, natural killer cells, and dendritic cells, to the site of infection. Among these, natural killer cells can directly kill infected cells, whereas dendritic cells process and present viral antigens to activate the adaptive immune responses [<xref rid="B17-vaccines-12-01345" ref-type="bibr">17</xref>]. These innate immune responses are rapid and coordinated, and they play an essential role in preventing viral replication during the early stages of RNA virus infections and limiting viral dissemination [<xref rid="B18-vaccines-12-01345" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-12-01345" ref-type="bibr">19</xref>]. However, RNA viruses have a number of counter-measures for suppressing host innate immune responses, employing complex strategies, such as interfering with antigen-presenting pathways, gene silencing, and protein cleavage [<xref rid="B20-vaccines-12-01345" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-12-01345" ref-type="bibr">21</xref>]. For example, to evade apoptosis, the SARS-CoV-2 virus masks epitopes by camouflaging its spike protein with glycan molecules, inhibiting interferon production and disrupting complete mitophagy, thereby resulting in an increment in virus replication [<xref rid="B22-vaccines-12-01345" ref-type="bibr">22</xref>].</p></sec><sec id="sec2dot2-vaccines-12-01345"><title>2.2. Adaptive Immune Response to Viral Infections</title><p>Adaptive immunity is characterized by an antigen-specific response against pathogens and a capacity to retain an immune memory. Among the different types of adaptive response, cellular adaptive immunity is conferred by T cells, whereas humoral immunity is promoted by antibodies produced by B cells. T cell immunity is the most important component of immunity against natural infections with RNA viruses, in which the action 8 of both CD4 T-helper cells and CD cytotoxic T-cells have been well-established as playing pivotal roles in protection against diseases caused by a diverse range of viruses, including influenza A virus, coronaviruses, respiratory syncytial virus (RSV), dengue, and hepatitis A, B, and C [<xref rid="B23-vaccines-12-01345" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01345" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-01345" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01345" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-12-01345" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-12-01345" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-12-01345" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-12-01345" ref-type="bibr">30</xref>]. Among the different types of T cells, cytolytic CD8+ T cells can directly eliminate infected cells, whereas CD4+ helper cells activate B cells and recruit other innate immune cells via cytokine release. In a mouse model of influenza, populations of both these T cell types have been demonstrated to be essential for effective viral clearance and protection against lethal disease. While eliminating one T cell population results in only a slight delay in viral clearance, the elimination of both CD4+ and CD8+ cells significantly increases mortality [<xref rid="B31-vaccines-12-01345" ref-type="bibr">31</xref>]. In terms of immune memory, T cell responses are generally slower to develop but tend to be more cross-protective across different strains and variants. For example, among SARS-CoV-1 survivors, a significant T cell response to the virus has been observed to persist for up to six years after infection [<xref rid="B32-vaccines-12-01345" ref-type="bibr">32</xref>]. In contrast, although emergent SARS-CoV-2 variants show significant immune escape with respect to the B cell response, T cell responses remain relatively stable across different variants [<xref rid="B33-vaccines-12-01345" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-12-01345" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-12-01345" ref-type="bibr">35</xref>]. In the case of dengue, CD8+ T cells have been shown to provide cross-protection against multiple serotypes [<xref rid="B36-vaccines-12-01345" ref-type="bibr">36</xref>], while secondary influenza infections are associated with a notably faster expansion of T cells in the lungs and more rapid viral clearance [<xref rid="B37-vaccines-12-01345" ref-type="bibr">37</xref>]. Given the pivotal role of T cells in protection against viral infections, any dysregulation of these cells, especially in specific sub-populations, can have detrimental effects under certain circumstances. For example, a deficiency in Th17 cells has been shown to result in severe lung inflammation in a mouse model of influenza [<xref rid="B38-vaccines-12-01345" ref-type="bibr">38</xref>]. Similarly, in infections with the murine coronavirus strain JHM, regulatory T cells are essential for preventing demyelination in chronically infected mice [<xref rid="B39-vaccines-12-01345" ref-type="bibr">39</xref>]. There is substantial clinical, in vitro, and in vivo evidence to indicate the efficacy of T cell immunity in the context of viral clearance and protection against viral disease.</p><p>In contrast, the protection conferred by antibodies remains less clear. For example, with the exception of enteroviruses, it has been established that individuals with the X-linked agammaglobulinemia, who are unable to produce antibodies, do not show increased susceptibility to viral diseases [<xref rid="B40-vaccines-12-01345" ref-type="bibr">40</xref>]. Furthermore, in immune-na&#239;ve individuals infected with COVID-19, higher IgG concentrations correlate with a more severe disease course [<xref rid="B26-vaccines-12-01345" ref-type="bibr">26</xref>,<xref rid="B41-vaccines-12-01345" ref-type="bibr">41</xref>]. Moreover, treatment with convalescent serum containing the antigenic antibodies has been ineffective against both influenza and COVID-19 [<xref rid="B41-vaccines-12-01345" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-12-01345" ref-type="bibr">42</xref>]. One plausible explanation for the poor efficacy of antibodies in cases of natural infections is the low levels of antigen-specific antibodies during early infection [<xref rid="B43-vaccines-12-01345" ref-type="bibr">43</xref>]. In many viral infections, including influenza, COVID-19, and dengue, the viremia often begins to decline between days 3 and 10 after the onset of symptoms, before a significant antibody response develops [<xref rid="B44-vaccines-12-01345" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-12-01345" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-12-01345" ref-type="bibr">46</xref>].</p><p>Antibodies can also have pathogenic effects. For example, in dengue, antibodies have been shown to enhance infection and disease (antibody-dependent enhancement) at sub-neutralizing titers via Fc-receptor interactions. Recent studies have demonstrated that afucosylated IgG1 antibodies, characterized by the absence of fucose residues on the Fc region, exhibit high affinity for the Fc&#947;IIIa (CD16a) receptor, which correlates with enhanced disease severity in mouse models [<xref rid="B47-vaccines-12-01345" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-12-01345" ref-type="bibr">48</xref>]. Notably, nanobodies that block the binding of afucosylated IgG1 to CD16 can ameliorate disease progression [<xref rid="B49-vaccines-12-01345" ref-type="bibr">49</xref>]. Given that certain viral epitopes may be similar to those of the host organism, viruses can effectively evade immune responses via molecular mimicry. Accordingly, it is plausible that if antibodies are elicited against such epitopes, it might have detrimental autoantibody effects. However, molecular mimicry alone may not be sufficient to trigger autoimmune diseases [<xref rid="B50-vaccines-12-01345" ref-type="bibr">50</xref>].</p></sec><sec id="sec2dot3-vaccines-12-01345"><title>2.3. Vaccine-Induced Immunity</title><p>The adaptive immune response is the primary mechanism through which vaccines confer their protective effects. Moreover, the relative importance of different T cell populations varies across viral infections. For instance, in a study of hepatovirus A infection in chimpanzees, the CD4+ response was associated with protection and significantly contributed to viral clearance [<xref rid="B25-vaccines-12-01345" ref-type="bibr">25</xref>]. In contrast, following T cell vaccination of mice against SARS-CoV-1, the CD8+ response alone was sufficient for protection [<xref rid="B51-vaccines-12-01345" ref-type="bibr">51</xref>]. Similarly, while T cells play important roles in viral clearance during RSV infection, skewing the T cell population toward a Th2 phenotype has been linked to severe inflammatory pathology [<xref rid="B28-vaccines-12-01345" ref-type="bibr">28</xref>]. This Th2 skewing has also been observed in SARS-CoV-1 vaccine trials, where it was associated with severe immunopathology [<xref rid="B52-vaccines-12-01345" ref-type="bibr">52</xref>]. Certain autoimmune reactions to COVID-19 vaccines, such as autoimmune hepatitis and myocarditis, have been correlated with the expansion of both CD4+ and CD8+ T cells [<xref rid="B53-vaccines-12-01345" ref-type="bibr">53</xref>,<xref rid="B54-vaccines-12-01345" ref-type="bibr">54</xref>]. Additionally, hyperactivation of T cells in response to COVID-19 infection may contribute to severe inflammation [<xref rid="B55-vaccines-12-01345" ref-type="bibr">55</xref>].</p><p>Despite the uncertainties surrounding the role of antibodies in natural infections, there is compelling evidence for their protective effects in the context of vaccination and antibody therapies, where much higher antigen-specific antibody concentrations can be achieved. For example, antibody titers correlate strongly with protection against both COVID-19 and influenza, reflecting vaccine efficacy [<xref rid="B56-vaccines-12-01345" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-12-01345" ref-type="bibr">57</xref>]. Antibodies contribute to protection through neutralization, suppression of infection, and the activation of secondary immune effectors via the Fc domain. These mechanisms include antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC), which are associated with viral clearance [<xref rid="B43-vaccines-12-01345" ref-type="bibr">43</xref>]. Furthermore, antibodies can activate the complement system and neutrophils through antibody-dependent complement deposition.</p><p>The protective mechanisms of antibodies differ among viral strains. Mouse models of influenza vaccination and antibody therapy suggest that Fc-mediated functions, particularly ADCC, are critical for protection [<xref rid="B58-vaccines-12-01345" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-12-01345" ref-type="bibr">59</xref>]. In contrast, complement system involvement varies; for instance, complement knockout mouse models of influenza exhibit higher mortality and morbidity, underscoring the complement system&#8217;s protective role in this context [<xref rid="B60-vaccines-12-01345" ref-type="bibr">60</xref>]. However, some experimental influenza vaccines, such as those targeting the M2 protein, act independently of the complement system [<xref rid="B58-vaccines-12-01345" ref-type="bibr">58</xref>]. In humans, complement deficiency increases the risk of bacterial infections but does not significantly affect susceptibility to viral diseases [<xref rid="B61-vaccines-12-01345" ref-type="bibr">61</xref>]. Similarly, studies of COVID-19 mRNA vaccination and antibody therapies have shown that Fc-mediated functions are critical for protection [<xref rid="B62-vaccines-12-01345" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-12-01345" ref-type="bibr">63</xref>]. In contract, a study in mice revealed that antibody-mediated protection against COVID-19 depended on alveolar macrophages rather than neutrophils or the complement system [<xref rid="B63-vaccines-12-01345" ref-type="bibr">63</xref>].</p><p>In addition to adaptive immune responses, evidence indicates that live-attenuated vaccines (LAVs) can induce epigenetic changes in the innate immune system, leading to a trained immunity. These epigenetic modifications, such as histone modifications, DNA methylation, and non-coding RNA regulation, alter gene expression without changing DNA sequences. For example, specific histone marks like H3K4me3 (trimethylation of histone H3 at lysine 4) and H3K27ac (acetylation of histone H3 at lysine 27) have been shown to increase after pathogen exposure, enhancing accessibility to genes critical for inflammatory responses [<xref rid="B64-vaccines-12-01345" ref-type="bibr">64</xref>]. Such mechanisms are believed to underlie the non-specific health benefits observed with LAVs, including those for measles, Bacillus Calmette-Gu&#233;rin (BCG), and polio [<xref rid="B65-vaccines-12-01345" ref-type="bibr">65</xref>]. These findings illustrate the varied roles of antibodies, T cells, and innate immune mechanisms in vaccine-induced protection, with differences observed across pathogens and vaccine platforms. This diversity highlights the complexity of immune responses to vaccination and underscores the need for further investigation to optimize efficacy and safety.</p></sec></sec><sec id="sec3-vaccines-12-01345"><title>3. Vaccine Platforms for RNA Viruses</title><p>Humans are continually striving to develop effective strategies for the control of RNA viruses that are responsible for numerous diseases, including the influenza virus, dengue virus (DENV), human immunodeficiency virus (HIV), and SARS-CoV-2 [<xref rid="B66-vaccines-12-01345" ref-type="bibr">66</xref>]. The rapid rates at which RNA viruses mutate pose a perpetual threat to public health, necessitating the development of innovative and effective vaccine platforms. However, although traditional vaccines have provided a foundation for disease prevention, the ever-evolving nature of RNA viruses necessitates continual advances in modern vaccine technologies that will contribute to providing more rapid and adaptable responses to emerging viral threats, thereby ensuring better protection from and control of outbreaks. The development and implementation of these diverse vaccine strategies will be essential for maintaining global health and combatting future pandemics [<xref rid="B67-vaccines-12-01345" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-12-01345" ref-type="bibr">68</xref>]. Whereas vaccine platforms constitute the core mechanisms underlying the generation of the immune response, it is the vaccine formulations, which encompass the combination of constituents, including the antigen, adjuvants, stabilizers, and delivery systems, that contribute to optimizing stability, delivery, and efficacy [<xref rid="B69-vaccines-12-01345" ref-type="bibr">69</xref>]. This is particularly important for the manufacture of RNA virus vaccines, as effective formulations can enhance immune responses, ensure stability against rapid mutation, and improve delivery, ultimately enhancing protection against emerging viral threats.</p><sec id="sec3dot1-vaccines-12-01345"><title>3.1. Traditional Approaches</title><p>Traditional vaccine platforms, such as inactivated and LAVs (<xref rid="vaccines-12-01345-f001" ref-type="fig">Figure 1</xref>), have long played a central role in controlling RNA viral diseases. Inactivated vaccines are made from pathogens that have been killed or inactivated, such that they can no longer cause disease, whereas LAVs are made from weakened forms of a virus that although still capable of replication, do not cause severe illness. By mimicking natural infections, these approaches have proven effective against numerous RNA viruses.</p><sec id="sec3dot1dot1-vaccines-12-01345"><title>3.1.1. Inactivated Vaccines</title><p>The first inactivated vaccine used for the control of an RNA virus was the inactivated rabies vaccine developed by Louis Pasteur and Emile Roux in 1885. Pasteur inactivated the virus by drying the spinal cords of infected rabbits, which effectively neutralized the virus, whilst retaining its immunogenic properties [<xref rid="B71-vaccines-12-01345" ref-type="bibr">71</xref>]. Inactivated vaccines are developed by cultivating the target virus in culture, followed by inactivation of the virus using chemical agents, such as formaldehyde, or by applying heat. Formaldehyde inactivation is based on the cross-linking of viral proteins and nucleic acids, thereby effectively neutralizing the capacity of the virus to replicate, whilst preserving its structural integrity. Thus, although rendered non-infectious, the virus retains its antigenic structure, enabling it to stimulate an immune response [<xref rid="B72-vaccines-12-01345" ref-type="bibr">72</xref>]. Inactivated vaccines have been developed to target a diverse range of RNA viruses and can provide significant protection against numerous pathogens. For example, inactivated viral vaccines are used against influenza to induce cross-protective CD8+ cytotoxic T lymphocytes that confer immunity against multiple strains [<xref rid="B73-vaccines-12-01345" ref-type="bibr">73</xref>]. In the case of the rabies virus, inactivated vaccines have been found to prevent infection, with recent advances contributing to an enhancement of their immunogenicity, based on the expression of dendritic cell-targeting proteins via recombinant virus technology [<xref rid="B74-vaccines-12-01345" ref-type="bibr">74</xref>]. Similarly, inactivated vaccines are being assessed for the control of emerging RNA viruses, such as Zika, and have been shown to protect pregnant marmosets from Zika infection [<xref rid="B75-vaccines-12-01345" ref-type="bibr">75</xref>]. Similarly, Covaxin, a beta-propiolactone inactivated vaccine developed by Bharat Biotech, has shown promising results in clinical trials for the prevention of COVID-19 [<xref rid="B76-vaccines-12-01345" ref-type="bibr">76</xref>]. Additionally, advances in dengue vaccine development have shown that combining inactivated vaccines with specific immunogenic proteins (non-structural protein 3, NS3) enhances immune responses [<xref rid="B77-vaccines-12-01345" ref-type="bibr">77</xref>]. These examples serve to highlight the broad applicability of inactivated vaccines in controlling and preventing different RNA viral infections. These vaccines offer several advantages in terms of safety and stability. As the viruses used in these vaccines are inactivated, they are unable to replicate, and are thus generally considered to be safe for administration to immunocompromised individuals [<xref rid="B78-vaccines-12-01345" ref-type="bibr">78</xref>]. In addition, compared with LAVs, inactivated vaccines are more stable, as they do not require cold chain conditions, and are thus more convenient for distribution in regions with limited infrastructure [<xref rid="B79-vaccines-12-01345" ref-type="bibr">79</xref>]. Furthermore, these vaccines can elicit a strong immune response, as evidenced by the whole-virion inactivated SARS-CoV-2 vaccine, which induces a Th1-biased immune response and high levels of specific T lymphocyte response [<xref rid="B80-vaccines-12-01345" ref-type="bibr">80</xref>].</p><p>However, inactivated vaccines do have certain limitations. Notably, multiple doses are often necessary to achieve and maintain sufficient immunity. For example, studies have revealed that booster doses are necessary to sustain immunity, particularly against emerging variants, such as the SARS-CoV-2 Omicron variant [<xref rid="B81-vaccines-12-01345" ref-type="bibr">81</xref>,<xref rid="B82-vaccines-12-01345" ref-type="bibr">82</xref>]. Moreover, compared with other vaccine platforms, inactivated vaccines may induce a weaker immune response, necessitating adjuvants or supplementary doses. Additionally, these vaccines may not provide sufficiently broad cross-protection against different strains or variants of a given virus, as they primarily target specific viral antigenic components, thereby potentially limiting their efficacy against evolving pathogens [<xref rid="B83-vaccines-12-01345" ref-type="bibr">83</xref>,<xref rid="B84-vaccines-12-01345" ref-type="bibr">84</xref>]. Recent efforts that have sought to enhance inactivated vaccine platforms have focused on optimizing the manufacturing process. For example, cell culture systems have been improved by using suspension cultures and perfusion bioreactors that are efficient and conducive to the production of higher viral yields [<xref rid="B85-vaccines-12-01345" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-12-01345" ref-type="bibr">86</xref>]. In addition, novel inactivation methods, such as the use of hydrogen peroxide, UV irradiation, and gamma irradiation, are being evaluated as alternatives to traditional chemical inactivation [<xref rid="B87-vaccines-12-01345" ref-type="bibr">87</xref>,<xref rid="B88-vaccines-12-01345" ref-type="bibr">88</xref>,<xref rid="B89-vaccines-12-01345" ref-type="bibr">89</xref>]. Moreover, with the aim of enhancing vaccine immunogenicity, recent research has focused on next-generation adjuvants, including TLR agonists and nanoparticle-based formulations, such as biocompatible calcium phosphate, gold, and silica particles [<xref rid="B90-vaccines-12-01345" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-12-01345" ref-type="bibr">91</xref>]. However, although these innovations aim to enhance the safety and stability of inactivated vaccines, their adoption in licensed vaccines will require a thorough regulatory review and extensive testing.</p></sec><sec id="sec3dot1dot2-vaccines-12-01345"><title>3.1.2. Live-Attenuated Vaccines (LAVs)</title><p>The first LAV against an RNA virus was the yellow fever vaccine developed by Max Theiler in 1930. Theiler attenuated this virus via serial passage from mouse embryo to chicken embryo tissue, with genetic mutations accumulating over the course of serial passage [<xref rid="B92-vaccines-12-01345" ref-type="bibr">92</xref>]. LAVs are developed via a multi-step process designed to generate weakened viruses that although unable cause disease, can still induce robust immune responses. The process is initiated by selecting and isolating pathogenic virus strains, followed by adaptation to cell cultures or other mammalian hosts, which contributes to the accumulation of mutations that reduce viral virulence [<xref rid="B93-vaccines-12-01345" ref-type="bibr">93</xref>]. Recent approaches have included genetic engineering techniques, including reverse genetics, designed to introduce targeted mutations and optimize codons, thereby directly attenuating the virus and enhancing vaccine safety and efficacy [<xref rid="B94-vaccines-12-01345" ref-type="bibr">94</xref>]. Having de-optimized the virus, it undergoes rigorous screening and validation via in vitro and animal model studies to ensure that it does not cause disease and retains its immunogenic properties [<xref rid="B95-vaccines-12-01345" ref-type="bibr">95</xref>]. In addition, ensuring the genetic stability of the attenuated virus is essential for preventing reversion to a more virulent form. LAVs have been evaluated for their efficacy against a range of RNA viruses, including the chikungunya virus, influenza virus, dengue virus, and SARS-CoV-2, offering several advantages, although also having some notable disadvantages [<xref rid="B96-vaccines-12-01345" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-12-01345" ref-type="bibr">97</xref>,<xref rid="B98-vaccines-12-01345" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-12-01345" ref-type="bibr">99</xref>]. One of the primary advantages of LAVs is their ability to induce a strong and enduring immune response based on closely mimicking natural infections. This results in broad and durable immunity, often requiring only a single or two doses [<xref rid="B100-vaccines-12-01345" ref-type="bibr">100</xref>]. Additionally, LAVs are known for their ability to exploit both humoral and cellular immune responses, thereby providing protection against multiple viral antigens [<xref rid="B101-vaccines-12-01345" ref-type="bibr">101</xref>]. However, LAVs also have certain limitations. Notably, from a safety perspective, there remains the possibility that attenuated viruses could revert to a more virulent form, particularly in immunocompromised patients [<xref rid="B102-vaccines-12-01345" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-12-01345" ref-type="bibr">103</xref>]. Given that RNA viruses are mutation-prone, one study has shown that pre-existing immunity limits live-attenuated influenza vaccines&#8217; ability to generate or boost T cell responses, particularly by hindering the formation of de novo T cell populations [<xref rid="B104-vaccines-12-01345" ref-type="bibr">104</xref>]. Moreover, LAVs require careful storage and handling, often necessitating storage at low temperatures, which limits their accessibility to resource-limited areas. Studies have, nevertheless, shown that apart from freeze drying or foam drying, using an appropriate stabilizer, such as trehalose-based stabilizers, can sufficiently increase stability [<xref rid="B105-vaccines-12-01345" ref-type="bibr">105</xref>]. Given these challenges, further investigations are required to identify suitable means of enhancing the safety and stability of LAVs, particularly to minimize the risks of reversion and improve their usability in diverse global settings.</p></sec></sec><sec id="sec3dot2-vaccines-12-01345"><title>3.2. Modern Approaches</title><p>By building on the foundations established by traditional vaccine platforms, modern vaccine approaches have contributed to significant advances in our ability to combat RNA viruses. Although traditional vaccines, including inactivated and LAVs, can provide essential protection against numerous RNA viral diseases, the rapid evolution and mutation of RNA viruses have driven the need for more innovative solutions [<xref rid="B106-vaccines-12-01345" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-12-01345" ref-type="bibr">107</xref>]. Modern strategies, including subunit, viral vector, nucleic acid, and self-amplifying RNA vaccines, offer more adaptable and scalable options (<xref rid="vaccines-12-01345-f002" ref-type="fig">Figure 2</xref>). Moreover, these approaches are designed to enhance the efficacy, safety, and speed of production, while also addressing the limitations of traditional methods. As RNA viruses continue to evolve and present new challenges, the development of novel vaccine designs will become increasingly important for maintaining global health and combatting future pandemics.</p><sec id="sec3dot2dot1-vaccines-12-01345"><title>3.2.1. Subunit Vaccines</title><p>Subunit vaccines use viral proteins or peptides to stimulate immune responses in the absence of living pathogens. These vaccines include virus-derived components, such as surface proteins or peptides, which are commonly recognized by the immune system and stimulate both humoral and cellular immunity. This approach facilitates targeted immune responses with a reduced risk of side effects associated with whole-virus vaccines. In this regard, surface proteins or peptides have been selected as ideal antigens and are generally membrane-integrated proteins in the case of enveloped viruses and capsid proteins for non-enveloped viruses, which are unstable when solubilized. The stabilization of proteins or peptides in subunit vaccines is important for maintaining their structural integrity and enhancing immunogenicity. One approach in this respect is molecular clamping, in which a synthetic peptide is fused to a viral protein to maintain the protein in its native conformation and prevent unfolding. By stabilizing the protein in this manner, the molecular clamp ensures that the antigen remains in a form that is most likely to be recognized by the immune system, thereby enhancing vaccine efficacy [<xref rid="B108-vaccines-12-01345" ref-type="bibr">108</xref>]. A further method involves protein engineering, such as the fusion of antigens with the Fc fragment of human IgG or the generation of mutations that contribute to structural stabilization [<xref rid="B109-vaccines-12-01345" ref-type="bibr">109</xref>]. For example, cross-linking agents, including 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide [<xref rid="B110-vaccines-12-01345" ref-type="bibr">110</xref>] and 3,3&#8242;-dithiobis(sulfosuccinimidyl propionate), have been used to generate covalent bonds between protein molecules, thereby maintaining their structure under different conditions [<xref rid="B111-vaccines-12-01345" ref-type="bibr">111</xref>,<xref rid="B112-vaccines-12-01345" ref-type="bibr">112</xref>]. In addition, by focusing on three-dimensional neutralizing epitopes that can be designed to avoid autoimmune responses, peptide-based vaccines can offer further alternatives. Moreover, peptides can be readily scaled up and modified in the event of identifying of a new mutant variant strain [<xref rid="B113-vaccines-12-01345" ref-type="bibr">113</xref>].</p><p>However, to ensure efficacy, subunit vaccines also require associated delivery systems for administration. Numerous delivery methods have been accordingly developed with a view to enhancing the stability, immunogenicity, and specificity of these vaccines. For example, lipid nanoparticles (LNPs) are commonly used to encapsulate and deliver proteins or peptides as antigens in subunit vaccines. These nanoparticles can protect against antigen degradation and enhance their delivery to antigen-presenting cells [<xref rid="B114-vaccines-12-01345" ref-type="bibr">114</xref>]. In addition, polymer-based nanoparticles, such as poly(lactic-co-glycolic) acid, have also been used, given their tunable properties and sustained-release capabilities [<xref rid="B115-vaccines-12-01345" ref-type="bibr">115</xref>]. In addition, virus-like particles (VLPs), which structurally mimic viruses but do not carry genetic material, thus rendering them non-infectious, have been used in subunit vaccines to present antigens in a manner that closely resembles that of natural viruses, thereby enhancing immune responses [<xref rid="B116-vaccines-12-01345" ref-type="bibr">116</xref>,<xref rid="B117-vaccines-12-01345" ref-type="bibr">117</xref>].</p><p>The recent integration of artificial intelligence (AI) in structural biology has contributed to a significant acceleration in the development of subunit vaccines. Among the approaches adopted to date, the use of AlphaFold AI tools has substantially enhanced the speed with which the three-dimensional structures of viral proteins and their biomolecular interactions can be predicted, thereby enabling researchers to identify potential epitope-specific portions of the virus that can be targeted by the immune system [<xref rid="B118-vaccines-12-01345" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-12-01345" ref-type="bibr">119</xref>]. In turn, by ensuring that the selected viral proteins or peptides are optimally structured to elicit strong immune responses, these developments have facilitated the design of more effective vaccines. As AI continues to evolve, its role in vaccine development is expected to grow in prominence, contributing to a more rapid and accurate vaccine design processes [<xref rid="B120-vaccines-12-01345" ref-type="bibr">120</xref>,<xref rid="B121-vaccines-12-01345" ref-type="bibr">121</xref>].</p></sec><sec id="sec3dot2dot2-vaccines-12-01345"><title>3.2.2. Viral Vector Vaccines</title><p>The use of viral vector vaccines dates back over 30 years, with the first successful application of a vaccinia virus vector for hepatitis B immunization, in which a hepatitis B surface antigen gene was inserted into simian virus 40 [<xref rid="B122-vaccines-12-01345" ref-type="bibr">122</xref>]. Since then, a range of viruses have been engineered to generate viral vaccine vectors, including retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, cytomegaloviruses, and Sendai viruses [<xref rid="B123-vaccines-12-01345" ref-type="bibr">123</xref>,<xref rid="B124-vaccines-12-01345" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-12-01345" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-12-01345" ref-type="bibr">126</xref>,<xref rid="B127-vaccines-12-01345" ref-type="bibr">127</xref>]. These vaccines utilize viral vectors to deliver genetic material from a pathogen into host cells, which is then expressed to stimulate an immune response that mimics a natural infection [<xref rid="B128-vaccines-12-01345" ref-type="bibr">128</xref>]. The importance of viral vector vaccines was particularly highlighted during the COVID-19 pandemic, with the production of adenovirus-vectored vaccines, such as those developed by a collaborative venture between Oxford University and AstraZeneca plc. (ChAdOx1 nCoV-19), Johnson &amp; Johnson (JNJ-78435735, Ad26.COV2.S), Gamaleya Research Institute of Epidemiology and Microbiology (Sputnik V), and CanSino Biologics lnc. (Convidecia), which have played pivotal roles in global vaccination efforts. These vaccines encode the spike protein of the SARS-CoV-2 virus that induces robust immune responses, and they have shown demonstrable efficacy against a number of COVID-19 variants [<xref rid="B129-vaccines-12-01345" ref-type="bibr">129</xref>].</p><p>One of the primary advantages of viral-vectored vaccines is their ability to generate strong immune responses at lower doses than those of traditional vaccines. Moreover, they are also relatively stable and do not require ultra-cold storage, making them accessible in regions with limited infrastructure [<xref rid="B130-vaccines-12-01345" ref-type="bibr">130</xref>]. As part of the continuing maturation of viral vector vaccine technology, the Coalition for Epidemic Preparedness Innovations has introduced a &#8220;100-day mission&#8221;, with the aim of developing and deploying effective vaccines within 100 days of identifying a new pathogen [<xref rid="B131-vaccines-12-01345" ref-type="bibr">131</xref>]. However, despite the value of these vaccines, they do have certain disadvantages, notably the potential for pre-existing immunity to the viral vector, which can contribute to reduced vaccine efficacy [<xref rid="B132-vaccines-12-01345" ref-type="bibr">132</xref>]. Additionally, over the course of the COVID-19 pandemic, billions of individuals were vaccinated, some of whom have developed mild-to-moderate side effects, thereby highlighting the need for the more extensive monitoring of long-term safety [<xref rid="B133-vaccines-12-01345" ref-type="bibr">133</xref>].</p></sec><sec id="sec3dot2dot3-vaccines-12-01345"><title>3.2.3. Bacterial Vector Vaccines</title><p>A further potential delivery system that can serve as a means of ferrying DNA vaccines entails the use of live bacterial vectors, whereby genetically modified bacteria can be administered intranasally, orally, or intravaginally, thus offering multiple delivery routes. The innate immune response induced by the pathogen-associated molecular patterns of bacteria, as well as the potential adaptive immune responses they stimulate, mean that such modified bacteria serve not only as a vehicle conveying the DNA vaccine but also function as effective immunostimulatory adjuvants. To date, numerous bacterial strains have been extensively evaluated for their potential application as DNA vaccine vehicles, thereby providing a well-characterized genetic background and mutations for virulence attenuation [<xref rid="B134-vaccines-12-01345" ref-type="bibr">134</xref>,<xref rid="B135-vaccines-12-01345" ref-type="bibr">135</xref>,<xref rid="B136-vaccines-12-01345" ref-type="bibr">136</xref>,<xref rid="B137-vaccines-12-01345" ref-type="bibr">137</xref>]. Whereas the proposed DNA transfer mechanisms involve bacterial invasion, non-pathogenic commensal bacteria such as lactic acid bacteria (LAB) are generally considered more suitable for immunocompromised patients, although these may still pose a threat of potential invasive infections [<xref rid="B138-vaccines-12-01345" ref-type="bibr">138</xref>,<xref rid="B139-vaccines-12-01345" ref-type="bibr">139</xref>]. Given their resistance to acidic environments, LAB, including strains that are widely used as probiotics, can be delivered via the gastrointestinal route. Furthermore, attenuated pathogenic bacteria, such as strains in the genera <italic toggle="yes">Salmonella</italic>, <italic toggle="yes">Listeria</italic>, and <italic toggle="yes">Mycobacterium</italic>, have also shown promise as vectors for DNA transfer, in that they are capable of inducing both cellular and humoral immune responses, although there remains the possibility of reversion to the pathogenic state. Nevertheless, several live-attenuated bacterially vectored vaccines for viral infections have reached clinical trials, among which attenuated <italic toggle="yes">Listeria monocytogenes</italic> (BMB72) has been used to transfer the influenza A nucleoprotein [<xref rid="B140-vaccines-12-01345" ref-type="bibr">140</xref>,<xref rid="B141-vaccines-12-01345" ref-type="bibr">141</xref>], and <italic toggle="yes">L. monocytogenes</italic> (XFL-7) has been used to administer the rHPV-16 E7 antigen [<xref rid="B142-vaccines-12-01345" ref-type="bibr">142</xref>]. Additionally, Syrian hamsters have been immunized using <italic toggle="yes">Salmonella</italic>-mediated bactofection, a bacterially mediated form of genetic transfer, carrying replicon-based mRNA or attenuated <italic toggle="yes">Francisella tularensis</italic> platforms expressing structural proteins, which have been shown to provide protection against SARS-CoV-2 infection, with ameliorated lung pathology and efficacious antibody production [<xref rid="B143-vaccines-12-01345" ref-type="bibr">143</xref>,<xref rid="B144-vaccines-12-01345" ref-type="bibr">144</xref>]. These proof-of-concept findings could offer viable alternatives for needle-free vaccination, although further assessments are required.</p></sec><sec id="sec3dot2dot4-vaccines-12-01345"><title>3.2.4. Nucleic Acid Vaccines</title><sec><title>mRNA Vaccines</title><p>Nucleic acid vaccines, particularly mRNA vaccines, are groundbreaking vaccine platforms that are adaptable and can be readily modified in response to rapidly emerging viral epidemics/pandemics. mRNA vaccines deliver viral protein-encoded mRNA, such as that of the SARS-CoV-2 spike protein, into host cells. Therein, mRNA is subsequently translated to produce a viral protein that is displayed on the cell surface and triggers a viral protein-specific immune response. These vaccines have attracted considerable attention in the wake of the development of SARS-CoV-2 vaccines by Pfizer-BioNTech and Moderna, which were the first mRNA vaccines to be granted emergency use authorization from many countries during the pandemic. These vaccines have shown high efficacy, providing approximately 95% protection against COVID-19, as revealed in clinical studies, and have made a significant contribution in controlling the spread of SARS-CoV-2 [<xref rid="B145-vaccines-12-01345" ref-type="bibr">145</xref>]. Moreover, Drs. Katalin Karik&#243; and Drew Weissman were honored with the Nobel Prize for their development of the mRNA vaccine [<xref rid="B146-vaccines-12-01345" ref-type="bibr">146</xref>,<xref rid="B147-vaccines-12-01345" ref-type="bibr">147</xref>,<xref rid="B148-vaccines-12-01345" ref-type="bibr">148</xref>,<xref rid="B149-vaccines-12-01345" ref-type="bibr">149</xref>]. Their work on this technology not only constituted a pivotal breakthrough in combatting COVID-19 but also represented a substantial advance in vaccine science.</p><p>Unlike traditional vaccines, which can take years to develop, one of the key advantages of mRNA vaccine technology is that these vaccines can be designed, manufactured, and produced within a comparatively short space of time, thereby making them ideal for responding to pandemics. Additionally, mRNA vaccines are flexible, as their sequences can be readily modified to target different variants of RNA viruses or even different viruses [<xref rid="B150-vaccines-12-01345" ref-type="bibr">150</xref>], which is an essential facet for combatting rapidly mutating RNA viruses such as SARS-CoV-2, influenza viruses, or mpox viruses, among which, there is a high likelihood of the emergence of novel variants that might evade pre-existing immunity [<xref rid="B151-vaccines-12-01345" ref-type="bibr">151</xref>,<xref rid="B152-vaccines-12-01345" ref-type="bibr">152</xref>,<xref rid="B153-vaccines-12-01345" ref-type="bibr">153</xref>].</p><p>Although mRNA vaccines have multiple advantages, their application does have certain drawbacks, of which a key disadvantage is that RNA molecules can lack stability and may be readily degraded. To overcome such problems, lipid nanoparticles are often used to encapsulate mRNAs, thereby protecting these molecules from degradation and facilitating delivery into host cells. A further disadvantage is their limited shelf life of less than 24 h, and thus the demand for stringent storage and transport conditions [<xref rid="B154-vaccines-12-01345" ref-type="bibr">154</xref>]. Nevertheless, researchers are striving to improve the stability of mRNA vaccines at higher temperatures, which will substantially contribute to reducing the costs and challenges of vaccine distribution [<xref rid="B155-vaccines-12-01345" ref-type="bibr">155</xref>]. New-generation platforms are currently being developed to address these challenges and to enhance the efficacy and accessibility of mRNA vaccines, among which are self-amplifying RNA vaccines, in which RNA molecules can be amplified within host cells, and circular RNA vaccines, which are more stable than linear mRNAs [<xref rid="B156-vaccines-12-01345" ref-type="bibr">156</xref>,<xref rid="B157-vaccines-12-01345" ref-type="bibr">157</xref>]. With these innovations, new-generation mRNA vaccines promise to reduce the dosage requirements and enhance the thermal stability of RNA vaccines, thus paving the way for the development of products that are more robust and easier to distribute globally [<xref rid="B158-vaccines-12-01345" ref-type="bibr">158</xref>]. Moreover, the potential application of mRNA vaccines extends beyond infectious diseases, for example, as therapeutics for cancers, autoimmune diseases, and other rare diseases [<xref rid="B159-vaccines-12-01345" ref-type="bibr">159</xref>,<xref rid="B160-vaccines-12-01345" ref-type="bibr">160</xref>,<xref rid="B161-vaccines-12-01345" ref-type="bibr">161</xref>]. Indeed, the triumphal development and deployment of mRNA vaccines during the COVID-19 pandemic have opened a window for further applications of this technology, in which it is predicted that AI will play a key role in optimizing and accelerating vaccine development, with the promise of a new era in vaccinology and personalized medicine [<xref rid="B162-vaccines-12-01345" ref-type="bibr">162</xref>].</p></sec><sec><title>DNA Vaccines</title><p>DNA vaccines, first conceptualized in the early 1990s, represent a novel approach to immunization using genetically engineered plasmid DNA to encode pathogen-derived antigens. Using this approach, engineered DNA is taken up by host cells, wherein the encoded antigen is synthesized and presented on the cell surface, thereby triggering both humoral and cellular immune responses [<xref rid="B163-vaccines-12-01345" ref-type="bibr">163</xref>,<xref rid="B164-vaccines-12-01345" ref-type="bibr">164</xref>]. Among the notable examples of this technology is ZyCoV-D, developed by Zydus, which was the first DNA vaccine to target COVID-19 and be approved for humans, and INO-4800, developed by Inovio, which has shown promise in clinical trials against SARS-CoV-2 as a safe booster [<xref rid="B165-vaccines-12-01345" ref-type="bibr">165</xref>]. The key advantages of DNA vaccines include their safety, as they do not involve live pathogens, and their stability, which often eliminates the need for refrigeration, making them easier to distribute in low-resource environments [<xref rid="B166-vaccines-12-01345" ref-type="bibr">166</xref>]. In addition, DNA vaccines can be rapidly developed in response to emerging RNA viruses. However, their use is not without limitations, among which is the relatively low immunogenicity in humans, which could be ascribed to the amounts used [<xref rid="B167-vaccines-12-01345" ref-type="bibr">167</xref>]. Different delivery methods, codon usage, and adjuvants are, nevertheless, being assessed in efforts to enhance the efficacy of these vaccines [<xref rid="B168-vaccines-12-01345" ref-type="bibr">168</xref>].</p></sec></sec><sec id="sec3dot2dot5-vaccines-12-01345"><title>3.2.5. Phage-like Particle Vaccines</title><p>Phage-like particle vaccines are an emerging technology that utilizes the structural properties of bacteriophages for displaying antigens from RNA viruses, thereby effectively stimulating a virus-specific immune response. A pioneering study of phage-like particles by George P. Smith in 1985 built a foundation for the broader application of this approach in vaccine development [<xref rid="B169-vaccines-12-01345" ref-type="bibr">169</xref>]. The Smith lab used a filamentous bacteriophage (M13) to display a foreign peptide in an immunologically accessible form. The concept of using bacteriophages for antigen delivery has been adopted in a number of formal vaccine development studies. For example, the lambda bacteriophage has been engineered to display the receptor-binding domain of SARS-CoV-2, which has been demonstrated to have high immunogenicity and elicit durable antibody responses. This phage-like particle vaccine not only offers protection against lung infections caused by coronaviruses but also highlights the potential application of phage-like particles as a versatile platform for vaccine development [<xref rid="B170-vaccines-12-01345" ref-type="bibr">170</xref>,<xref rid="B171-vaccines-12-01345" ref-type="bibr">171</xref>]. The advantages of phage-like particle vaccines include their capacity to elicit strong and targeted immune responses, owing to the multivalent display of antigens, as well as their stability and ease of production. However, a number of issues with their use are yet to be resolved, such as optimizing the expression of viral antigens on the phage surface and ensuring consistent immune responses among different populations [<xref rid="B172-vaccines-12-01345" ref-type="bibr">172</xref>]. Future research should focus on enhancing the design and delivery of these vaccines and examine the potential integration of synthetic biology and AI-driven optimization to enhance their efficacy and broaden their application in the treatment of infectious diseases.</p></sec><sec id="sec3dot2dot6-vaccines-12-01345"><title>3.2.6. Novel Antigen Delivery Systems</title><p>In a constant effort to counter emerging and re-emerging infectious diseases, the development of novel antigen delivery systems is an ongoing pursuit that seeks to broaden the scope of protective immune responses. In this section, we describe studies that envision new strategies for vaccination with respect to LNPs and exosome-based carrier systems. LNPs are versatile platforms that enable the delivery of nucleic acid materials and liposomal drugs with potential clinical applications as antigen-presenting agents. Common liposome constituents include phospholipids, such as phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, and phosphatidylglycerols. These particles, which are generally 50&#8211;500 nm in diameter, mediate fusion with the cell membrane and the subsequent release of nucleic acid materials via endocytic uptake [<xref rid="B173-vaccines-12-01345" ref-type="bibr">173</xref>]. The use of LNPs in the distribution of SARS-CoV-2 mRNA vaccines developed by Pfizer-BioNTech and Moderna offered the promise of safe and efficacious delivery of this and other vaccines. In addition, LNPs have been approved for the delivery of small-molecule drugs for cancer treatment [<xref rid="B174-vaccines-12-01345" ref-type="bibr">174</xref>]. Liposomes can also be designed with surface-attached ligands to facilitate receptor binding or to present antigens directly [<xref rid="B174-vaccines-12-01345" ref-type="bibr">174</xref>,<xref rid="B175-vaccines-12-01345" ref-type="bibr">175</xref>]. In 2022, Sia et al. provided evidence for the use of LNPs as antigen-presenting agents that facilitated the presentation of recombinant influenza hemagglutinin on modified immunogenic liposome surfaces. These LNPs, containing cobalt porphyrin-phospholipid, can bind to His-tagged hemagglutinin trimers, and have been shown to confer protection against the influenza virus in animal models [<xref rid="B176-vaccines-12-01345" ref-type="bibr">176</xref>]. In their recent studies, these authors demonstrated that multivalent LNPs displaying both hemagglutinin and neuraminidase antigens on their surfaces elicit potent protection against several strains of influenza virus in different animal models, including mice and ferrets [<xref rid="B177-vaccines-12-01345" ref-type="bibr">177</xref>]. Exosomes, which are specialized lipid-bound extracellular vehicles derived from cells, ranging in size from 30 to 200 nm, represent a further promising approach to vaccine delivery [<xref rid="B174-vaccines-12-01345" ref-type="bibr">174</xref>,<xref rid="B178-vaccines-12-01345" ref-type="bibr">178</xref>] and can fuse with cells to facilitate the delivery of requisite cargoes, including peptides, lipids, proteins, and nucleic acids. The findings of several studies conducted to date have demonstrated the use of exosomes as potential vaccine delivery vehicles for the treatment of viral infections, including hepatitis B, HIV, and SARS-CoV-2 [<xref rid="B179-vaccines-12-01345" ref-type="bibr">179</xref>,<xref rid="B180-vaccines-12-01345" ref-type="bibr">180</xref>,<xref rid="B181-vaccines-12-01345" ref-type="bibr">181</xref>,<xref rid="B182-vaccines-12-01345" ref-type="bibr">182</xref>,<xref rid="B183-vaccines-12-01345" ref-type="bibr">183</xref>,<xref rid="B184-vaccines-12-01345" ref-type="bibr">184</xref>,<xref rid="B185-vaccines-12-01345" ref-type="bibr">185</xref>,<xref rid="B186-vaccines-12-01345" ref-type="bibr">186</xref>]. These vehicles also provide an alternative to LNPs, with fewer reported toxicity concerns [<xref rid="B187-vaccines-12-01345" ref-type="bibr">187</xref>]. Collectively, these strategies will pave the way for the development of the next generation of vaccines.</p></sec></sec></sec><sec id="sec4-vaccines-12-01345"><title>4. Case Studies of RNA Virus Vaccines</title><p>The development of vaccines against RNA viruses has advanced rapidly in recent years. Various vaccine platforms have proven to be effective in combating a wide range of RNA viruses, marking a new era in vaccine development. This section examines case studies of several RNA viruses, highlighting the different vaccine types developed, the challenges encountered during their development, and the technological innovations that have shaped the current landscape of RNA virus vaccines. A comparative overview of selected viruses is presented, highlighting their unique characteristics, current vaccine status, and the specific challenges encountered during vaccine development (<xref rid="vaccines-12-01345-t001" ref-type="table">Table 1</xref>).</p><sec id="sec4dot1-vaccines-12-01345"><title>4.1. SARS-CoV-2 (COVID-19): mRNA and Viral Vector Vaccines</title><p>The development of various types of vaccine was rapidly accelerated in response to the COVID-19 pandemic, among which are multi-antigen and internasal vaccines that are currently being developed with a view toward enhancing the immunogenicity/efficacy and ease of administration. A noteworthy example in this regard is a multi-antigen intranasal vaccine that provides board protection against a range of betacoronaviruses and alphacoronaviruses. This vaccine utilizes NanoSTING, a liposomally encapsulated endogenous stimulator of interferon gene agonist (STINGa, 2&#8242;,3&#8242; cGAMP), combining target spike and nucleocapsid proteins, designed to promote a more comprehensive immunity and reduce the risk of immune escape [<xref rid="B188-vaccines-12-01345" ref-type="bibr">188</xref>]. In addition, a study has highlighted the importance of spike protein structural stability by employing the pentameric cholera toxin B subunit in conjunction with a self-assembling nanoparticle chassis, which contributes to influencing vaccine efficacy and provides a basis for the design of future inhaled vaccine platforms [<xref rid="B189-vaccines-12-01345" ref-type="bibr">189</xref>].</p><p>The most widely used vaccines against COVID-19 include mRNA vaccines such as the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines. These vaccines, which were among the first to be developed and granted emergency use authorization during the COVID-19 pandemic, utilize LNPs to deliver mRNA encoding the spike protein of SARS-CoV-2 into host cells, wherein it is expressed and induces an immune response. The groundbreaking success of these vaccines was emphasized by the high efficacy and speed of development with which they were deployed during the pandemic, even in fields such as cancer [<xref rid="B145-vaccines-12-01345" ref-type="bibr">145</xref>]. Viral vector vaccines, such as AstraZeneca&#8217;s ChAdOx1 nCoV-19 and Johnson and Johnson&#8217;s JNJ-78435735, have similarly played pivotal roles in global vaccination programs. These vaccines utilize modified chimpanzee or human adenoviruses as vectors to deliver SARS-CoV-2 spike protein-encoded nucleic acids into host cells, and, notably, the stability of these viral vector vaccines ensures widespread accessibility in areas that lack &#8722;80 &#176;C storage facilities [<xref rid="B133-vaccines-12-01345" ref-type="bibr">133</xref>].</p><p>Vaccine-induced side effects, particularly with adenoviral vector-based vaccines, have raised concerns. Severe thromboembolic events such as cerebral venous sinus thrombosis (CVST) and splanchnic vein thrombosis (SVT), often accompanied by thrombocytopenia, have been reported 4&#8211;14 days after vaccination. No such events have been observed with mRNA-based vaccines. This has led to the identification of vaccine-induced immune thrombotic thrombocytopenia, likely caused by an immune-based response to adenoviral vectors [<xref rid="B190-vaccines-12-01345" ref-type="bibr">190</xref>,<xref rid="B191-vaccines-12-01345" ref-type="bibr">191</xref>]. In contrast, mRNA vaccines, which have significantly reduced COVID-19 morbidity and mortality, have been associated with rare cardiovascular complications such as myocarditis, acute coronary syndrome, thrombosis, and hypertension. These events may be linked to angiotensin-converting enzyme 2 (ACE2) dysregulation caused by spike protein mimicry. Despite these rare risks, the benefit&#8211;risk ratio of mRNA vaccines remains highly favorable, with medical monitoring recommended for individuals with pre-existing cardiovascular conditions [<xref rid="B192-vaccines-12-01345" ref-type="bibr">192</xref>].</p></sec><sec id="sec4dot2-vaccines-12-01345"><title>4.2. Influenza: Seasonal and Pandemic Influenza Vaccines</title><p>Influenza viruses, which are typically characterized by high rates of mutation, necessitate annual updates of vaccines to counter the prevailing circulating strains, with the World Health Organization [<xref rid="B193-vaccines-12-01345" ref-type="bibr">193</xref>] announcing recommendations for vaccine use. For the 2024&#8211;2025 season, a trivalent influenza vaccine that protects against three different influenza viruses (influenza A H1N1, H3N2, and B/Victoria lineage) was recommended to reduce the global burden of influenza viral infection-related illnesses [<xref rid="B194-vaccines-12-01345" ref-type="bibr">194</xref>]. To control the seasonal outbreaks of influenza, such as the H1N1 pandemic in 2009 and the H7N9 pandemic in 2013, it is essential to have measures in place that enable the rapid development and deployment of vaccines. In this regard, advances in the development of RNA vaccines, initially driven by the COVID-19 outbreak, are now being employed to develop novel or improved universal influenza vaccines that can be used against different variants of the influenza virus [<xref rid="B195-vaccines-12-01345" ref-type="bibr">195</xref>].</p></sec><sec id="sec4dot3-vaccines-12-01345"><title>4.3. Dengue: Dengvaxia and Other Candidates</title><p>Dengue fever presents significant challenges for vaccine development, particularly with respect to the risk of antibody-dependent enhancement, which can occur when prior exposure to one of the four distinct serotypes increases the severity of infection with a different serotype [<xref rid="B196-vaccines-12-01345" ref-type="bibr">196</xref>]. In this regard, although the live-attenuated Dengvaxia (CYD-TDV) vaccine, approved in 2022, has shown efficacy in preventing dengue, it is only recommended for individuals with prior dengue virus infection. In individuals who have had no previous infection, vaccination could increase the likelihood of severe dengue fever or hospitalization if subsequently contracting a natural infection post-vaccination [<xref rid="B197-vaccines-12-01345" ref-type="bibr">197</xref>]. Moreover, in addition to necessitating serological testing prior to use, the vaccine needs to be administered in three doses and given 6 months apart [<xref rid="B198-vaccines-12-01345" ref-type="bibr">198</xref>]. Thus, although the Dengvaxia vaccine represents a significant breakthrough, its limitations highlight the need for alternative approaches. A major factor contributing to antibody-dependent enhancement is the emergence of fucosylated anti-dengue IgG1 antibodies [<xref rid="B48-vaccines-12-01345" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-12-01345" ref-type="bibr">49</xref>,<xref rid="B62-vaccines-12-01345" ref-type="bibr">62</xref>], and studies have indicated that viral infections and LAVs can induce a higher rate of afucosylated antibody production [<xref rid="B199-vaccines-12-01345" ref-type="bibr">199</xref>]. In contrast, experience with COVID-19 vaccines has indicated that protein subunit and adenovector DNA vaccines do not produce afucosylated IgG1, whereas mRNA vaccines may only induce transient afucosylation [<xref rid="B200-vaccines-12-01345" ref-type="bibr">200</xref>,<xref rid="B201-vaccines-12-01345" ref-type="bibr">201</xref>]. These insights accordingly raise the possibility that employing protein or adenovector vaccination schemes for dengue, in combination with protein subunit vaccines, followed by mRNA vaccinations, could mitigate the generation of afucosylated anti-dengue antibodies. However, it remains uncertain as to whether vaccination against dengue antigens will promote responses comparable to those elicited by SARS-CoV-2 spike proteins during vaccination for COVID-19. Nevertheless, the more recent approval of Qdenga, a tetravalent chimeric live-attenuated vaccine, which, notably, does not appear to enhance antibody-dependent diseases [<xref rid="B202-vaccines-12-01345" ref-type="bibr">202</xref>], has further advanced the field. Collectively, these developments highlight the complexities and ongoing challenges in producing effective and safe dengue vaccines.</p></sec><sec id="sec4dot4-vaccines-12-01345"><title>4.4. Zika: Current Status and Challenges</title><p>Zika virus, an emerging mosquito-borne virus that triggered a global health emergency in 2015&#8211;2016 due to its association with microcephaly (a developmental defect in the brains of infants), has spurred efforts to develop effective vaccines [<xref rid="B203-vaccines-12-01345" ref-type="bibr">203</xref>]. However, one of the difficulties in developing Zika vaccines is the requirement for long-lasting immunity, particularly in pregnant women, who have the highest risk for mother-to-infant viral transmission. Currently, multiple vaccine candidates are at different stages of development, including DNA, mRNA, viral vector, virus-like particle, inactivated virus, peptide-based, and recombinant protein vaccines [<xref rid="B134-vaccines-12-01345" ref-type="bibr">134</xref>]. However, a recent marked decline in Zika cases has significantly limited the occurrence of natural infections, thereby making it difficult to conduct clinical trials for the evaluation of vaccine efficacy. Nonetheless, some researchers are continuing to develop vaccines and initiate phase-1 clinal trials, such that a vaccine could be rapidly deployed in the event of a resurgence [<xref rid="B204-vaccines-12-01345" ref-type="bibr">204</xref>].</p></sec><sec id="sec4dot5-vaccines-12-01345"><title>4.5. Enterovirus A71: EnVAX-A71</title><p>Enterovirus A71 (EV-A71) is a major cause of hand, foot, and mouth disease (HFMD), which is particularly prevalent in children below 5 years of age and can lead to severe neurological complications. In Asia, where the virus is most prevalent, the development of vaccines against EV-A71 has been a priority. The first inactivated EV-A71 vaccine using C4 genogroup strains was licensed in China and demonstrated high efficacy in preventing HFMD. EnVAX-A71 (an inactivated vaccine based on the B4 sub-genotype) provides an efficacy of at least 96.8% and is safe for administration to infants between 2 and 6 months of age [<xref rid="B205-vaccines-12-01345" ref-type="bibr">205</xref>]. Current efforts are focused on the development of next-generation vaccines such as EV-A71 VLP production using <italic toggle="yes">Pichia pastoris</italic>, which could provide broader protection, facilitate wider distribution, and potentially enable the incorporation of new adjuvants or delivery systems to enhance their efficacy [<xref rid="B110-vaccines-12-01345" ref-type="bibr">110</xref>].</p></sec><sec id="sec4dot6-vaccines-12-01345"><title>4.6. Nipah Virus: Prospects and Opportunities</title><p>Given its capacity for human&#8211;human transmission and the associated high mortality rate reaching up to 75%, the Nipah virus is considered to have pandemic potential [<xref rid="B206-vaccines-12-01345" ref-type="bibr">206</xref>]. Currently, there are no approved vaccines or treatments for Nipah virus infections, and it has accordingly been identified as a high-priority pathogen according to the World Health Organization and Centers for Disease Control and Prevention [<xref rid="B197-vaccines-12-01345" ref-type="bibr">197</xref>,<xref rid="B207-vaccines-12-01345" ref-type="bibr">207</xref>,<xref rid="B208-vaccines-12-01345" ref-type="bibr">208</xref>]. Recent advances in Nipah virus vaccine research have identified several promising candidates, among which is a recombinant vesicular stomatitis virus (rVSV)-based vaccine that has been demonstrated to elicit long-lasting immunity in non-human primates, with 100% protection maintained even a year after vaccination [<xref rid="B209-vaccines-12-01345" ref-type="bibr">209</xref>]. Additionally, both the ChAdOx1 NiVB vaccine, developed using a viral vector vaccine platform, and mRNA-1215, an mRNA vaccine platform developed by Moderna, are currently undergoing clinical trials. The ChAdOx1 NiVB vaccine has been shown to provide full protection in hamsters and African green monkeys, with robust immune responses and no viral replication [<xref rid="B210-vaccines-12-01345" ref-type="bibr">210</xref>,<xref rid="B211-vaccines-12-01345" ref-type="bibr">211</xref>], whereas the mRNA Nipah vaccine has been found to elicit effective antibody responses in pigs, thereby prompting its ongoing evaluation for human use [<xref rid="B212-vaccines-12-01345" ref-type="bibr">212</xref>].</p></sec><sec id="sec4dot7-vaccines-12-01345"><title>4.7. Comparison of Vaccine Platforms Against Selected RNA Viruses</title><p>To provide a clearer comparison of vaccine platforms, we have created a summarized table highlighting the different platforms used for developing vaccines against selected RNA viruses (<xref rid="vaccines-12-01345-t002" ref-type="table">Table 2</xref>). This table presents an overview of the traditional and modern vaccine approaches, including inactivated, live-attenuated, mRNA, DNA, and viral vector vaccines, and their applications in combating viruses such as SARS-CoV-2, influenza, Zika, and dengue. It serves as a concise reference to understand the strengths and limitations of each platform in the context of these viral threats.</p></sec></sec><sec id="sec5-vaccines-12-01345"><title>5. Challenges and Opportunities in RNA Virus Vaccine Development</title><p>Challenges invariably bring opportunities, and the development of RNA virus vaccines is no exception. The rapid evolution of RNA viruses, driven by constant mutations, such as antigenic drift and shift, presents innumerable challenges in that it necessitates frequent vaccine updates in the continual drive to maintain efficacy [<xref rid="B213-vaccines-12-01345" ref-type="bibr">213</xref>,<xref rid="B214-vaccines-12-01345" ref-type="bibr">214</xref>]. Moreover, these challenges have also propelled the development of cutting-edge vaccine technologies, such as mRNA and self-amplifying mRNA vaccine platforms, which offer novel approaches for initiating swift responses to viral changes.</p><p>RNA viruses, such as influenza virus and SARS-CoV-2, are known for their rapid evolution, driven by mutations via mechanisms such as antigenic drift and shift [<xref rid="B215-vaccines-12-01345" ref-type="bibr">215</xref>,<xref rid="B216-vaccines-12-01345" ref-type="bibr">216</xref>,<xref rid="B217-vaccines-12-01345" ref-type="bibr">217</xref>]. Antigenic drift refers to small changes in viral surface proteins that accumulate over time, potentially reducing vaccine efficacy. At the time of writing, there have been more than 20 human SARS-CoV-2 variants since October 2020, with thousands of genome sequence submissions to the Global Initiative on Sharing All Influenza Data (GISAID), which includes coronavirus data obtained during the COVID-19 pandemic [<xref rid="B218-vaccines-12-01345" ref-type="bibr">218</xref>]. In contrast, antigenic shift involves more pronounced changes in sequence, often leading to new viral strains and pandemics, such as the H1N1 influenza outbreak in 2009. There are potentially 144 different sub-types of the influenza A virus associated with antigenic shifts among 18 different hemagglutinin types and 9 different neuraminidase types [<xref rid="B219-vaccines-12-01345" ref-type="bibr">219</xref>]. This is particularly evident in influenza and SARS-CoV-2, for which constant viral mutations necessitate frequent vaccine updates [<xref rid="B220-vaccines-12-01345" ref-type="bibr">220</xref>,<xref rid="B221-vaccines-12-01345" ref-type="bibr">221</xref>]. However, these challenges have fueled research on broad-spectrum and universal vaccines that can target a wider range of viral variants, thereby potentially reducing the need for constant modification [<xref rid="B222-vaccines-12-01345" ref-type="bibr">222</xref>,<xref rid="B223-vaccines-12-01345" ref-type="bibr">223</xref>]. A further important aspect in this context is the necessity to achieve a balance between immunogenicity and safety [<xref rid="B224-vaccines-12-01345" ref-type="bibr">224</xref>]. Effective vaccines induce strong immune responses without causing adverse events or harmful side effects, and in this regard, innovations such as protein subunit vaccines, VLPs, and viral vector vaccines are leading the way by offering safer, non-replicating options that still ensure a robust defense against evolving RNA viruses [<xref rid="B225-vaccines-12-01345" ref-type="bibr">225</xref>,<xref rid="B226-vaccines-12-01345" ref-type="bibr">226</xref>,<xref rid="B227-vaccines-12-01345" ref-type="bibr">227</xref>,<xref rid="B228-vaccines-12-01345" ref-type="bibr">228</xref>].</p><p>For numerous viruses, distribution and access are major barriers, particularly in low-resource settings. Many RNA vaccines, including mRNA-based vaccines, require ultracold storage, which poses logistical challenges in regions with limited infrastructure [<xref rid="B229-vaccines-12-01345" ref-type="bibr">229</xref>], as was prominently highlighted during the course of the global response to COVID-19, and has accordingly prompted rapid advances in vaccine stability and transport systems designed to overcome these difficulties [<xref rid="B230-vaccines-12-01345" ref-type="bibr">230</xref>]. Improving access to vaccines in underserved areas will be essential for enhancing the efficacy of global public health efforts [<xref rid="B231-vaccines-12-01345" ref-type="bibr">231</xref>]. Finally, a lack of public trust and vaccine hesitancy, which are often driven by misinformation and fear, have become significant barriers to achieving high vaccination rates, and addressing this issue will require transparent communication, robust public education, and community engagement to build confidence in the safety and efficacy of vaccines [<xref rid="B232-vaccines-12-01345" ref-type="bibr">232</xref>]. This challenge, exacerbated by the spread of misinformation on social media, highlights the need for better public health outreach strategies to dispel fears and hesitancy, and thereby ensure broad vaccine acceptance [<xref rid="B233-vaccines-12-01345" ref-type="bibr">233</xref>].</p><p>Nevertheless, despite these multiple challenges hindering vaccine development, scientific innovation has found and will continue to find effective solutions. Addressing these difficulties requires not only adaptation but also breakthroughs in vaccine technology. Recent technological and scientific advances, particularly in nanotechnology and cryo-electron microscopy, have significantly improved RNA viral vaccines. Nanotechnology has facilitated considerable progress in vaccine delivery by enabling the precise engineering of nanoparticles, such as LNPs, which are essential for stabilizing mRNA vaccines and facilitating cellular uptake, as demonstrated in COVID-19 vaccines [<xref rid="B234-vaccines-12-01345" ref-type="bibr">234</xref>,<xref rid="B235-vaccines-12-01345" ref-type="bibr">235</xref>]. Moreover, nanoparticles can be designed to mimic viral structures, thereby enhancing immune system recognition and response [<xref rid="B235-vaccines-12-01345" ref-type="bibr">235</xref>]. In addition, by resolving viral protein structures at near-atomic resolution, enabling the detailed mapping of essential antigens, such as spike proteins and cryo-electron microscopy, has further advanced vaccine design [<xref rid="B236-vaccines-12-01345" ref-type="bibr">236</xref>]. This technology not only clarifies complex protein structures but also aids in improving pre-fusion-stabilized proteins, thus optimizing these for immune recognition and enhancing vaccine efficacy against rapidly evolving pathogens [<xref rid="B237-vaccines-12-01345" ref-type="bibr">237</xref>]. Other developments include ongoing advances in adjuvants and delivery systems that will contribute to boosting vaccine efficacy by enhancing the immune response at smaller doses, thereby facilitating more efficient protection [<xref rid="B238-vaccines-12-01345" ref-type="bibr">238</xref>]. An example in this field is graphene oxide (GO), a water-soluble single-layer carbon that spontaneously adsorbs different antigens. As an adjuvant, GO recruits antigen-presenting cells and induces both cellular and humoral immune responses [<xref rid="B239-vaccines-12-01345" ref-type="bibr">239</xref>,<xref rid="B240-vaccines-12-01345" ref-type="bibr">240</xref>]. Among the next generation of adjuvants, researchers have developed small-molecule immune potentiators as TLR7 agonists and optimized these using aluminum salts (alum) for vaccines. For example, the TLR7-based adjuvant AS37 has been shown to elicit enhanced immunogenicity in animal studies and has now entered clinical evaluation, with results to date indicating a good safety profile and effective immune activation in humans, consistent with earlier findings in non-human primates [<xref rid="B241-vaccines-12-01345" ref-type="bibr">241</xref>,<xref rid="B242-vaccines-12-01345" ref-type="bibr">242</xref>]. As novel delivery methods, nasal vaccines against COVID-19 are now explored in phase 1 trials sponsored by the National Institutes of Health, aiming for higher efficacy and reducing the need for needles, which will predictably contribute to improving compliance with existing vaccines [<xref rid="B243-vaccines-12-01345" ref-type="bibr">243</xref>,<xref rid="B244-vaccines-12-01345" ref-type="bibr">244</xref>]. These innovations not only address current issues but also bolster our preparedness for future pandemics.</p></sec><sec id="sec6-vaccines-12-01345"><title>6. Future Directions and Emerging Strategies</title><p>The future of RNA virus vaccine development is moving toward more comprehensive and adaptable solutions, with the aim of providing broad protection against different viruses or strains of viruses. Among recent developments, Moderna has announced the completion of phase 3 clinical trials for a single vaccine targeting both SARS-CoV-2 and influenzas viruses. Among the different strategies being assessed, the mRNA vaccine platform facilitates rapid development and flexibility in response to changes in the target virus. In addition, Moderna is attempting to incorporate antigens of a third virus, the RSV, into the dual COVID-flu vaccines, and maximize the number of antigen instructions that can be encapsulated within an LNP [<xref rid="B245-vaccines-12-01345" ref-type="bibr">245</xref>]. Moreover, by targeting the conserved regions that remain stable among different mutants, a universal vaccine could provide long-term immunity and reduce the frequency of vaccination. In this regard, the potential application of a nucleoside-modified mRNA-lipid nanoparticle vaccine encoding antigens from 20 known influenza A subtypes and B lineages has been demonstrated. This multivalent vaccine was found to induce strong, cross-reactive, and subtype-specific antibodies in both mice and ferrets, thereby providing protection against a wide range of viral strains [<xref rid="B245-vaccines-12-01345" ref-type="bibr">245</xref>]. These findings accordingly provide compelling evidence to indicate the efficacy of mRNA vaccines in providing broad protection against antigenically diverse viruses, thereby offering a promising basis for future pandemic preparedness.</p><p>The integration of AI into RNA vaccine development represents a transformative advance in the fields of immunology and infectious disease preparedness [<xref rid="B246-vaccines-12-01345" ref-type="bibr">246</xref>,<xref rid="B247-vaccines-12-01345" ref-type="bibr">247</xref>]. AI has the potential to enhance multiple aspects of vaccine design, including the development of personalized vaccines, optimization of vaccine formulations, and prediction of future pandemic viral strains. One application of AI in the development of RNA vaccines is in the production of personalized vaccines. By analyzing an individual&#8217;s genomic data, AI algorithms can identify specific genetic variants that may influence immune responses [<xref rid="B248-vaccines-12-01345" ref-type="bibr">248</xref>,<xref rid="B249-vaccines-12-01345" ref-type="bibr">249</xref>]. In addition, the MIT group has developed a machine learning-based design system, OptiVax, and a validation tool, EvalVax, which can be used to optimize and evaluate peptide vaccine formulations for SARS-CoV-2 [<xref rid="B250-vaccines-12-01345" ref-type="bibr">250</xref>,<xref rid="B251-vaccines-12-01345" ref-type="bibr">251</xref>]. This will contribute to the optimization of personalized vaccines to better complement an individual&#8217;s immune profile, thereby enhancing vaccine efficacy. By addressing factors such original antigenic sin, in which initial immune responses limit adaptability to new variants, and potential autoantigen triggers, personalized vaccines will offer more precise and effective protection. Furthermore, AI tools, such as machine learning and deep learning, will facilitate the design of vaccines against RNA viruses based on antigenic epitope prediction, vaccine candidate identification, and protein folding prediction [<xref rid="B252-vaccines-12-01345" ref-type="bibr">252</xref>,<xref rid="B253-vaccines-12-01345" ref-type="bibr">253</xref>,<xref rid="B254-vaccines-12-01345" ref-type="bibr">254</xref>,<xref rid="B255-vaccines-12-01345" ref-type="bibr">255</xref>]. Among the AI-driven platforms being assessed, Rapidly Adaptive Viral Response utilizes machine learning algorithms to assess different factors, including antigen selection and peptide presentation, thereby ensuring that the developed vaccines induce an effective stimulation of the immune system [<xref rid="B256-vaccines-12-01345" ref-type="bibr">256</xref>,<xref rid="B257-vaccines-12-01345" ref-type="bibr">257</xref>]. The combination of these innovations will improve the efficacy and safety of vaccines, particularly in the context of rapidly evolving pathogens and personalized medicine strategies.</p><p>In addition, the One Health approach highlights the importance of addressing the network of human, animal, and environmental health, recognizing that many RNA viruses have crossed the species barrier [<xref rid="B258-vaccines-12-01345" ref-type="bibr">258</xref>]. Health vaccinology is an emerging field that incorporates the principles of the One Health approach into vaccine development to address the interconnected health of humans, animals, and the environment. Health vaccinology focuses on multispecies vaccination strategies to control zoonotic diseases at their source, thereby preventing the transmission of pathogens from animals to humans [<xref rid="B259-vaccines-12-01345" ref-type="bibr">259</xref>,<xref rid="B260-vaccines-12-01345" ref-type="bibr">260</xref>]. By utilizing advanced tools, such as systems biology and computational models, researchers are enhancing vaccine design and improving the efficacy of vaccines in preventing zoonotic diseases. Notably, this strategy places particular emphasis on the importance of multisectoral collaboration, encompassing veterinary science, human medicine, and environmental monitoring, in addressing the complex dynamics of zoonotic diseases [<xref rid="B193-vaccines-12-01345" ref-type="bibr">193</xref>].</p><p>The development of RNA virus vaccines is advancing through the generation of multivalent mRNA vaccines, AI-driven designs, and the One Health vaccination approach. These innovations have facilitated the development of broad protection against diverse RNA viruses, personalized vaccines, and enhanced zoonotic disease control. Collectively, these advances represent a transformative step toward more effective, adaptable, and durable solutions for pandemic preparedness and future viral threats.</p></sec><sec sec-type="conclusions" id="sec7-vaccines-12-01345"><title>7. Conclusions</title><p>In recent years, significant progress has been made in the development of RNA virus vaccines, driven in particular by the challenges posed by the global COVID-19 pandemic. Different vaccine platforms, coupled with research on immune responses elicited by a viral infection or vaccination, have enabled us to gain a better assessment of vaccine efficacy and safety. Biomedical laboratories and pharmaceutical companies are focusing on developing single vaccines with the capacity to protect against multiple viruses or different strains of the same virus. Furthermore, the integration of AI is revolutionizing vaccine design and offering the prospect of personalized vaccine development and formulation adjustments based on different external factors.</p><p>Using demographic modeling and data from the Vaccine Impact Model Consortium (VIMC) for 110 countries, vaccinations administered between 2021 and 2030 are expected to avert 51.5 million deaths [<xref rid="B261-vaccines-12-01345" ref-type="bibr">261</xref>]. The integration of the One Health approach, which emphasizes the interconnectedness of human, animal, and environmental health, is essential for addressing zoonotic diseases, many of which are caused by RNA viruses. The development of RNA virus vaccines will continue to evolve in the future. With the potential for universal vaccines targeting conserved viral regions and AI tools capable of predicting future viral threats, the future holds considerable promise in providing more comprehensive and long-lasting protection. These advances will transform the global response to emerging and re-emerging RNA viruses, ensuring more rapid, targeted, and effective vaccines for combatting evolving threats.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: K.-C.H. and S.-R.S.; Investigation: K.-C.H., H.-J.C., S.R. and S.-R.S.; Writing&#8212;Original Draft Preparation: K.-C.H., H.-J.C. and S.R.; Writing&#8212;Review and Editing: K.-C.H., H.-J.C., S.R. and S.-R.S.; Visualization: K.-C.H. and H.-J.C.; Supervision: S.-R.S.; project administration: S.-R.S.; Funding acquisition: S.-R.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01345"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Storeygard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gittleman</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Daszak</surname><given-names>P.</given-names></name></person-group><article-title>Global trends in emerging infectious diseases</article-title><source>Nature</source><year>2008</year><volume>451</volume><fpage>990</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1038/nature06536</pub-id><pub-id pub-id-type="pmid">18288193</pub-id><pub-id pub-id-type="pmcid">PMC5960580</pub-id></element-citation></ref><ref id="B2-vaccines-12-01345"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piret</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boivin</surname><given-names>G.</given-names></name></person-group><article-title>Pandemics Throughout History</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><fpage>631736</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.631736</pub-id><pub-id pub-id-type="pmid">33584597</pub-id><pub-id pub-id-type="pmcid">PMC7874133</pub-id></element-citation></ref><ref id="B3-vaccines-12-01345"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berche</surname><given-names>P.</given-names></name></person-group><article-title>History of measles</article-title><source>Presse Med.</source><year>2022</year><volume>51</volume><fpage>104149</fpage><pub-id pub-id-type="doi">10.1016/j.lpm.2022.104149</pub-id><pub-id pub-id-type="pmid">36414136</pub-id></element-citation></ref><ref id="B4-vaccines-12-01345"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brathwaite Dick</surname><given-names>O.</given-names></name><name name-style="western"><surname>San Martin</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>del Diego</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zambrano</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dayan</surname><given-names>G.H.</given-names></name></person-group><article-title>The history of dengue outbreaks in the Americas</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2012</year><volume>87</volume><fpage>584</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2012.11-0770</pub-id><pub-id pub-id-type="pmid">23042846</pub-id><pub-id pub-id-type="pmcid">PMC3516305</pub-id></element-citation></ref><ref id="B5-vaccines-12-01345"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mesle</surname><given-names>M.M.I.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mook</surname><given-names>P.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pastore</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benka</surname><given-names>B.</given-names></name><name name-style="western"><surname>Redlberger-Fritz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stouten</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: A retrospective surveillance study</article-title><source>Lancet Respir. Med.</source><year>2024</year><pub-id pub-id-type="doi">10.1016/S2213-2600(24)00179-6</pub-id><pub-id pub-id-type="pmid">39127051</pub-id></element-citation></ref><ref id="B6-vaccines-12-01345"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolahchi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>De Domenico</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>L.Q.</given-names></name><name name-style="western"><surname>Cauda</surname><given-names>V.</given-names></name><name name-style="western"><surname>Grossmann</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lacasa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grancini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mahmoudi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>N.</given-names></name></person-group><article-title>COVID-19 and Its Global Economic Impact</article-title><source>Adv. Exp. Med. Biol.</source><year>2021</year><volume>1318</volume><fpage>825</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-63761-3_46</pub-id><pub-id pub-id-type="pmid">33973214</pub-id></element-citation></ref><ref id="B7-vaccines-12-01345"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collaborators</surname><given-names>G.B.D.I.</given-names></name></person-group><article-title>Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: An analysis for the Global Burden of Disease Study 2017</article-title><source>Lancet Respir. Med.</source><year>2019</year><volume>7</volume><fpage>69</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(18)30496-X</pub-id><pub-id pub-id-type="pmid">30553848</pub-id><pub-id pub-id-type="pmcid">PMC6302221</pub-id></element-citation></ref><ref id="B8-vaccines-12-01345"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>C.M.C.</given-names></name><name name-style="western"><surname>Plotkin</surname><given-names>S.A.</given-names></name></person-group><article-title>Impact of Vaccines; Health, Economic and Social Perspectives</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><fpage>1526</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.01526</pub-id><pub-id pub-id-type="pmid">32760367</pub-id><pub-id pub-id-type="pmcid">PMC7371956</pub-id></element-citation></ref><ref id="B9-vaccines-12-01345"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norhayati</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Che Yusof</surname><given-names>R.</given-names></name><name name-style="western"><surname>Azman</surname><given-names>Y.M.</given-names></name></person-group><article-title>Systematic Review and Meta-Analysis of COVID-19 Vaccination Acceptance</article-title><source>Front. Med.</source><year>2021</year><volume>8</volume><fpage>783982</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.783982</pub-id><pub-id pub-id-type="pmcid">PMC8828741</pub-id><pub-id pub-id-type="pmid">35155467</pub-id></element-citation></ref><ref id="B10-vaccines-12-01345"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>S.</given-names></name></person-group><article-title>Why are RNA virus mutation rates so damn high?</article-title><source>PLoS Biol.</source><year>2018</year><volume>16</volume><fpage>e3000003</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.3000003</pub-id><pub-id pub-id-type="pmid">30102691</pub-id><pub-id pub-id-type="pmcid">PMC6107253</pub-id></element-citation></ref><ref id="B11-vaccines-12-01345"><label>11.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>W.M.</given-names></name></person-group><article-title>Middle East Respiratory Syndrome Coronavirus (MERS-CoV)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1" ext-link-type="uri">https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-16">(accessed on 16 November 2024)</date-in-citation></element-citation></ref><ref id="B12-vaccines-12-01345"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parums</surname><given-names>D.V.</given-names></name></person-group><article-title>Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection-Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance</article-title><source>Med. Sci. Monit.</source><year>2024</year><volume>30</volume><fpage>e944600</fpage><pub-id pub-id-type="doi">10.12659/MSM.944600</pub-id><pub-id pub-id-type="pmid">38557932</pub-id><pub-id pub-id-type="pmcid">PMC10996429</pub-id></element-citation></ref><ref id="B13-vaccines-12-01345"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shattock</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Sim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lambach</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hutubessy</surname><given-names>R.C.W.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Badizadegan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Contribution of vaccination to improved survival and health: Modelling 50 years of the Expanded Programme on Immunization</article-title><source>Lancet</source><year>2024</year><volume>403</volume><fpage>2307</fpage><lpage>2316</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)00850-X</pub-id><pub-id pub-id-type="pmid">38705159</pub-id><pub-id pub-id-type="pmcid">PMC11140691</pub-id></element-citation></ref><ref id="B14-vaccines-12-01345"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lund</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Alexopoulou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>N.W.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>R.A.</given-names></name></person-group><article-title>Recognition of single-stranded RNA viruses by Toll-like receptor 7</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>5598</fpage><lpage>5603</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400937101</pub-id><pub-id pub-id-type="pmid">15034168</pub-id><pub-id pub-id-type="pmcid">PMC397437</pub-id></element-citation></ref><ref id="B15-vaccines-12-01345"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goubau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Deddouche</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reis e Sousa</surname><given-names>C.</given-names></name></person-group><article-title>Cytosolic sensing of viruses</article-title><source>Immunity</source><year>2013</year><volume>38</volume><fpage>855</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.05.007</pub-id><pub-id pub-id-type="pmid">23706667</pub-id><pub-id pub-id-type="pmcid">PMC7111113</pub-id></element-citation></ref><ref id="B16-vaccines-12-01345"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Kiss-Toth</surname><given-names>E.</given-names></name></person-group><article-title>Regulating STING in health and disease</article-title><source>J. Inflamm.</source><year>2017</year><volume>14</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s12950-017-0159-2</pub-id><pub-id pub-id-type="pmcid">PMC5463399</pub-id><pub-id pub-id-type="pmid">28596706</pub-id></element-citation></ref><ref id="B17-vaccines-12-01345"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>G.</given-names></name></person-group><article-title>The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1124</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01124</pub-id><pub-id pub-id-type="pmid">28955340</pub-id><pub-id pub-id-type="pmcid">PMC5601256</pub-id></element-citation></ref><ref id="B18-vaccines-12-01345"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rozman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zidovec-Lepej</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jambrosic</surname><given-names>K.</given-names></name><name name-style="western"><surname>Babic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Drmic Hofman</surname><given-names>I.</given-names></name></person-group><article-title>Role of TLRs in HIV-1 Infection and Potential of TLR Agonists in HIV-1 Vaccine Development and Treatment Strategies</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>92</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12010092</pub-id><pub-id pub-id-type="pmid">36678440</pub-id><pub-id pub-id-type="pmcid">PMC9866513</pub-id></element-citation></ref><ref id="B19-vaccines-12-01345"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beachboard</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Horner</surname><given-names>S.M.</given-names></name></person-group><article-title>Innate immune evasion strategies of DNA and RNA viruses</article-title><source>Curr. Opin. Microbiol.</source><year>2016</year><volume>32</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2016.05.015</pub-id><pub-id pub-id-type="pmid">27288760</pub-id><pub-id pub-id-type="pmcid">PMC4983539</pub-id></element-citation></ref><ref id="B20-vaccines-12-01345"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yewdell</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.B.</given-names></name></person-group><article-title>Viral interference with antigen presentation</article-title><source>Nat. Immunol.</source><year>2002</year><volume>3</volume><fpage>1019</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1038/ni1102-1019</pub-id><pub-id pub-id-type="pmid">12407410</pub-id></element-citation></ref><ref id="B21-vaccines-12-01345"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melano</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Su</surname><given-names>W.C.</given-names></name></person-group><article-title>Characterization of host substrates of SARS-CoV-2 main protease</article-title><source>Front. Microbiol.</source><year>2023</year><volume>14</volume><fpage>1251705</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2023.1251705</pub-id><pub-id pub-id-type="pmid">37670988</pub-id><pub-id pub-id-type="pmcid">PMC10475589</pub-id></element-citation></ref><ref id="B22-vaccines-12-01345"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubio-Casillas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Redwan</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Uversky</surname><given-names>V.N.</given-names></name></person-group><article-title>SARS-CoV-2: A Master of Immune Evasion</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>1339</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10061339</pub-id><pub-id pub-id-type="pmid">35740361</pub-id><pub-id pub-id-type="pmcid">PMC9220273</pub-id></element-citation></ref><ref id="B23-vaccines-12-01345"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Quinones-Parra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Loh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>6833</fpage><pub-id pub-id-type="doi">10.1038/ncomms7833</pub-id><pub-id pub-id-type="pmid">25967273</pub-id><pub-id pub-id-type="pmcid">PMC4479016</pub-id></element-citation></ref><ref id="B24-vaccines-12-01345"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.H.</given-names></name></person-group><article-title>Immune responses and immunopathology in acute and chronic viral hepatitis</article-title><source>Nat. Rev. Immunol.</source><year>2016</year><volume>16</volume><fpage>509</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.69</pub-id><pub-id pub-id-type="pmid">27374637</pub-id></element-citation></ref><ref id="B25-vaccines-12-01345"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Callendret</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brasky</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Guedj</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perelson</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Lemon</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lanford</surname><given-names>R.E.</given-names></name><etal/></person-group><article-title>Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection</article-title><source>J. Exp. Med.</source><year>2012</year><volume>209</volume><fpage>1481</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1084/jem.20111906</pub-id><pub-id pub-id-type="pmid">22753925</pub-id><pub-id pub-id-type="pmcid">PMC3409494</pub-id></element-citation></ref><ref id="B26-vaccines-12-01345"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Linster</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Le Bert</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Kunasegaran</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tham</surname><given-names>C.Y.L.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.J.D.</given-names></name><etal/></person-group><article-title>Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients</article-title><source>Cell Rep.</source><year>2021</year><volume>34</volume><fpage>108728</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108728</pub-id><pub-id pub-id-type="pmid">33516277</pub-id><pub-id pub-id-type="pmcid">PMC7826084</pub-id></element-citation></ref><ref id="B27-vaccines-12-01345"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattoo</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Myoung</surname><given-names>J.</given-names></name></person-group><article-title>T cell responses to SARS-CoV-2 in humans and animals</article-title><source>J. Microbiol.</source><year>2022</year><volume>60</volume><fpage>276</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1007/s12275-022-1624-z</pub-id><pub-id pub-id-type="pmid">35157219</pub-id><pub-id pub-id-type="pmcid">PMC8852923</pub-id></element-citation></ref><ref id="B28-vaccines-12-01345"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Openshaw</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>C.</given-names></name></person-group><article-title>Protective and dysregulated T cell immunity in RSV infection</article-title><source>Curr. Opin. Virol.</source><year>2013</year><volume>3</volume><fpage>468</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2013.05.005</pub-id><pub-id pub-id-type="pmid">23806514</pub-id><pub-id pub-id-type="pmcid">PMC4295022</pub-id></element-citation></ref><ref id="B29-vaccines-12-01345"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St John</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Rathore</surname><given-names>A.P.S.</given-names></name></person-group><article-title>Adaptive immune responses to primary and secondary dengue virus infections</article-title><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><fpage>218</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0123-x</pub-id><pub-id pub-id-type="pmid">30679808</pub-id></element-citation></ref><ref id="B30-vaccines-12-01345"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wijeratne</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Fernando</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jeewandara</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ginneliya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Samarasekara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wijewickrama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hardman</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Ogg</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Malavige</surname><given-names>G.N.</given-names></name></person-group><article-title>Quantification of dengue virus specific T cell responses and correlation with viral load and clinical disease severity in acute dengue infection</article-title><source>PLoS Negl. Trop. Dis.</source><year>2018</year><volume>12</volume><fpage>e0006540</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0006540</pub-id><pub-id pub-id-type="pmid">30273352</pub-id><pub-id pub-id-type="pmcid">PMC6181435</pub-id></element-citation></ref><ref id="B31-vaccines-12-01345"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Roman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Swain</surname><given-names>S.L.</given-names></name></person-group><article-title>CD4 T cell responses to influenza infection</article-title><source>Semin. Immunol.</source><year>2004</year><volume>16</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2004.02.004</pub-id><pub-id pub-id-type="pmid">15130501</pub-id></element-citation></ref><ref id="B32-vaccines-12-01345"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>Z.T.</given-names></name><name name-style="western"><surname>Wrammert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Richardus</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: A six-year follow-up study</article-title><source>J. Immunol.</source><year>2011</year><volume>186</volume><fpage>7264</fpage><lpage>7268</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903490</pub-id><pub-id pub-id-type="pmid">21576510</pub-id></element-citation></ref><ref id="B33-vaccines-12-01345"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shamier</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Bogers</surname><given-names>S.</given-names></name><name name-style="western"><surname>den Hartog</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gommers</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nieuwkoop</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Rijsbergen</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>van Osch</surname><given-names>J.A.T.</given-names></name><name name-style="western"><surname>Dijkhuizen</surname><given-names>E.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees</article-title><source>Sci. Immunol.</source><year>2021</year><volume>6</volume><fpage>eabj1750</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abj1750</pub-id><pub-id pub-id-type="pmid">34035118</pub-id><pub-id pub-id-type="pmcid">PMC9268159</pub-id></element-citation></ref><ref id="B34-vaccines-12-01345"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages</article-title><source>Emerg. Microbes Infect.</source><year>2023</year><volume>12</volume><fpage>2202263</fpage><pub-id pub-id-type="doi">10.1080/22221751.2023.2202263</pub-id><pub-id pub-id-type="pmid">37037791</pub-id><pub-id pub-id-type="pmcid">PMC10155635</pub-id></element-citation></ref><ref id="B35-vaccines-12-01345"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keeton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tincho</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Ngomti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baguma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benede</surname><given-names>N.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cele</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karim</surname><given-names>F.</given-names></name><etal/></person-group><article-title>T cell responses to SARS-CoV-2 spike cross-recognize Omicron</article-title><source>Nature</source><year>2022</year><volume>603</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04460-3</pub-id><pub-id pub-id-type="pmid">35102311</pub-id><pub-id pub-id-type="pmcid">PMC8930768</pub-id></element-citation></ref><ref id="B36-vaccines-12-01345"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elong Ngono</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Joo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>King</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shresta</surname><given-names>S.</given-names></name></person-group><article-title>Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection</article-title><source>EBioMedicine</source><year>2016</year><volume>13</volume><fpage>284</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.10.006</pub-id><pub-id pub-id-type="pmid">27746192</pub-id><pub-id pub-id-type="pmcid">PMC5264312</pub-id></element-citation></ref><ref id="B37-vaccines-12-01345"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flynn</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Belz</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name><name name-style="western"><surname>Woodland</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>P.C.</given-names></name></person-group><article-title>Virus-specific CD8+ T cells in primary and secondary influenza pneumonia</article-title><source>Immunity</source><year>1998</year><volume>8</volume><fpage>683</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80573-7</pub-id><pub-id pub-id-type="pmid">9655482</pub-id></element-citation></ref><ref id="B38-vaccines-12-01345"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.T.</given-names></name></person-group><article-title>An IL-17-EGFR-TRAF4 axis contributes to the alleviation of lung inflammation in severe influenza</article-title><source>Commun. Biol.</source><year>2023</year><volume>6</volume><fpage>600</fpage><pub-id pub-id-type="doi">10.1038/s42003-023-04982-0</pub-id><pub-id pub-id-type="pmid">37270623</pub-id><pub-id pub-id-type="pmcid">PMC10239044</pub-id></element-citation></ref><ref id="B39-vaccines-12-01345"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trandem</surname><given-names>K.</given-names></name><name name-style="western"><surname>Anghelina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Regulatory T cells inhibit T cell proliferation and decrease demyelination in mice chronically infected with a coronavirus</article-title><source>J. Immunol.</source><year>2010</year><volume>184</volume><fpage>4391</fpage><lpage>4400</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903918</pub-id><pub-id pub-id-type="pmid">20208000</pub-id><pub-id pub-id-type="pmcid">PMC2851486</pub-id></element-citation></ref><ref id="B40-vaccines-12-01345"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>C.I.E.</given-names></name><name name-style="western"><surname>Berglof</surname><given-names>A.</given-names></name></person-group><article-title>X-Linked Agammaglobulinemia</article-title><source>GeneReviews<sup>&#174;</sup></source><person-group person-group-type="editor"><name name-style="western"><surname>Adam</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mirzaa</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Pagon</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Bean</surname><given-names>L.J.H.</given-names></name><name name-style="western"><surname>Gripp</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Amemiya</surname><given-names>A.</given-names></name></person-group><publisher-name>University of Washington</publisher-name><publisher-loc>Seattle, WA, USA</publisher-loc><year>1993</year><pub-id pub-id-type="pmid">20301626</pub-id></element-citation></ref><ref id="B41-vaccines-12-01345"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Post</surname><given-names>N.</given-names></name><name name-style="western"><surname>Eddy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Schalkwyk</surname><given-names>M.C.I.</given-names></name><name name-style="western"><surname>Shrotri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leeman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rigby</surname><given-names>S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Bermingham</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Kellam</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Antibody response to SARS-CoV-2 infection in humans: A systematic review</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><fpage>e0244126</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0244126</pub-id><pub-id pub-id-type="pmid">33382764</pub-id><pub-id pub-id-type="pmcid">PMC7775097</pub-id></element-citation></ref><ref id="B42-vaccines-12-01345"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Efficacy of convalescent plasma for the treatment of severe influenza</article-title><source>Crit. Care</source><year>2020</year><volume>24</volume><fpage>469</fpage><pub-id pub-id-type="doi">10.1186/s13054-020-03189-7</pub-id><pub-id pub-id-type="pmid">32727526</pub-id><pub-id pub-id-type="pmcid">PMC7388480</pub-id></element-citation></ref><ref id="B43-vaccines-12-01345"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>S.R.</given-names></name></person-group><article-title>Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies</article-title><source>Biomed. J.</source><year>2024</year><volume>47</volume><fpage>100666</fpage><pub-id pub-id-type="doi">10.1016/j.bj.2023.100666</pub-id><pub-id pub-id-type="pmid">37778697</pub-id><pub-id pub-id-type="pmcid">PMC10825350</pub-id></element-citation></ref><ref id="B44-vaccines-12-01345"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baccam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Beauchemin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Macken</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Perelson</surname><given-names>A.S.</given-names></name></person-group><article-title>Kinetics of influenza A virus infection in humans</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>7590</fpage><lpage>7599</lpage><pub-id pub-id-type="doi">10.1128/JVI.01623-05</pub-id><pub-id pub-id-type="pmid">16840338</pub-id><pub-id pub-id-type="pmcid">PMC1563736</pub-id></element-citation></ref><ref id="B45-vaccines-12-01345"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Killingley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Kalinova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boyers</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goonawardane</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lindsell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hare</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frise</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1031</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01780-9</pub-id><pub-id pub-id-type="pmid">35361992</pub-id></element-citation></ref><ref id="B46-vaccines-12-01345"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tricou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Minh</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>C.P.</given-names></name></person-group><article-title>Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue</article-title><source>PLoS Negl. Trop. Dis.</source><year>2011</year><volume>5</volume><fpage>e1309</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0001309</pub-id><pub-id pub-id-type="pmid">21909448</pub-id><pub-id pub-id-type="pmcid">PMC3167785</pub-id></element-citation></ref><ref id="B47-vaccines-12-01345"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bournazos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vo</surname><given-names>H.T.M.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>V.</given-names></name><name name-style="western"><surname>Auerswald</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sakuntabhai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dussart</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cantaert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Antibody fucosylation predicts disease severity in secondary dengue infection</article-title><source>Science</source><year>2021</year><volume>372</volume><fpage>1102</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1126/science.abc7303</pub-id><pub-id pub-id-type="pmid">34083490</pub-id><pub-id pub-id-type="pmcid">PMC8262508</pub-id></element-citation></ref><ref id="B48-vaccines-12-01345"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Cantaert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ravetch</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Bournazos</surname><given-names>S.</given-names></name></person-group><article-title>Human FcgammaRIIIa activation on splenic macrophages drives dengue pathogenesis in mice</article-title><source>Nat. Microbiol.</source><year>2023</year><volume>8</volume><fpage>1468</fpage><lpage>1479</lpage><pub-id pub-id-type="doi">10.1038/s41564-023-01421-y</pub-id><pub-id pub-id-type="pmid">37429907</pub-id><pub-id pub-id-type="pmcid">PMC10753935</pub-id></element-citation></ref><ref id="B49-vaccines-12-01345"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Yamin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oren</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Goldgur</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lollar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sundberg</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>2853</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-38453-1</pub-id><pub-id pub-id-type="pmid">37202422</pub-id><pub-id pub-id-type="pmcid">PMC10195009</pub-id></element-citation></ref><ref id="B50-vaccines-12-01345"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martins</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Jurberg</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Daniel-Ribeiro</surname><given-names>C.T.</given-names></name></person-group><article-title>Visiting Molecular Mimicry Once More: Pathogenicity, Virulence, and Autoimmunity</article-title><source>Microorganisms</source><year>2023</year><volume>11</volume><elocation-id>1472</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms11061472</pub-id><pub-id pub-id-type="pmid">37374974</pub-id><pub-id pub-id-type="pmcid">PMC10301193</pub-id></element-citation></ref><ref id="B51-vaccines-12-01345"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>9318</fpage><lpage>9325</lpage><pub-id pub-id-type="doi">10.1128/JVI.01049-10</pub-id><pub-id pub-id-type="pmid">20610717</pub-id><pub-id pub-id-type="pmcid">PMC2937604</pub-id></element-citation></ref><ref id="B52-vaccines-12-01345"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padron-Regalado</surname><given-names>E.</given-names></name></person-group><article-title>Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains</article-title><source>Infect. Dis. Ther.</source><year>2020</year><volume>9</volume><fpage>255</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1007/s40121-020-00300-x</pub-id><pub-id pub-id-type="pmid">32328406</pub-id><pub-id pub-id-type="pmcid">PMC7177048</pub-id></element-citation></ref><ref id="B53-vaccines-12-01345"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boettler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Csernalabics</surname><given-names>B.</given-names></name><name name-style="western"><surname>Salie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luxenburger</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wischer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Salimi Alizei</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zoldan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krimmel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bronsert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schwabenland</surname><given-names>M.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis</article-title><source>J. Hepatol.</source><year>2022</year><volume>77</volume><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2022.03.040</pub-id><pub-id pub-id-type="pmid">35461912</pub-id><pub-id pub-id-type="pmcid">PMC9021033</pub-id></element-citation></ref><ref id="B54-vaccines-12-01345"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barmada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ramaswamy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brodsky</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Jaycox</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Sheikha</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Habet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sumida</surname><given-names>T.S.</given-names></name><etal/></person-group><article-title>Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis</article-title><source>Sci. Immunol.</source><year>2023</year><volume>8</volume><fpage>eadh3455</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.adh3455</pub-id><pub-id pub-id-type="pmid">37146127</pub-id><pub-id pub-id-type="pmcid">PMC10468758</pub-id></element-citation></ref><ref id="B55-vaccines-12-01345"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalfaoglu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Almeida-Santos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tye</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Satou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ono</surname><given-names>M.</given-names></name></person-group><article-title>T-cell dysregulation in COVID-19</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2021</year><volume>538</volume><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.10.079</pub-id><pub-id pub-id-type="pmid">33220925</pub-id><pub-id pub-id-type="pmcid">PMC7648511</pub-id></element-citation></ref><ref id="B56-vaccines-12-01345"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.R.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Q.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.X.</given-names></name><etal/></person-group><article-title>Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: A systematic review and meta-analysis of randomised controlled trials</article-title><source>Lancet Microbe</source><year>2023</year><volume>4</volume><fpage>e236</fpage><lpage>e246</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(22)00390-1</pub-id><pub-id pub-id-type="pmid">36868258</pub-id><pub-id pub-id-type="pmcid">PMC9974155</pub-id></element-citation></ref><ref id="B57-vaccines-12-01345"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name></person-group><article-title>Correlates of protection to influenza virus, where do we go from here?</article-title><source>Hum. Vaccines Immunother.</source><year>2013</year><volume>9</volume><fpage>405</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.4161/hv.22908</pub-id><pub-id pub-id-type="pmid">23291930</pub-id><pub-id pub-id-type="pmcid">PMC3859764</pub-id></element-citation></ref><ref id="B58-vaccines-12-01345"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.M.</given-names></name></person-group><article-title>Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines</article-title><source>Immune Netw.</source><year>2015</year><volume>15</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.4110/in.2015.15.5.213</pub-id><pub-id pub-id-type="pmid">26557805</pub-id><pub-id pub-id-type="pmcid">PMC4637342</pub-id></element-citation></ref><ref id="B59-vaccines-12-01345"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jegaskanda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vanderven</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Kent</surname><given-names>S.J.</given-names></name></person-group><article-title>Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design</article-title><source>Hum. Vaccines Immunother.</source><year>2017</year><volume>13</volume><fpage>1288</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1290018</pub-id><pub-id pub-id-type="pmid">28332900</pub-id><pub-id pub-id-type="pmcid">PMC5489290</pub-id></element-citation></ref><ref id="B60-vaccines-12-01345"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boudreau</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G.</given-names></name></person-group><article-title>Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>440</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00440</pub-id><pub-id pub-id-type="pmid">30949165</pub-id><pub-id pub-id-type="pmcid">PMC6436086</pub-id></element-citation></ref><ref id="B61-vaccines-12-01345"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>P.A.</given-names></name></person-group><article-title>Infections of people with complement deficiencies and patients who have undergone splenectomy</article-title><source>Clin. Microbiol. Rev.</source><year>2010</year><volume>23</volume><fpage>740</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1128/CMR.00048-09</pub-id><pub-id pub-id-type="pmid">20930072</pub-id><pub-id pub-id-type="pmcid">PMC2952982</pub-id></element-citation></ref><ref id="B62-vaccines-12-01345"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ravetch</surname><given-names>J.V.</given-names></name><etal/></person-group><article-title>Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy</article-title><source>Nature</source><year>2021</year><volume>599</volume><fpage>465</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04017-w</pub-id><pub-id pub-id-type="pmid">34547765</pub-id><pub-id pub-id-type="pmcid">PMC9038156</pub-id></element-citation></ref><ref id="B63-vaccines-12-01345"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackin</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Whitener</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Karl</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Chicz</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>McNamara</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Fc-gammaR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2</article-title><source>Nat. Microbiol.</source><year>2023</year><volume>8</volume><fpage>569</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1038/s41564-023-01359-1</pub-id><pub-id pub-id-type="pmid">37012355</pub-id><pub-id pub-id-type="pmcid">PMC10797606</pub-id></element-citation></ref><ref id="B64-vaccines-12-01345"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name></person-group><article-title>Epigenetic regulation of the innate immune response to infection</article-title><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><fpage>417</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0151-6</pub-id><pub-id pub-id-type="pmid">30918351</pub-id></element-citation></ref><ref id="B65-vaccines-12-01345"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benn</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Selin</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Aaby</surname><given-names>P.</given-names></name></person-group><article-title>A small jab&#8212;A big effect: Nonspecific immunomodulation by vaccines</article-title><source>Trends Immunol.</source><year>2013</year><volume>34</volume><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.it.2013.04.004</pub-id><pub-id pub-id-type="pmid">23680130</pub-id></element-citation></ref><ref id="B66-vaccines-12-01345"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villa</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Abril</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Miguel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sanchez-Perez</surname><given-names>A.</given-names></name></person-group><article-title>Animal and human RNA viruses: Genetic variability and ability to overcome vaccines</article-title><source>Arch. Microbiol.</source><year>2021</year><volume>203</volume><fpage>443</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1007/s00203-020-02040-5</pub-id><pub-id pub-id-type="pmid">32989475</pub-id><pub-id pub-id-type="pmcid">PMC7521576</pub-id></element-citation></ref><ref id="B67-vaccines-12-01345"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Riel</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name></person-group><article-title>Next-generation vaccine platforms for COVID-19</article-title><source>Nat. Mater.</source><year>2020</year><volume>19</volume><fpage>810</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/s41563-020-0746-0</pub-id><pub-id pub-id-type="pmid">32704139</pub-id></element-citation></ref><ref id="B68-vaccines-12-01345"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jafari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Danesh Pouya</surname><given-names>F.</given-names></name><name name-style="western"><surname>Niknam</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Abdollahpour-Alitappeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rezaei-Tavirani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rasmi</surname><given-names>Y.</given-names></name></person-group><article-title>Current advances and challenges in COVID-19 vaccine development: From conventional vaccines to next-generation vaccine platforms</article-title><source>Mol. Biol. Rep.</source><year>2022</year><volume>49</volume><fpage>4943</fpage><lpage>4957</lpage><pub-id pub-id-type="doi">10.1007/s11033-022-07132-7</pub-id><pub-id pub-id-type="pmid">35235159</pub-id><pub-id pub-id-type="pmcid">PMC8890022</pub-id></element-citation></ref><ref id="B69-vaccines-12-01345"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peletta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lemoine</surname><given-names>C.</given-names></name><name name-style="western"><surname>Courant</surname><given-names>T.</given-names></name><name name-style="western"><surname>Collin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Borchard</surname><given-names>G.</given-names></name></person-group><article-title>Meeting vaccine formulation challenges in an emergency setting: Towards the development of accessible vaccines</article-title><source>Pharmacol. Res.</source><year>2023</year><volume>189</volume><fpage>106699</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2023.106699</pub-id><pub-id pub-id-type="pmid">36796463</pub-id></element-citation></ref><ref id="B70-vaccines-12-01345"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>C.S.</given-names></name></person-group><article-title>Endogenous Antigen Presentation of MHC Class II Epitopes through Non-Autophagic Pathways</article-title><source>Front. Immunol.</source><year>2015</year><volume>6</volume><fpage>464</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2015.00464</pub-id><pub-id pub-id-type="pmid">26441969</pub-id><pub-id pub-id-type="pmcid">PMC4563256</pub-id></element-citation></ref><ref id="B71-vaccines-12-01345"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhulipala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uversky</surname><given-names>V.N.</given-names></name></person-group><article-title>Looking at the Pathogenesis of the Rabies Lyssavirus Strain Pasteur Vaccins through a Prism of the Disorder-Based Bioinformatics</article-title><source>Biomolecules</source><year>2022</year><volume>12</volume><elocation-id>1436</elocation-id><pub-id pub-id-type="doi">10.3390/biom12101436</pub-id><pub-id pub-id-type="pmid">36291645</pub-id><pub-id pub-id-type="pmcid">PMC9599798</pub-id></element-citation></ref><ref id="B72-vaccines-12-01345"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elveborg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Monteil</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Mirazimi</surname><given-names>A.</given-names></name></person-group><article-title>Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes</article-title><source>Pathogens</source><year>2022</year><volume>11</volume><elocation-id>271</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11020271</pub-id><pub-id pub-id-type="pmid">35215213</pub-id><pub-id pub-id-type="pmcid">PMC8879476</pub-id></element-citation></ref><ref id="B73-vaccines-12-01345"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Budimir</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huckriede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meijerhof</surname><given-names>T.</given-names></name><name name-style="western"><surname>Boon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gostick</surname><given-names>E.</given-names></name><name name-style="western"><surname>Price</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Haan</surname><given-names>A.</given-names></name></person-group><article-title>Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: The role of viral membrane fusion activity</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e30898</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0030898</pub-id><pub-id pub-id-type="pmid">22303469</pub-id><pub-id pub-id-type="pmcid">PMC3267744</pub-id></element-citation></ref><ref id="B74-vaccines-12-01345"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A recombinant rabies virus chimera expressing the DC-targeting molecular MAB2560 shows enhanced vaccine immunogenicity through activation of dendritic cells</article-title><source>PLoS Negl. Trop. Dis.</source><year>2023</year><volume>17</volume><fpage>e0011254</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0011254</pub-id><pub-id pub-id-type="pmid">37093869</pub-id><pub-id pub-id-type="pmcid">PMC10124880</pub-id></element-citation></ref><ref id="B75-vaccines-12-01345"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tighe</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Lanthier</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Travis</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Low-Beer</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Lanzer</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Bernacki</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Szaba</surname><given-names>F.M.</given-names></name><etal/></person-group><article-title>Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets</article-title><source>NPJ Vaccines</source><year>2024</year><volume>9</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-00824-0</pub-id><pub-id pub-id-type="pmid">38368443</pub-id><pub-id pub-id-type="pmcid">PMC10874403</pub-id></element-citation></ref><ref id="B76-vaccines-12-01345"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ella</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sarangi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ganneru</surname><given-names>B.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Das</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raju</surname><given-names>D.</given-names></name><name name-style="western"><surname>Praturi</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sapkal</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>950</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00070-0</pub-id><pub-id pub-id-type="pmid">33705727</pub-id><pub-id pub-id-type="pmcid">PMC8221739</pub-id></element-citation></ref><ref id="B77-vaccines-12-01345"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simmons</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Putnak</surname><given-names>R.</given-names></name></person-group><article-title>Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><fpage>e0152811</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0152811</pub-id><pub-id pub-id-type="pmid">27035715</pub-id><pub-id pub-id-type="pmcid">PMC4818016</pub-id></element-citation></ref><ref id="B78-vaccines-12-01345"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bemben</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>M.L.</given-names></name></person-group><article-title>Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy</article-title><source>Pharmacotherapy</source><year>2022</year><volume>42</volume><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1002/phar.2671</pub-id><pub-id pub-id-type="pmid">35146780</pub-id><pub-id pub-id-type="pmcid">PMC9088666</pub-id></element-citation></ref><ref id="B79-vaccines-12-01345"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mapletoft</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vahedi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chew</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szewczyk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jahanshahi-Anbuhi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cowbrough</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Thermal Stabilization of Viral Vaccines in Low-Cost Sugar Films</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>7631</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-44020-w</pub-id><pub-id pub-id-type="pmid">31113974</pub-id><pub-id pub-id-type="pmcid">PMC6529427</pub-id></element-citation></ref><ref id="B80-vaccines-12-01345"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganneru</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H.</given-names></name><name name-style="western"><surname>Daram</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Das</surname><given-names>D.</given-names></name><name name-style="western"><surname>Molugu</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Kannappa</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Ella</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Ravikrishnan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Awasthi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation</article-title><source>iScience</source><year>2021</year><volume>24</volume><fpage>102298</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2021.102298</pub-id><pub-id pub-id-type="pmid">33723528</pub-id><pub-id pub-id-type="pmcid">PMC7944858</pub-id></element-citation></ref><ref id="B81-vaccines-12-01345"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages</article-title><source>J. Clin. Med.</source><year>2022</year><volume>12</volume><elocation-id>146</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12010146</pub-id><pub-id pub-id-type="pmid">36614948</pub-id><pub-id pub-id-type="pmcid">PMC9821285</pub-id></element-citation></ref><ref id="B82-vaccines-12-01345"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mellis</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Valdez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gherasim</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>D.D.</given-names></name></person-group><article-title>XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1</article-title><source>Cell Host Microbe</source><year>2024</year><volume>32</volume><fpage>315</fpage><lpage>321.e3</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2024.01.014</pub-id><pub-id pub-id-type="pmid">38377995</pub-id><pub-id pub-id-type="pmcid">PMC10948033</pub-id></element-citation></ref><ref id="B83-vaccines-12-01345"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>Advances in the development of influenza virus vaccines</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>167</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/nrd4529</pub-id><pub-id pub-id-type="pmid">25722244</pub-id></element-citation></ref><ref id="B84-vaccines-12-01345"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bhide</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sicca</surname><given-names>F.</given-names></name><name name-style="western"><surname>Meijerhof</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guilfoyle</surname><given-names>K.</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Boon</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Haan</surname><given-names>C.A.M.</given-names></name><name name-style="western"><surname>Carnell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Temperton</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2312</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02312</pub-id><pub-id pub-id-type="pmid">30356772</pub-id><pub-id pub-id-type="pmcid">PMC6189474</pub-id></element-citation></ref><ref id="B85-vaccines-12-01345"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dill</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eschbaumer</surname><given-names>M.</given-names></name></person-group><article-title>Influence of cell type and cell culture media on the propagation of foot-and-mouth disease virus with regard to vaccine quality</article-title><source>Virol. J.</source><year>2018</year><volume>15</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/s12985-018-0956-0</pub-id><pub-id pub-id-type="pmid">29548334</pub-id><pub-id pub-id-type="pmcid">PMC5857075</pub-id></element-citation></ref><ref id="B86-vaccines-12-01345"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendes</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pineda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kudugunti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bransby</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gantier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peixoto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Roldao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>R.J.S.</given-names></name></person-group><article-title>AAV process intensification by perfusion bioreaction and integrated clarification</article-title><source>Front. Bioeng. Biotechnol.</source><year>2022</year><volume>10</volume><fpage>1020174</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2022.1020174</pub-id><pub-id pub-id-type="pmid">36420444</pub-id><pub-id pub-id-type="pmcid">PMC9676353</pub-id></element-citation></ref><ref id="B87-vaccines-12-01345"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amanna</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Raue</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Slifka</surname><given-names>M.K.</given-names></name></person-group><article-title>Development of a new hydrogen peroxide-based vaccine platform</article-title><source>Nat. Med.</source><year>2012</year><volume>18</volume><fpage>974</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1038/nm.2763</pub-id><pub-id pub-id-type="pmid">22635006</pub-id><pub-id pub-id-type="pmcid">PMC3506259</pub-id></element-citation></ref><ref id="B88-vaccines-12-01345"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Storm</surname><given-names>N.</given-names></name><name name-style="western"><surname>McKay</surname><given-names>L.G.A.</given-names></name><name name-style="western"><surname>Downs</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Birru</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Samber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Willaert</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cennini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>A.</given-names></name></person-group><article-title>Rapid and complete inactivation of SARS-CoV-2 by ultraviolet-C irradiation</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>22421</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-79600-8</pub-id><pub-id pub-id-type="pmid">33380727</pub-id><pub-id pub-id-type="pmcid">PMC7773738</pub-id></element-citation></ref><ref id="B89-vaccines-12-01345"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>C.X.</given-names></name></person-group><article-title>Viral inactivation by irradiation rays</article-title><source>Light Sci. Appl.</source><year>2023</year><volume>12</volume><fpage>72</fpage><pub-id pub-id-type="doi">10.1038/s41377-023-01108-3</pub-id><pub-id pub-id-type="pmid">36918547</pub-id><pub-id pub-id-type="pmcid">PMC10011759</pub-id></element-citation></ref><ref id="B90-vaccines-12-01345"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name></person-group><article-title>Emerging concepts in the science of vaccine adjuvants</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>454</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></element-citation></ref><ref id="B91-vaccines-12-01345"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mallajosyula</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Constantz</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2</article-title><source>Nat. Mater.</source><year>2023</year><volume>22</volume><fpage>380</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1038/s41563-022-01464-2</pub-id><pub-id pub-id-type="pmid">36717665</pub-id><pub-id pub-id-type="pmcid">PMC9981462</pub-id></element-citation></ref><ref id="B92-vaccines-12-01345"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theiler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>H.H.</given-names></name></person-group><article-title>The Use of Yellow Fever Virus Modified by in Vitro Cultivation for Human Immunization</article-title><source>J. Exp. Med.</source><year>1937</year><volume>65</volume><fpage>787</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1084/jem.65.6.787</pub-id><pub-id pub-id-type="pmid">19870634</pub-id><pub-id pub-id-type="pmcid">PMC2133527</pub-id></element-citation></ref><ref id="B93-vaccines-12-01345"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanley</surname><given-names>K.A.</given-names></name></person-group><article-title>The double-edged sword: How evolution can make or break a live-attenuated virus vaccine</article-title><source>Evolution</source><year>2011</year><volume>4</volume><fpage>635</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1007/s12052-011-0365-y</pub-id><pub-id pub-id-type="pmid">22468165</pub-id><pub-id pub-id-type="pmcid">PMC3314307</pub-id></element-citation></ref><ref id="B94-vaccines-12-01345"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira-Gomez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carrau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fajardo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moratorio</surname><given-names>G.</given-names></name></person-group><article-title>Altering Compositional Properties of Viral Genomes to Design Live-Attenuated Vaccines</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><fpage>676582</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2021.676582</pub-id><pub-id pub-id-type="pmid">34276608</pub-id><pub-id pub-id-type="pmcid">PMC8278477</pub-id></element-citation></ref><ref id="B95-vaccines-12-01345"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reedy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nogales</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murcia</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name></person-group><article-title>Development of a novel equine influenza virus live-attenuated vaccine</article-title><source>Virology</source><year>2018</year><volume>516</volume><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2018.01.005</pub-id><pub-id pub-id-type="pmid">29331866</pub-id><pub-id pub-id-type="pmcid">PMC5840510</pub-id></element-citation></ref><ref id="B96-vaccines-12-01345"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voigt</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Fuerte-Stone</surname><given-names>J.</given-names></name><name name-style="western"><surname>Granger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Hoeven</surname><given-names>N.</given-names></name></person-group><article-title>Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus</article-title><source>Mol. Ther.</source><year>2021</year><volume>29</volume><fpage>2782</fpage><lpage>2793</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.05.018</pub-id><pub-id pub-id-type="pmid">34058388</pub-id><pub-id pub-id-type="pmcid">PMC8417506</pub-id></element-citation></ref><ref id="B97-vaccines-12-01345"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Si</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Generation of a live attenuated influenza A vaccine by proteolysis targeting</article-title><source>Nat. Biotechnol.</source><year>2022</year><volume>40</volume><fpage>1370</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1038/s41587-022-01381-4</pub-id><pub-id pub-id-type="pmid">35788567</pub-id></element-citation></ref><ref id="B98-vaccines-12-01345"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kallas</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Cintra</surname><given-names>M.A.T.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Patino</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Braga</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Tenorio</surname><given-names>J.C.V.</given-names></name><name name-style="western"><surname>Infante</surname><given-names>V.</given-names></name><name name-style="western"><surname>Palacios</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Lacerda</surname><given-names>M.V.G.</given-names></name><name name-style="western"><surname>Batista Pereira</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults</article-title><source>N. Engl. J. Med.</source><year>2024</year><volume>390</volume><fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2301790</pub-id><pub-id pub-id-type="pmid">38294972</pub-id></element-citation></ref><ref id="B99-vaccines-12-01345"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohn</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sjursen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name></person-group><article-title>Immune responses after live attenuated influenza vaccination</article-title><source>Hum. Vaccines Immunother.</source><year>2018</year><volume>14</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1377376</pub-id><pub-id pub-id-type="pmid">28933664</pub-id><pub-id pub-id-type="pmcid">PMC5861782</pub-id></element-citation></ref><ref id="B100-vaccines-12-01345"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnyder</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Bache</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Schaumburg</surname><given-names>F.</given-names></name><name name-style="western"><surname>Grobusch</surname><given-names>M.P.</given-names></name></person-group><article-title>Long-term immunity following yellow fever vaccination: A systematic review and meta-analysis</article-title><source>Lancet Glob. Health</source><year>2024</year><volume>12</volume><fpage>e445</fpage><lpage>e456</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(23)00556-9</pub-id><pub-id pub-id-type="pmid">38272044</pub-id></element-citation></ref><ref id="B101-vaccines-12-01345"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoft</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Babusis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Worku</surname><given-names>S.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Lottenbach</surname><given-names>K.</given-names></name><name name-style="western"><surname>Truscott</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Abate</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sakala</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Creech</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>204</volume><fpage>845</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir436</pub-id><pub-id pub-id-type="pmid">21846636</pub-id><pub-id pub-id-type="pmcid">PMC3156924</pub-id></element-citation></ref><ref id="B102-vaccines-12-01345"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thorley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Paladin</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Brussen</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Stambos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Utama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>13512</fpage><lpage>13521</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.24.13512-13521.2004</pub-id><pub-id pub-id-type="pmid">15564462</pub-id><pub-id pub-id-type="pmcid">PMC533948</pub-id></element-citation></ref><ref id="B103-vaccines-12-01345"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poyhonen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bustamante</surname><given-names>J.</given-names></name><name name-style="western"><surname>Casanova</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Jouanguy</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name></person-group><article-title>Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity</article-title><source>J. Clin. Immunol.</source><year>2019</year><volume>39</volume><fpage>376</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/s10875-019-00642-3</pub-id><pub-id pub-id-type="pmid">31123910</pub-id><pub-id pub-id-type="pmcid">PMC7192346</pub-id></element-citation></ref><ref id="B104-vaccines-12-01345"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobby</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Danzy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Lowen</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Kohlmeier</surname><given-names>J.E.</given-names></name></person-group><article-title>Both Humoral and Cellular Immunity Limit the Ability of Live Attenuated Influenza Vaccines to Promote T Cell Responses</article-title><source>J. Immunol.</source><year>2024</year><volume>212</volume><fpage>107</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2300343</pub-id><pub-id pub-id-type="pmid">37982700</pub-id><pub-id pub-id-type="pmcid">PMC10842048</pub-id></element-citation></ref><ref id="B105-vaccines-12-01345"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shokri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shahkarami</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Shafyi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esna-Ashari</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hamta</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of the thermal stability of live-attenuated Rubella vaccine (Takahashi strain) formulated and lyophilized in different stabilizers</article-title><source>J. Virol. Methods</source><year>2019</year><volume>264</volume><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2018.08.013</pub-id><pub-id pub-id-type="pmid">30144493</pub-id></element-citation></ref><ref id="B106-vaccines-12-01345"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medhi</surname><given-names>B.</given-names></name></person-group><article-title>New generation vaccine: Novel approaches of vaccine design and delivery and current challenges of vaccine development</article-title><source>Indian J. Pharmacol.</source><year>2022</year><volume>54</volume><fpage>241</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.4103/ijp.ijp_555_22</pub-id><pub-id pub-id-type="pmid">36204806</pub-id><pub-id pub-id-type="pmcid">PMC9804121</pub-id></element-citation></ref><ref id="B107-vaccines-12-01345"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebre</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Brito</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Carfi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barouch</surname><given-names>D.H.</given-names></name></person-group><article-title>Novel approaches for vaccine development</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>1589</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.02.030</pub-id><pub-id pub-id-type="pmid">33740454</pub-id><pub-id pub-id-type="pmcid">PMC8049514</pub-id></element-citation></ref><ref id="B108-vaccines-12-01345"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watterson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wijesundara</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mordant</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Avumegah</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Lackenby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guilfoyle</surname><given-names>K.</given-names></name><name name-style="western"><surname>van Amerongen</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2</article-title><source>Clin. Transl. Immunol.</source><year>2021</year><volume>10</volume><fpage>e1269</fpage><pub-id pub-id-type="doi">10.1002/cti2.1269</pub-id><pub-id pub-id-type="pmcid">PMC8021130</pub-id><pub-id pub-id-type="pmid">33841880</pub-id></element-citation></ref><ref id="B109-vaccines-12-01345"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wozniak-Knopp</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stadlmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ruker</surname><given-names>F.</given-names></name></person-group><article-title>Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e30083</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0030083</pub-id><pub-id pub-id-type="pmid">22272277</pub-id><pub-id pub-id-type="pmcid">PMC3260182</pub-id></element-citation></ref><ref id="B110-vaccines-12-01345"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kingston</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Snowden</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Martyna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shegdar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grehan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tedcastle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pegg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>H.</given-names></name><name name-style="western"><surname>Macadam</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Production of antigenically stable enterovirus A71 virus-like particles in Pichia pastoris as a vaccine candidate</article-title><source>J. Gen. Virol.</source><year>2023</year><volume>104</volume><fpage>001867</fpage><pub-id pub-id-type="doi">10.1099/jgv.0.001867</pub-id><pub-id pub-id-type="pmid">37390009</pub-id><pub-id pub-id-type="pmcid">PMC10773253</pub-id></element-citation></ref><ref id="B111-vaccines-12-01345"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Mundsperger</surname><given-names>P.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jovanoska</surname><given-names>L.</given-names></name><name name-style="western"><surname>Trajano</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Schiffner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fabian</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tolazzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scarlatti</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens</article-title><source>NPJ Vaccines</source><year>2023</year><volume>8</volume><fpage>101</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00696-w</pub-id><pub-id pub-id-type="pmid">37443366</pub-id><pub-id pub-id-type="pmcid">PMC10345191</pub-id></element-citation></ref><ref id="B112-vaccines-12-01345"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>T.Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matsuyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>E7758</fpage><lpage>E7767</lpage><pub-id pub-id-type="doi">10.1073/pnas.1805713115</pub-id><pub-id pub-id-type="pmid">30065113</pub-id><pub-id pub-id-type="pmcid">PMC6099848</pub-id></element-citation></ref><ref id="B113-vaccines-12-01345"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zieneldien</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>449</elocation-id><pub-id pub-id-type="doi">10.3390/v14030449</pub-id><pub-id pub-id-type="pmid">35336856</pub-id><pub-id pub-id-type="pmcid">PMC8954996</pub-id></element-citation></ref><ref id="B114-vaccines-12-01345"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lindgren</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ols</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rohss</surname><given-names>J.</given-names></name><name name-style="western"><surname>John</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hassett</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yuzhakov</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bahl</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques</article-title><source>Mol. Ther.</source><year>2017</year><volume>25</volume><fpage>2635</fpage><lpage>2647</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.08.006</pub-id><pub-id pub-id-type="pmid">28958578</pub-id><pub-id pub-id-type="pmcid">PMC5768558</pub-id></element-citation></ref><ref id="B115-vaccines-12-01345"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Soema</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Slutter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name></person-group><article-title>PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity</article-title><source>Hum. Vaccines Immunother.</source><year>2016</year><volume>12</volume><fpage>1056</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1117714</pub-id><pub-id pub-id-type="pmid">26752261</pub-id><pub-id pub-id-type="pmcid">PMC4962933</pub-id></element-citation></ref><ref id="B116-vaccines-12-01345"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nooraei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bahrulolum</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoseini</surname><given-names>Z.S.</given-names></name><name name-style="western"><surname>Katalani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hajizade</surname><given-names>A.</given-names></name><name name-style="western"><surname>Easton</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ahmadian</surname><given-names>G.</given-names></name></person-group><article-title>Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers</article-title><source>J. Nanobiotechnol.</source><year>2021</year><volume>19</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.1186/s12951-021-00806-7</pub-id><pub-id pub-id-type="pmid">33632278</pub-id><pub-id pub-id-type="pmcid">PMC7905985</pub-id></element-citation></ref><ref id="B117-vaccines-12-01345"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Advanced subunit vaccine delivery technologies: From vaccine cascade obstacles to design strategies</article-title><source>Acta Pharm. Sin. B</source><year>2023</year><volume>13</volume><fpage>3321</fpage><lpage>3338</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.01.006</pub-id><pub-id pub-id-type="pmid">37655334</pub-id><pub-id pub-id-type="pmcid">PMC10465871</pub-id></element-citation></ref><ref id="B118-vaccines-12-01345"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abramson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dunger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R.</given-names></name><name name-style="western"><surname>Green</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pritzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ronneberger</surname><given-names>O.</given-names></name><name name-style="western"><surname>Willmore</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bambrick</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Accurate structure prediction of biomolecular interactions with AlphaFold 3</article-title><source>Nature</source><year>2024</year><volume>630</volume><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07487-w</pub-id><pub-id pub-id-type="pmid">38718835</pub-id><pub-id pub-id-type="pmcid">PMC11168924</pub-id></element-citation></ref><ref id="B119-vaccines-12-01345"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Caetano-Anolles</surname><given-names>G.</given-names></name></person-group><article-title>AlphaFold2 Reveals Structural Patterns of Seasonal Haplotype Diversification in SARS-CoV-2 Spike Protein Variants</article-title><source>Biology</source><year>2024</year><volume>13</volume><elocation-id>134</elocation-id><pub-id pub-id-type="doi">10.3390/biology13030134</pub-id><pub-id pub-id-type="pmid">38534404</pub-id><pub-id pub-id-type="pmcid">PMC10968544</pub-id></element-citation></ref><ref id="B120-vaccines-12-01345"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirdita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schutze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moriwaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ovchinnikov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steinegger</surname><given-names>M.</given-names></name></person-group><article-title>ColabFold: Making protein folding accessible to all</article-title><source>Nat. Methods</source><year>2022</year><volume>19</volume><fpage>679</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/s41592-022-01488-1</pub-id><pub-id pub-id-type="pmid">35637307</pub-id><pub-id pub-id-type="pmcid">PMC9184281</pub-id></element-citation></ref><ref id="B121-vaccines-12-01345"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Davila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilamowski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Teraguchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Standley</surname><given-names>D.M.</given-names></name></person-group><article-title>Improved Antibody-Specific Epitope Prediction Using AlphaFold and AbAdapt</article-title><source>Chembiochem</source><year>2022</year><volume>23</volume><fpage>e202200303</fpage><pub-id pub-id-type="doi">10.1002/cbic.202200303</pub-id><pub-id pub-id-type="pmid">35893479</pub-id><pub-id pub-id-type="pmcid">PMC9543094</pub-id></element-citation></ref><ref id="B122-vaccines-12-01345"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Mackett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>B.</given-names></name></person-group><article-title>Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen</article-title><source>Nature</source><year>1983</year><volume>302</volume><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1038/302490a0</pub-id><pub-id pub-id-type="pmid">6835382</pub-id></element-citation></ref><ref id="B123-vaccines-12-01345"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tebas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>D.</given-names></name><name name-style="western"><surname>Binder-Scholl</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brady</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rebello</surname><given-names>T.</given-names></name><name name-style="western"><surname>Humeau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kalos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Papasavvas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Montaner</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>1524</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-07-447250</pub-id><pub-id pub-id-type="pmid">23264589</pub-id><pub-id pub-id-type="pmcid">PMC3587318</pub-id></element-citation></ref><ref id="B124-vaccines-12-01345"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dropulic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hermankova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pitha</surname><given-names>P.M.</given-names></name></person-group><article-title>A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1996</year><volume>93</volume><fpage>11103</fpage><lpage>11108</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.20.11103</pub-id><pub-id pub-id-type="pmid">8855316</pub-id><pub-id pub-id-type="pmcid">PMC38291</pub-id></element-citation></ref><ref id="B125-vaccines-12-01345"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>V.</given-names></name><name name-style="western"><surname>Petry</surname><given-names>H.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>F.</given-names></name></person-group><article-title>Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00082</pub-id><pub-id pub-id-type="pmid">24624131</pub-id><pub-id pub-id-type="pmcid">PMC3939780</pub-id></element-citation></ref><ref id="B126-vaccines-12-01345"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Coyne-Johnson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Whizin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Oswald</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shoemaker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine</article-title><source>Nature</source><year>2011</year><volume>473</volume><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nature10003</pub-id><pub-id pub-id-type="pmid">21562493</pub-id><pub-id pub-id-type="pmcid">PMC3102768</pub-id></element-citation></ref><ref id="B127-vaccines-12-01345"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slobod</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Shenep</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Lujan-Zilbermann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>B.</given-names></name><name name-style="western"><surname>Scroggs</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Portner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coleclough</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hurwitz</surname><given-names>J.L.</given-names></name></person-group><article-title>Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>3182</fpage><lpage>3186</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.01.053</pub-id><pub-id pub-id-type="pmid">15297072</pub-id></element-citation></ref><ref id="B128-vaccines-12-01345"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isakova-Sivak</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tretiak</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rudenko</surname><given-names>L.</given-names></name></person-group><article-title>Cold-adapted influenza viruses as a promising platform for viral-vector vaccines</article-title><source>Expert Rev. Vaccines</source><year>2016</year><volume>15</volume><fpage>1241</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1080/14760584.2016.1208088</pub-id><pub-id pub-id-type="pmid">27385419</pub-id></element-citation></ref><ref id="B129-vaccines-12-01345"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanaparthy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vasireddy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Atluri</surname><given-names>P.</given-names></name></person-group><article-title>Review of COVID-19 viral vector-based vaccines and COVID-19 variants</article-title><source>Infez. Med.</source><year>2021</year><volume>29</volume><fpage>328</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.53854/liim-2903-3</pub-id><pub-id pub-id-type="pmid">35146337</pub-id><pub-id pub-id-type="pmcid">PMC8805485</pub-id></element-citation></ref><ref id="B130-vaccines-12-01345"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dulal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stedman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fedosyuk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name><name name-style="western"><surname>Warimwe</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>A.D.</given-names></name></person-group><article-title>Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1249</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9111249</pub-id><pub-id pub-id-type="pmid">34835180</pub-id><pub-id pub-id-type="pmcid">PMC8623940</pub-id></element-citation></ref><ref id="B131-vaccines-12-01345"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joe</surname><given-names>C.C.D.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nestola</surname><given-names>P.</given-names></name><name name-style="western"><surname>Niemann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>A.D.</given-names></name></person-group><article-title>Rapid-response manufacturing of adenovirus-vectored vaccines</article-title><source>Nat. Biotechnol.</source><year>2023</year><volume>41</volume><fpage>314</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1038/s41587-023-01682-2</pub-id><pub-id pub-id-type="pmid">36890199</pub-id></element-citation></ref><ref id="B132-vaccines-12-01345"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saxena</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van</surname><given-names>T.T.H.</given-names></name><name name-style="western"><surname>Baird</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Coloe</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Smooker</surname><given-names>P.M.</given-names></name></person-group><article-title>Pre-existing immunity against vaccine vectors&#8212;friend or foe?</article-title><source>Microbiology</source><year>2013</year><volume>159</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1099/mic.0.049601-0</pub-id><pub-id pub-id-type="pmid">23175507</pub-id><pub-id pub-id-type="pmcid">PMC3542731</pub-id></element-citation></ref><ref id="B133-vaccines-12-01345"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoshnood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghanavati</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shirani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghahramanpour</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sholeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shariati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sadeghifard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heidary</surname><given-names>M.</given-names></name></person-group><article-title>Viral vector and nucleic acid vaccines against COVID-19: A narrative review</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><fpage>984536</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2022.984536</pub-id><pub-id pub-id-type="pmid">36118203</pub-id><pub-id pub-id-type="pmcid">PMC9470835</pub-id></element-citation></ref><ref id="B134-vaccines-12-01345"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Marin-Lopez</surname><given-names>A.</given-names></name></person-group><article-title>Current Advances in Zika Vaccine Development</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1816</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10111816</pub-id><pub-id pub-id-type="pmid">36366325</pub-id><pub-id pub-id-type="pmcid">PMC9694033</pub-id></element-citation></ref><ref id="B135-vaccines-12-01345"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolotin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wincker</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mauger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jaillon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Malarme</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weissenbach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ehrlich</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Sorokin</surname><given-names>A.</given-names></name></person-group><article-title>The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403</article-title><source>Genome Res.</source><year>2001</year><volume>11</volume><fpage>731</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1101/gr.169701</pub-id><pub-id pub-id-type="pmid">11337471</pub-id><pub-id pub-id-type="pmcid">PMC311110</pub-id></element-citation></ref><ref id="B136-vaccines-12-01345"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wegmann</surname><given-names>U.</given-names></name><name name-style="western"><surname>O&#8217;Connell-Motherway</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zomer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buist</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shearman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Canchaya</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goesmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gasson</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kuipers</surname><given-names>O.P.</given-names></name><etal/></person-group><article-title>Complete genome sequence of the prototype lactic acid bacterium Lactococcus lactis subsp. cremoris MG1363</article-title><source>J. Bacteriol.</source><year>2007</year><volume>189</volume><fpage>3256</fpage><lpage>3270</lpage><pub-id pub-id-type="doi">10.1128/JB.01768-06</pub-id><pub-id pub-id-type="pmid">17307855</pub-id><pub-id pub-id-type="pmcid">PMC1855848</pub-id></element-citation></ref><ref id="B137-vaccines-12-01345"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linares</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>J.</given-names></name><name name-style="western"><surname>Poolman</surname><given-names>B.</given-names></name></person-group><article-title>Genome sequences of Lactococcus lactis MG1363 (revised) and NZ9000 and comparative physiological studies</article-title><source>J. Bacteriol.</source><year>2010</year><volume>192</volume><fpage>5806</fpage><lpage>5812</lpage><pub-id pub-id-type="doi">10.1128/JB.00533-10</pub-id><pub-id pub-id-type="pmid">20639323</pub-id><pub-id pub-id-type="pmcid">PMC2953693</pub-id></element-citation></ref><ref id="B138-vaccines-12-01345"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Luh</surname><given-names>K.T.</given-names></name></person-group><article-title>Clones of Lactobacillus casei and Torulopsis glabrata associated with recurrent abdominal wall abscess</article-title><source>J. Formos. Med. Assoc.</source><year>1999</year><volume>98</volume><fpage>356</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">10420704</pub-id></element-citation></ref><ref id="B139-vaccines-12-01345"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tena</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Losa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Saez-Nieto</surname><given-names>J.A.</given-names></name></person-group><article-title>Acute acalculous cholecystitis complicated with peritonitis caused by Lactobacillus plantarum</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2013</year><volume>76</volume><fpage>510</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2013.03.018</pub-id><pub-id pub-id-type="pmid">23886436</pub-id></element-citation></ref><ref id="B140-vaccines-12-01345"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Zeller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kotton</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Hohmann</surname><given-names>E.L.</given-names></name></person-group><article-title>Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: Preclinical evaluation and oral inoculation of volunteers</article-title><source>Microbiol. Immunol.</source><year>2011</year><volume>55</volume><fpage>304</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1111/j.1348-0421.2011.00322.x</pub-id><pub-id pub-id-type="pmid">21338384</pub-id><pub-id pub-id-type="pmcid">PMC3082616</pub-id></element-citation></ref><ref id="B141-vaccines-12-01345"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eypper</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Purro</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Hohmann</surname><given-names>E.L.</given-names></name></person-group><article-title>Transcutaneous immunization of healthy volunteers with an attenuated Listeria monocytogenes vaccine strain and cholera toxin adjuvant</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>3257</fpage><lpage>3261</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.05.028</pub-id><pub-id pub-id-type="pmid">23707162</pub-id><pub-id pub-id-type="pmcid">PMC3831363</pub-id></element-citation></ref><ref id="B142-vaccines-12-01345"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maciag</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Radulovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rothman</surname><given-names>J.</given-names></name></person-group><article-title>The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>3975</fpage><lpage>3983</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.04.041</pub-id><pub-id pub-id-type="pmid">19389451</pub-id></element-citation></ref><ref id="B143-vaccines-12-01345"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jawalagatti</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kirthika</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hewawaduge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name></person-group><article-title>Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2</article-title><source>Mol. Ther.</source><year>2022</year><volume>30</volume><fpage>1926</fpage><lpage>1940</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2022.01.042</pub-id><pub-id pub-id-type="pmid">35123065</pub-id><pub-id pub-id-type="pmcid">PMC8810265</pub-id></element-citation></ref><ref id="B144-vaccines-12-01345"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bielefeldt-Ohmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Maison</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Maslesa-Galic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>M.A.</given-names></name></person-group><article-title>Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00321-8</pub-id><pub-id pub-id-type="pmid">33785745</pub-id><pub-id pub-id-type="pmcid">PMC8009914</pub-id></element-citation></ref><ref id="B145-vaccines-12-01345"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.S.</given-names></name></person-group><article-title>From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>679344</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.679344</pub-id><pub-id pub-id-type="pmid">34305909</pub-id><pub-id pub-id-type="pmcid">PMC8293291</pub-id></element-citation></ref><ref id="B146-vaccines-12-01345"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kariko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Buckstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA</article-title><source>Immunity</source><year>2005</year><volume>23</volume><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2005.06.008</pub-id><pub-id pub-id-type="pmid">16111635</pub-id></element-citation></ref><ref id="B147-vaccines-12-01345"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kariko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability</article-title><source>Mol. Ther.</source><year>2008</year><volume>16</volume><fpage>1833</fpage><lpage>1840</lpage><pub-id pub-id-type="doi">10.1038/mt.2008.200</pub-id><pub-id pub-id-type="pmid">18797453</pub-id><pub-id pub-id-type="pmcid">PMC2775451</pub-id></element-citation></ref><ref id="B148-vaccines-12-01345"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nallagatla</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Bevilacqua</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Sansing</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kariko</surname><given-names>K.</given-names></name></person-group><article-title>Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation</article-title><source>Nucleic Acids Res.</source><year>2010</year><volume>38</volume><fpage>5884</fpage><lpage>5892</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq347</pub-id><pub-id pub-id-type="pmid">20457754</pub-id><pub-id pub-id-type="pmcid">PMC2943593</pub-id></element-citation></ref><ref id="B149-vaccines-12-01345"><label>149.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>NobelPrize</collab></person-group><article-title>NobelPrize Outreach</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nobelprize.org/prizes/medicine/2023/press-release/" ext-link-type="uri">https://www.nobelprize.org/prizes/medicine/2023/press-release/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-04">(accessed on 4 October 2024)</date-in-citation></element-citation></ref><ref id="B150-vaccines-12-01345"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.C.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Q.S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.F.</given-names></name><etal/></person-group><article-title>Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant</article-title><source>Cell Res.</source><year>2022</year><volume>32</volume><fpage>401</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1038/s41422-022-00626-w</pub-id><pub-id pub-id-type="pmid">35165421</pub-id><pub-id pub-id-type="pmcid">PMC8853430</pub-id></element-citation></ref><ref id="B151-vaccines-12-01345"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harvey</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Carabelli</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ludden</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reeve</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Consortium</surname><given-names>C.-G.U.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>409</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00573-0</pub-id><pub-id pub-id-type="pmid">34075212</pub-id><pub-id pub-id-type="pmcid">PMC8167834</pub-id></element-citation></ref><ref id="B152-vaccines-12-01345"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doud</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>J.D.</given-names></name></person-group><article-title>How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>1386</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-03665-3</pub-id><pub-id pub-id-type="pmid">29643370</pub-id><pub-id pub-id-type="pmcid">PMC5895760</pub-id></element-citation></ref><ref id="B153-vaccines-12-01345"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Toole</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neher</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Ndodo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gannon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Groves</surname><given-names>N.</given-names></name><name name-style="western"><surname>King</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Maloney</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lemey</surname><given-names>P.</given-names></name><etal/></person-group><article-title>APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016</article-title><source>Science</source><year>2023</year><volume>382</volume><fpage>595</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1126/science.adg8116</pub-id><pub-id pub-id-type="pmid">37917680</pub-id><pub-id pub-id-type="pmcid">PMC10880385</pub-id></element-citation></ref><ref id="B154-vaccines-12-01345"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Roni</surname><given-names>M.A.</given-names></name></person-group><article-title>Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1033</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9091033</pub-id><pub-id pub-id-type="pmid">34579270</pub-id><pub-id pub-id-type="pmcid">PMC8473088</pub-id></element-citation></ref><ref id="B155-vaccines-12-01345"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavda</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khadela</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ajabiya</surname><given-names>J.</given-names></name></person-group><article-title>mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>2150</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10122150</pub-id><pub-id pub-id-type="pmid">36560560</pub-id><pub-id pub-id-type="pmcid">PMC9785933</pub-id></element-citation></ref><ref id="B156-vaccines-12-01345"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voigt</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Gerhardt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jennewein</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Battisti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mohamath</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bakken</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beaver</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability</article-title><source>NPJ Vaccines</source><year>2022</year><volume>7</volume><fpage>136</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00549-y</pub-id><pub-id pub-id-type="pmid">36323666</pub-id><pub-id pub-id-type="pmcid">PMC9628444</pub-id></element-citation></ref><ref id="B157-vaccines-12-01345"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amaya</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grigoryan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wender</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.Y.</given-names></name></person-group><article-title>Circular RNA vaccine induces potent T cell responses</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2023</year><volume>120</volume><fpage>e2302191120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2302191120</pub-id><pub-id pub-id-type="pmid">37155869</pub-id><pub-id pub-id-type="pmcid">PMC10193964</pub-id></element-citation></ref><ref id="B158-vaccines-12-01345"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Vaccines&#8217; New Era-RNA Vaccine</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1760</elocation-id><pub-id pub-id-type="doi">10.3390/v15081760</pub-id><pub-id pub-id-type="pmid">37632102</pub-id><pub-id pub-id-type="pmcid">PMC10458896</pub-id></element-citation></ref><ref id="B159-vaccines-12-01345"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name></person-group><article-title>Recent advances in mRNA cancer vaccines: Meeting challenges and embracing opportunities</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1246682</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1246682</pub-id><pub-id pub-id-type="pmid">37744371</pub-id><pub-id pub-id-type="pmcid">PMC10511650</pub-id></element-citation></ref><ref id="B160-vaccines-12-01345"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kackos</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>DeBeauchamp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davitt</surname><given-names>C.J.H.</given-names></name><name name-style="western"><surname>Lonzaric</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sealy</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Hurwitz</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Samsa</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Webby</surname><given-names>R.J.</given-names></name></person-group><article-title>Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection</article-title><source>NPJ Vaccines</source><year>2023</year><volume>8</volume><fpage>157</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00752-5</pub-id><pub-id pub-id-type="pmid">37828126</pub-id><pub-id pub-id-type="pmcid">PMC10570305</pub-id></element-citation></ref><ref id="B161-vaccines-12-01345"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chehrazi-Raffle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Budde</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>S.K.</given-names></name></person-group><article-title>Boosting CAR T cells with anti-tumor mRNA vaccines</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>2711</fpage><lpage>2712</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02623-x</pub-id><pub-id pub-id-type="pmid">37932550</pub-id></element-citation></ref><ref id="B162-vaccines-12-01345"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Algorithm for optimized mRNA design improves stability and immunogenicity</article-title><source>Nature</source><year>2023</year><volume>621</volume><fpage>396</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06127-z</pub-id><pub-id pub-id-type="pmid">37130545</pub-id><pub-id pub-id-type="pmcid">PMC10499610</pub-id></element-citation></ref><ref id="B163-vaccines-12-01345"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leitner</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>H.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>DNA and RNA-based vaccines: Principles, progress and prospects</article-title><source>Vaccine</source><year>1999</year><volume>18</volume><fpage>765</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00271-6</pub-id><pub-id pub-id-type="pmid">10580187</pub-id><pub-id pub-id-type="pmcid">PMC1986720</pub-id></element-citation></ref><ref id="B164-vaccines-12-01345"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutzler</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.B.</given-names></name></person-group><article-title>DNA vaccines: Ready for prime time?</article-title><source>Nat. Rev. Genet.</source><year>2008</year><volume>9</volume><fpage>776</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1038/nrg2432</pub-id><pub-id pub-id-type="pmid">18781156</pub-id><pub-id pub-id-type="pmcid">PMC4317294</pub-id></element-citation></ref><ref id="B165-vaccines-12-01345"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tebas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Christensen-Quick</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Kraynyak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agnes</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial</article-title><source>EClinicalMedicine</source><year>2021</year><volume>31</volume><fpage>100689</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100689</pub-id><pub-id pub-id-type="pmid">33392485</pub-id><pub-id pub-id-type="pmcid">PMC7759123</pub-id></element-citation></ref><ref id="B166-vaccines-12-01345"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jazayeri</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Poh</surname><given-names>C.L.</given-names></name></person-group><article-title>Recent advances in delivery of veterinary DNA vaccines against avian pathogens</article-title><source>Vet. Res.</source><year>2019</year><volume>50</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.1186/s13567-019-0698-z</pub-id><pub-id pub-id-type="pmid">31601266</pub-id><pub-id pub-id-type="pmcid">PMC6785882</pub-id></element-citation></ref><ref id="B167-vaccines-12-01345"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hobernik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name></person-group><article-title>DNA Vaccines-How Far From Clinical Use?</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>3605</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19113605</pub-id><pub-id pub-id-type="pmid">30445702</pub-id><pub-id pub-id-type="pmcid">PMC6274812</pub-id></element-citation></ref><ref id="B168-vaccines-12-01345"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neeli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sobhani</surname><given-names>N.</given-names></name><name name-style="western"><surname>K</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Kurapati</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The next-generation DNA vaccine platforms and delivery systems: Advances, challenges and prospects</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><fpage>1332939</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1332939</pub-id><pub-id pub-id-type="pmid">38361919</pub-id><pub-id pub-id-type="pmcid">PMC10867258</pub-id></element-citation></ref><ref id="B169-vaccines-12-01345"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>G.P.</given-names></name></person-group><article-title>Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface</article-title><source>Science</source><year>1985</year><volume>228</volume><fpage>1315</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1126/science.4001944</pub-id><pub-id pub-id-type="pmid">4001944</pub-id></element-citation></ref><ref id="B170-vaccines-12-01345"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davenport</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Catala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weston</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Ardanuy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Dillen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Frieman</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Catalano</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>T.E.</given-names></name></person-group><article-title>Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease</article-title><source>NPJ Vaccines</source><year>2022</year><volume>7</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00481-1</pub-id><pub-id pub-id-type="pmid">35618725</pub-id><pub-id pub-id-type="pmcid">PMC9135756</pub-id></element-citation></ref><ref id="B171-vaccines-12-01345"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staquicini</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>F.H.F.</given-names></name><name name-style="western"><surname>Markosian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Staquicini</surname><given-names>F.I.</given-names></name><name name-style="western"><surname>Dodero-Rojas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Contessoto</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>D.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>P.</given-names></name><name name-style="western"><surname>Habib</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2105739118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2105739118</pub-id><pub-id pub-id-type="pmid">34234013</pub-id><pub-id pub-id-type="pmcid">PMC8325333</pub-id></element-citation></ref><ref id="B172-vaccines-12-01345"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charlton Hume</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Vidigal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carrondo</surname><given-names>M.J.T.</given-names></name><name name-style="western"><surname>Middelberg</surname><given-names>A.P.J.</given-names></name><name name-style="western"><surname>Roldao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lua</surname><given-names>L.H.L.</given-names></name></person-group><article-title>Synthetic biology for bioengineering virus-like particle vaccines</article-title><source>Biotechnol. Bioeng.</source><year>2019</year><volume>116</volume><fpage>919</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1002/bit.26890</pub-id><pub-id pub-id-type="pmid">30597533</pub-id><pub-id pub-id-type="pmcid">PMC7161758</pub-id></element-citation></ref><ref id="B173-vaccines-12-01345"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nsairat</surname><given-names>H.</given-names></name><name name-style="western"><surname>Khater</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sayed</surname><given-names>U.</given-names></name><name name-style="western"><surname>Odeh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Al Bawab</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alshaer</surname><given-names>W.</given-names></name></person-group><article-title>Liposomes: Structure, composition, types, and clinical applications</article-title><source>Heliyon</source><year>2022</year><volume>8</volume><fpage>e09394</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e09394</pub-id><pub-id pub-id-type="pmid">35600452</pub-id><pub-id pub-id-type="pmcid">PMC9118483</pub-id></element-citation></ref><ref id="B174-vaccines-12-01345"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tenchov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bird</surname><given-names>R.</given-names></name><name name-style="western"><surname>Curtze</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name></person-group><article-title>Lipid Nanoparticles horizontal line From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement</article-title><source>ACS Nano</source><year>2021</year><volume>15</volume><fpage>16982</fpage><lpage>17015</lpage><pub-id pub-id-type="doi">10.1021/acsnano.1c04996</pub-id><pub-id pub-id-type="pmid">34181394</pub-id></element-citation></ref><ref id="B175-vaccines-12-01345"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torchilin</surname><given-names>V.P.</given-names></name></person-group><article-title>Liposomes as targetable drug carriers</article-title><source>Crit. Rev. Ther. Drug Carr. Syst.</source><year>1985</year><volume>2</volume><fpage>65</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">3913530</pub-id></element-citation></ref><ref id="B176-vaccines-12-01345"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sia</surname><given-names>Z.R.</given-names></name><name name-style="western"><surname>Chiem</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Seffouh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Teimouri Dereshgi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>J.F.</given-names></name></person-group><article-title>Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus</article-title><source>J. Virol.</source><year>2022</year><volume>96</volume><fpage>e0100622</fpage><pub-id pub-id-type="doi">10.1128/jvi.01006-22</pub-id><pub-id pub-id-type="pmid">36106872</pub-id><pub-id pub-id-type="pmcid">PMC9555155</pub-id></element-citation></ref><ref id="B177-vaccines-12-01345"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sia</surname><given-names>Z.R.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Arpin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kutscher</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine</article-title><source>Cell Rep. Med.</source><year>2024</year><volume>5</volume><fpage>101433</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101433</pub-id><pub-id pub-id-type="pmid">38401547</pub-id><pub-id pub-id-type="pmcid">PMC10982964</pub-id></element-citation></ref><ref id="B178-vaccines-12-01345"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pegtel</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Gould</surname><given-names>S.J.</given-names></name></person-group><article-title>Exosomes</article-title><source>Annu. Rev. Biochem.</source><year>2019</year><volume>88</volume><fpage>487</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-013118-111902</pub-id><pub-id pub-id-type="pmid">31220978</pub-id></element-citation></ref><ref id="B179-vaccines-12-01345"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimon</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Shapira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seni</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arber</surname><given-names>N.</given-names></name></person-group><article-title>The Big Potential of Small Particles: Lipid-Based Nanoparticles and Exosomes in Vaccination</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1119</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10071119</pub-id><pub-id pub-id-type="pmid">35891282</pub-id><pub-id pub-id-type="pmcid">PMC9320421</pub-id></element-citation></ref><ref id="B180-vaccines-12-01345"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Role of Extracellular Vesicles in Influenza Virus Infection</article-title><source>Front. Cell Infect. Microbiol.</source><year>2020</year><volume>10</volume><fpage>366</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2020.00366</pub-id><pub-id pub-id-type="pmid">32850473</pub-id><pub-id pub-id-type="pmcid">PMC7396637</pub-id></element-citation></ref><ref id="B181-vaccines-12-01345"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pocsfalvi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mammadova</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramos Juarez</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Bokka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Trepiccione</surname><given-names>F.</given-names></name><name name-style="western"><surname>Capasso</surname><given-names>G.</given-names></name></person-group><article-title>COVID-19 and Extracellular Vesicles: An Intriguing Interplay</article-title><source>Kidney Blood Press. Res.</source><year>2020</year><volume>45</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1159/000511402</pub-id><pub-id pub-id-type="pmid">32957112</pub-id><pub-id pub-id-type="pmcid">PMC7573892</pub-id></element-citation></ref><ref id="B182-vaccines-12-01345"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jesus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>O.</given-names></name></person-group><article-title>Exosomes as adjuvants for the recombinant hepatitis B antigen: First report</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2018</year><volume>133</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2018.09.029</pub-id><pub-id pub-id-type="pmid">30287267</pub-id></element-citation></ref><ref id="B183-vaccines-12-01345"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrantelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Manfredi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chiozzini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anticoli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Olivetta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Arenaccio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Federico</surname><given-names>M.</given-names></name></person-group><article-title>DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors</article-title><source>Mol. Biotechnol.</source><year>2018</year><volume>60</volume><fpage>773</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1007/s12033-018-0114-3</pub-id><pub-id pub-id-type="pmid">30167966</pub-id></element-citation></ref><ref id="B184-vaccines-12-01345"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiozzini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Manfredi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Arenaccio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ferrantelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>P.</given-names></name><name name-style="western"><surname>Federico</surname><given-names>M.</given-names></name></person-group><article-title>N-Terminal Fatty Acids of NEF(MUT) Are Required for the CD8(+) T-Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>243</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020243</pub-id><pub-id pub-id-type="pmid">32456079</pub-id><pub-id pub-id-type="pmcid">PMC7350016</pub-id></element-citation></ref><ref id="B185-vaccines-12-01345"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cacciottolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nice</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>LeClaire</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Twaddle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mora</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Young</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angeles</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins</article-title><source>Microbiol. Spectr.</source><year>2023</year><volume>11</volume><fpage>e0050323</fpage><pub-id pub-id-type="doi">10.1128/spectrum.00503-23</pub-id><pub-id pub-id-type="pmid">37093009</pub-id><pub-id pub-id-type="pmcid">PMC10269692</pub-id></element-citation></ref><ref id="B186-vaccines-12-01345"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cacciottolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nice</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>LeClaire</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Twaddle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mora</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Young</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angeles</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><fpage>e0290046</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0290046</pub-id><pub-id pub-id-type="pmid">37607200</pub-id><pub-id pub-id-type="pmcid">PMC10443850</pub-id></element-citation></ref><ref id="B187-vaccines-12-01345"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sim</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.K.</given-names></name></person-group><article-title>Engineered EVs with pathogen proteins: Promising vaccine alternatives to LNP-mRNA vaccines</article-title><source>J. Biomed. Sci.</source><year>2024</year><volume>31</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s12929-024-01000-1</pub-id><pub-id pub-id-type="pmid">38233833</pub-id><pub-id pub-id-type="pmcid">PMC10792899</pub-id></element-citation></ref><ref id="B188-vaccines-12-01345"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leekha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saeedi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sefat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez-Paniagua</surname><given-names>M.</given-names></name><name name-style="western"><surname>Damian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reichel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rezvan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Masoumi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>6193</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-50133-2</pub-id><pub-id pub-id-type="pmid">39043645</pub-id><pub-id pub-id-type="pmcid">PMC11266618</pub-id></element-citation></ref><ref id="B189-vaccines-12-01345"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization</article-title><source>Nature</source><year>2023</year><volume>624</volume><fpage>630</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06809-8</pub-id><pub-id pub-id-type="pmid">38093012</pub-id></element-citation></ref><ref id="B190-vaccines-12-01345"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safary</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akbarzadeh-Khiavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Omidi</surname><given-names>Y.</given-names></name></person-group><article-title>SARS-CoV-2 vaccine-triggered autoimmunity: Molecular mimicry and/or bystander activation of the immune system</article-title><source>Bioimpacts</source><year>2023</year><volume>13</volume><fpage>269</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.34172/bi.2023.27494</pub-id><pub-id pub-id-type="pmid">37645029</pub-id><pub-id pub-id-type="pmcid">PMC10460773</pub-id></element-citation></ref><ref id="B191-vaccines-12-01345"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowarz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Krutzke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Streb</surname><given-names>P.</given-names></name><name name-style="western"><surname>Larghero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bracharz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Engler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kochanek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marschalek</surname><given-names>R.</given-names></name></person-group><article-title>Vaccine-induced COVID-19 mimicry syndrome</article-title><source>Elife</source><year>2022</year><volume>11</volume><fpage>e74974</fpage><pub-id pub-id-type="doi">10.7554/eLife.74974</pub-id><pub-id pub-id-type="pmid">35084333</pub-id><pub-id pub-id-type="pmcid">PMC8846585</pub-id></element-citation></ref><ref id="B192-vaccines-12-01345"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devaux</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Camoin-Jau</surname><given-names>L.</given-names></name></person-group><article-title>Molecular Mimicry of the Viral Spike in the SARS-CoV-2 Vaccine Possibly Triggers Transient Dysregulation of ACE2, Leading to Vascular and Coagulation Dysfunction Similar to SARS-CoV-2 Infection</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1045</elocation-id><pub-id pub-id-type="doi">10.3390/v15051045</pub-id><pub-id pub-id-type="pmid">37243131</pub-id><pub-id pub-id-type="pmcid">PMC10222462</pub-id></element-citation></ref><ref id="B193-vaccines-12-01345"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Khare</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lawhon</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Lipton</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Turse</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Wylie</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Drake</surname><given-names>K.L.</given-names></name></person-group><article-title>Enhancing the role of veterinary vaccines reducing zoonotic diseases of humans: Linking systems biology with vaccine development</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>7197</fpage><lpage>7206</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.080</pub-id><pub-id pub-id-type="pmid">21651944</pub-id><pub-id pub-id-type="pmcid">PMC3170448</pub-id></element-citation></ref><ref id="B194-vaccines-12-01345"><label>194.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Recommended Composition of Influenza Virus Vaccines for Use in the 2024&#8211;2025 Northern Hemisphere Influenza Season</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season" ext-link-type="uri">https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-17">(accessed on 17 November 2024)</date-in-citation></element-citation></ref><ref id="B195-vaccines-12-01345"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meldgaard</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name></person-group><article-title>Novel Platforms for the Development of a Universal Influenza Vaccine</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>600</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00600</pub-id><pub-id pub-id-type="pmid">29628926</pub-id><pub-id pub-id-type="pmcid">PMC5877485</pub-id></element-citation></ref><ref id="B196-vaccines-12-01345"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Loy</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>C.L.L.</given-names></name></person-group><article-title>Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?</article-title><source>PLoS Pathog.</source><year>2023</year><volume>19</volume><fpage>e1011223</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1011223</pub-id><pub-id pub-id-type="pmid">36996026</pub-id><pub-id pub-id-type="pmcid">PMC10062565</pub-id></element-citation></ref><ref id="B197-vaccines-12-01345"><label>197.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>CDC</surname><given-names>U.S.</given-names></name></person-group><article-title>Dengue-Vaccine Eligibility &amp; Recommendations</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/dengue/hcp/vaccine/eligibility.html#:~:text=In%20people%20who%20have%20not,skip%20the%20first%2C%20natural%20infection" ext-link-type="uri">https://www.cdc.gov/dengue/hcp/vaccine/eligibility.html#:~:text=In%20people%20who%20have%20not,skip%20the%20first%2C%20natural%20infection</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-04">(accessed on 4 November 2024)</date-in-citation></element-citation></ref><ref id="B198-vaccines-12-01345"><label>198.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Prevention</surname><given-names>C.f.D.C.a.</given-names></name></person-group><article-title>Dengue Vaccine Schedule &amp; Dosing</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/dengue/hcp/vaccine/schedule-dosing.html#:~:text=Administer%20the%20Dengvaxia%20vaccine%20to,6%2C%20and%2012%20months" ext-link-type="uri">https://www.cdc.gov/dengue/hcp/vaccine/schedule-dosing.html#:~:text=Administer%20the%20Dengvaxia%20vaccine%20to,6%2C%20and%2012%20months</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-27">(accessed on 27 September 2024)</date-in-citation></element-citation></ref><ref id="B199-vaccines-12-01345"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>de Graaf</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Sonneveld</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Plomp</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Nouta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hoepel</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Linty</surname><given-names>F.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brinkhaus</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>eabc8378</fpage><pub-id pub-id-type="doi">10.1126/science.abc8378</pub-id><pub-id pub-id-type="pmid">33361116</pub-id><pub-id pub-id-type="pmcid">PMC7919849</pub-id></element-citation></ref><ref id="B200-vaccines-12-01345"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Coillie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pongracz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sustic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nouta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Le Gars</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keijzer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Linty</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cristianawati</surname><given-names>O.</given-names></name><name name-style="western"><surname>Keijser</surname><given-names>J.B.D.</given-names></name><etal/></person-group><article-title>Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines</article-title><source>iScience</source><year>2023</year><volume>26</volume><fpage>107619</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2023.107619</pub-id><pub-id pub-id-type="pmid">37670790</pub-id><pub-id pub-id-type="pmcid">PMC10475480</pub-id></element-citation></ref><ref id="B201-vaccines-12-01345"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>S.R.</given-names></name></person-group><article-title>Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines</article-title><source>J. Med. Virol.</source><year>2024</year><volume>96</volume><fpage>e29793</fpage><pub-id pub-id-type="doi">10.1002/jmv.29793</pub-id><pub-id pub-id-type="pmid">39023111</pub-id></element-citation></ref><ref id="B202-vaccines-12-01345"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name></person-group><article-title>Is new dengue vaccine efficacy data a relief or cause for concern?</article-title><source>NPJ Vaccines</source><year>2023</year><volume>8</volume><fpage>55</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00658-2</pub-id><pub-id pub-id-type="pmid">37061527</pub-id><pub-id pub-id-type="pmcid">PMC10105158</pub-id></element-citation></ref><ref id="B203-vaccines-12-01345"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brady</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Osgood-Zimmerman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kassebaum</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>de Araujo</surname><given-names>V.E.M.</given-names></name><name name-style="western"><surname>da Nobrega</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Frutuoso</surname><given-names>L.C.V.</given-names></name><name name-style="western"><surname>Lecca</surname><given-names>R.C.R.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zoca de Oliveira</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The association between Zika virus infection and microcephaly in Brazil 2015-2017: An observational analysis of over 4 million births</article-title><source>PLoS Med.</source><year>2019</year><volume>16</volume><fpage>e1002755</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1002755</pub-id><pub-id pub-id-type="pmid">30835728</pub-id><pub-id pub-id-type="pmcid">PMC6400331</pub-id></element-citation></ref><ref id="B204-vaccines-12-01345"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regla-Nava</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Fontes-Garfias</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Syed</surname><given-names>T.</given-names></name><name name-style="western"><surname>Susantono</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Viramontes</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A Zika virus mutation enhances transmission potential and confers escape from protective dengue virus immunity</article-title><source>Cell Rep.</source><year>2022</year><volume>39</volume><fpage>110655</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110655</pub-id><pub-id pub-id-type="pmid">35417697</pub-id><pub-id pub-id-type="pmcid">PMC9093040</pub-id></element-citation></ref><ref id="B205-vaccines-12-01345"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Le</surname><given-names>T.T.V.</given-names></name><name name-style="western"><surname>Le</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>T.N.</given-names></name><etal/></person-group><article-title>Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: A multiregion, double-blind, randomised, placebo-controlled, phase 3 trial</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>1708</fpage><lpage>1717</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00313-0</pub-id><pub-id pub-id-type="pmid">35427481</pub-id></element-citation></ref><ref id="B206-vaccines-12-01345"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolay</surname><given-names>B.</given-names></name><name name-style="western"><surname>Salje</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sazzad</surname><given-names>H.M.S.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Daszak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stroher</surname><given-names>U.</given-names></name><name name-style="western"><surname>Pulliam</surname><given-names>J.R.C.</given-names></name><name name-style="western"><surname>Kilpatrick</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Transmission of Nipah Virus-14 Years of Investigations in Bangladesh</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>1804</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1805376</pub-id><pub-id pub-id-type="pmid">31067370</pub-id><pub-id pub-id-type="pmcid">PMC6547369</pub-id></element-citation></ref><ref id="B207-vaccines-12-01345"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garbuglia</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Lapa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pauciullo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raoul</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pannetier</surname><given-names>D.</given-names></name></person-group><article-title>Nipah Virus: An Overview of the Current Status of Diagnostics and Their Role in Preparedness in Endemic Countries</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>2062</elocation-id><pub-id pub-id-type="doi">10.3390/v15102062</pub-id><pub-id pub-id-type="pmid">37896839</pub-id><pub-id pub-id-type="pmcid">PMC10612039</pub-id></element-citation></ref><ref id="B208-vaccines-12-01345"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaudino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aurine</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dumont</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fouret</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reynard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Volchkov</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Legras-Lachuer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Georges-Courbot</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>High Pathogenicity of Nipah Virus from Pteropus lylei Fruit Bats, Cambodia</article-title><source>Emerg. Infect. Dis.</source><year>2020</year><volume>26</volume><fpage>104</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.3201/eid2601.191284</pub-id><pub-id pub-id-type="pmid">31855143</pub-id><pub-id pub-id-type="pmcid">PMC6924896</pub-id></element-citation></ref><ref id="B209-vaccines-12-01345"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woolsey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Borisevich</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fears</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Agans</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Deer</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>O&#8217;Toole</surname><given-names>R.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Dobias</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Geisbert</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease</article-title><source>J. Clin. Investig.</source><year>2023</year><volume>133</volume><fpage>e164946</fpage><pub-id pub-id-type="doi">10.1172/JCI164946</pub-id><pub-id pub-id-type="pmid">36445779</pub-id><pub-id pub-id-type="pmcid">PMC9888376</pub-id></element-citation></ref><ref id="B210-vaccines-12-01345"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Avanzato</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Goldin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Haddock</surname><given-names>E.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lovaglio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Cordova</surname><given-names>K.</given-names></name><etal/></person-group><article-title>ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys</article-title><source>NPJ Vaccines</source><year>2022</year><volume>7</volume><fpage>171</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00592-9</pub-id><pub-id pub-id-type="pmid">36543806</pub-id><pub-id pub-id-type="pmcid">PMC9768398</pub-id></element-citation></ref><ref id="B211-vaccines-12-01345"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Haddock</surname><given-names>E.</given-names></name><name name-style="western"><surname>Letko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Avanzato</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Rissanen</surname><given-names>I.</given-names></name><etal/></person-group><article-title>A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters</article-title><source>PLoS Negl. Trop. Dis.</source><year>2019</year><volume>13</volume><fpage>e0007462</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0007462</pub-id><pub-id pub-id-type="pmid">31170144</pub-id><pub-id pub-id-type="pmcid">PMC6581282</pub-id></element-citation></ref><ref id="B212-vaccines-12-01345"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedrera</surname><given-names>M.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Medfai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>N.</given-names></name><name name-style="western"><surname>Todd</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Donofrio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><fpage>1384417</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1384417</pub-id><pub-id pub-id-type="pmid">38726013</pub-id><pub-id pub-id-type="pmcid">PMC11079202</pub-id></element-citation></ref><ref id="B213-vaccines-12-01345"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boni</surname><given-names>M.F.</given-names></name></person-group><article-title>Vaccination and antigenic drift in influenza</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><issue>(Suppl. 3)</issue><fpage>C8</fpage><lpage>C14</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.04.011</pub-id><pub-id pub-id-type="pmid">18773534</pub-id><pub-id pub-id-type="pmcid">PMC2603026</pub-id></element-citation></ref><ref id="B214-vaccines-12-01345"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>F.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>R.M.</given-names></name></person-group><article-title>Antigenic drift, antigenic shift and interferon antagonists: How bunyaviruses counteract the immune system</article-title><source>Virus Res.</source><year>2002</year><volume>88</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/S0168-1702(02)00125-9</pub-id><pub-id pub-id-type="pmid">12297332</pub-id></element-citation></ref><ref id="B215-vaccines-12-01345"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>T.J.C.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Odle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Matreyek</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>N.C.</given-names></name></person-group><article-title>Evidence of antigenic drift in the fusion machinery core of SARS-CoV-2 spike</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2024</year><volume>121</volume><fpage>e2317222121</fpage><pub-id pub-id-type="doi">10.1073/pnas.2317222121</pub-id><pub-id pub-id-type="pmid">38557175</pub-id><pub-id pub-id-type="pmcid">PMC11009667</pub-id></element-citation></ref><ref id="B216-vaccines-12-01345"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bancej</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>L.</given-names></name><name name-style="western"><surname>Champredon</surname><given-names>D.</given-names></name></person-group><article-title>Antigenic drift and epidemiological severity of seasonal influenza in Canada</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>15625</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-19996-7</pub-id><pub-id pub-id-type="pmid">36115880</pub-id><pub-id pub-id-type="pmcid">PMC9482630</pub-id></element-citation></ref><ref id="B217-vaccines-12-01345"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kung</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>S.R.</given-names></name></person-group><article-title>Molecular Virology of SARS-CoV-2 and Related Coronaviruses</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2022</year><volume>86</volume><fpage>e0002621</fpage><pub-id pub-id-type="doi">10.1128/mmbr.00026-21</pub-id><pub-id pub-id-type="pmid">35343760</pub-id><pub-id pub-id-type="pmcid">PMC9199417</pub-id></element-citation></ref><ref id="B218-vaccines-12-01345"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>McCauley</surname><given-names>J.</given-names></name></person-group><article-title>GISAID: Global initiative on sharing all influenza data-from vision to reality</article-title><source>Eurosurveillance</source><year>2017</year><volume>22</volume><fpage>30494</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2017.22.13.30494</pub-id><pub-id pub-id-type="pmid">28382917</pub-id><pub-id pub-id-type="pmcid">PMC5388101</pub-id></element-citation></ref><ref id="B219-vaccines-12-01345"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taubenberger</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Kash</surname><given-names>J.C.</given-names></name></person-group><article-title>Influenza virus evolution, host adaptation, and pandemic formation</article-title><source>Cell Host Microbe</source><year>2010</year><volume>7</volume><fpage>440</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2010.05.009</pub-id><pub-id pub-id-type="pmid">20542248</pub-id><pub-id pub-id-type="pmcid">PMC2892379</pub-id></element-citation></ref><ref id="B220-vaccines-12-01345"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zabidi</surname><given-names>N.Z.</given-names></name><name name-style="western"><surname>Liew</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Farouk</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Puniyamurti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>A.J.W.</given-names></name><name name-style="western"><surname>Wijesinghe</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Low</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>V.T.K.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>S.K.</given-names></name></person-group><article-title>Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>944</elocation-id><pub-id pub-id-type="doi">10.3390/v15040944</pub-id><pub-id pub-id-type="pmid">37112923</pub-id><pub-id pub-id-type="pmcid">PMC10145020</pub-id></element-citation></ref><ref id="B221-vaccines-12-01345"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>N.</given-names></name></person-group><article-title>Immune interference in effectiveness of influenza and COVID-19 vaccination</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1167214</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1167214</pub-id><pub-id pub-id-type="pmid">37153582</pub-id><pub-id pub-id-type="pmcid">PMC10154574</pub-id></element-citation></ref><ref id="B222-vaccines-12-01345"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillim-Ross</surname><given-names>L.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>Emerging respiratory viruses: Challenges and vaccine strategies</article-title><source>Clin. Microbiol. Rev.</source><year>2006</year><volume>19</volume><fpage>614</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1128/CMR.00005-06</pub-id><pub-id pub-id-type="pmid">17041137</pub-id><pub-id pub-id-type="pmcid">PMC1592697</pub-id></element-citation></ref><ref id="B223-vaccines-12-01345"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Valkenburg</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>L.L.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.F.</given-names></name></person-group><article-title>Broad-spectrum pan-genus and pan-family virus vaccines</article-title><source>Cell Host Microbe</source><year>2023</year><volume>31</volume><fpage>902</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2023.05.017</pub-id><pub-id pub-id-type="pmid">37321173</pub-id><pub-id pub-id-type="pmcid">PMC10265776</pub-id></element-citation></ref><ref id="B224-vaccines-12-01345"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amer</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Al-Zahrani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Imam</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ishteiwy</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Djelleb</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Abdullh</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Ballaj</surname><given-names>D.</given-names></name><name name-style="western"><surname>Amer</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>El-Sokkary</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Elshabrawy</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Exploring the reported adverse effects of COVID-19 vaccines among vaccinated Arab populations: A multi-national survey study</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><fpage>4785</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-54886-0</pub-id><pub-id pub-id-type="pmid">38413637</pub-id><pub-id pub-id-type="pmcid">PMC10899622</pub-id></element-citation></ref><ref id="B225-vaccines-12-01345"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aye</surname><given-names>P.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Edara</surname><given-names>V.V.</given-names></name><etal/></person-group><article-title>Adjuvanting a subunit COVID-19 vaccine to induce protective immunity</article-title><source>Nature</source><year>2021</year><volume>594</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03530-2</pub-id><pub-id pub-id-type="pmid">33873199</pub-id></element-citation></ref><ref id="B226-vaccines-12-01345"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kheirvari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tumban</surname><given-names>E.</given-names></name></person-group><article-title>Virus-like Particle Vaccines and Platforms for Vaccine Development</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1109</elocation-id><pub-id pub-id-type="doi">10.3390/v15051109</pub-id><pub-id pub-id-type="pmid">37243195</pub-id><pub-id pub-id-type="pmcid">PMC10223759</pub-id></element-citation></ref><ref id="B227-vaccines-12-01345"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klugar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mekhemar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Buchbender</surname><given-names>M.</given-names></name><name name-style="western"><surname>Howaldt</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Attia</surname><given-names>S.</given-names></name></person-group><article-title>Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers</article-title><source>Biology</source><year>2021</year><volume>10</volume><elocation-id>752</elocation-id><pub-id pub-id-type="doi">10.3390/biology10080752</pub-id><pub-id pub-id-type="pmid">34439984</pub-id><pub-id pub-id-type="pmcid">PMC8389568</pub-id></element-citation></ref><ref id="B228-vaccines-12-01345"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chentoufi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>BenMohamed</surname><given-names>L.</given-names></name></person-group><article-title>Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines</article-title><source>Future Virol.</source><year>2010</year><volume>5</volume><fpage>525</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.2217/fvl.10.44</pub-id><pub-id pub-id-type="pmid">21442030</pub-id><pub-id pub-id-type="pmcid">PMC3063648</pub-id></element-citation></ref><ref id="B229-vaccines-12-01345"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kokorelias</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Aghajafari</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ivers</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Martin-Misener</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aubrey-Bassler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Breton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Upshur</surname><given-names>R.E.G.</given-names></name><etal/></person-group><article-title>What are effective vaccine distribution approaches for equity-deserving and high-risk populations during COVID-19? Exploring best practices and recommendations in Canada: Protocol for a mixed-methods multiple case codesign study</article-title><source>BMJ Open</source><year>2023</year><volume>13</volume><fpage>e072238</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2023-072238</pub-id><pub-id pub-id-type="pmcid">PMC10632871</pub-id><pub-id pub-id-type="pmid">37940159</pub-id></element-citation></ref><ref id="B230-vaccines-12-01345"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Noroozi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ghanbari-Jahromi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>F.S.</given-names></name></person-group><article-title>Inequality in the distribution of Covid-19 vaccine: A systematic review</article-title><source>Int. J. Equity Health</source><year>2022</year><volume>21</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1186/s12939-022-01729-x</pub-id><pub-id pub-id-type="pmid">36042485</pub-id><pub-id pub-id-type="pmcid">PMC9425802</pub-id></element-citation></ref><ref id="B231-vaccines-12-01345"><label>231.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name name-style="western"><surname>Nicholson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Minicucci</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name></person-group><source>The Critical Public Health Value of Vaccines: Tackling Issues of Access and Hesitancy: Proceedings of a Workshop</source><comment>The National Academies Collection: Reports funded by National Institutes of Health</comment><publisher-name>National Academies Press</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2021</year><pub-id pub-id-type="pmid">34351726</pub-id></element-citation></ref><ref id="B232-vaccines-12-01345"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldenberg</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>B.</given-names></name><name name-style="western"><surname>von Seidlein</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheah</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>H.J.</given-names></name></person-group><article-title>Vaccine mandates and public trust do not have to be antagonistic</article-title><source>Nat. Hum. Behav.</source><year>2023</year><volume>7</volume><fpage>1605</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1038/s41562-023-01720-8</pub-id><pub-id pub-id-type="pmid">37752211</pub-id></element-citation></ref><ref id="B233-vaccines-12-01345"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Wiysonge</surname><given-names>C.</given-names></name></person-group><article-title>Social media and vaccine hesitancy</article-title><source>BMJ Glob. Health</source><year>2020</year><volume>5</volume><fpage>e004206</fpage><pub-id pub-id-type="doi">10.1136/bmjgh-2020-004206</pub-id><pub-id pub-id-type="pmcid">PMC7590343</pub-id><pub-id pub-id-type="pmid">33097547</pub-id></element-citation></ref><ref id="B234-vaccines-12-01345"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buschmann</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Alishetty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paige</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alameh</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>Nanomaterial Delivery Systems for mRNA Vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>65</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9010065</pub-id><pub-id pub-id-type="pmid">33478109</pub-id><pub-id pub-id-type="pmcid">PMC7836001</pub-id></element-citation></ref><ref id="B235-vaccines-12-01345"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chattopadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.J.</given-names></name></person-group><article-title>Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation</article-title><source>Nanotheranostics</source><year>2017</year><volume>1</volume><fpage>244</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.7150/ntno.19796</pub-id><pub-id pub-id-type="pmid">29071191</pub-id><pub-id pub-id-type="pmcid">PMC5646730</pub-id></element-citation></ref><ref id="B236-vaccines-12-01345"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="pmcid">PMC7164637</pub-id></element-citation></ref><ref id="B237-vaccines-12-01345"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Wappelhorst</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Rouse</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name></person-group><article-title>Elucidation of lipid nanoparticle surface structure in mRNA vaccines</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><fpage>16744</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-43898-x</pub-id><pub-id pub-id-type="pmid">37798336</pub-id><pub-id pub-id-type="pmcid">PMC10556076</pub-id></element-citation></ref><ref id="B238-vaccines-12-01345"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name></person-group><article-title>Vaccine adjuvants: Mechanisms and platforms</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>283</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01557-7</pub-id><pub-id pub-id-type="pmid">37468460</pub-id><pub-id pub-id-type="pmcid">PMC10356842</pub-id></element-citation></ref><ref id="B239-vaccines-12-01345"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fierens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Vanparijs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schuijs</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Van Steendam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Feiner Gracia</surname><given-names>N.</given-names></name><name name-style="western"><surname>De Rycke</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Beer</surname><given-names>T.</given-names></name><name name-style="western"><surname>De Beuckelaer</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Spontaneous Protein Adsorption on Graphene Oxide Nanosheets Allowing Efficient Intracellular Vaccine Protein Delivery</article-title><source>ACS Appl. Mater. Interfaces</source><year>2016</year><volume>8</volume><fpage>1147</fpage><lpage>1155</lpage><pub-id pub-id-type="doi">10.1021/acsami.5b08963</pub-id><pub-id pub-id-type="pmid">26694764</pub-id></element-citation></ref><ref id="B240-vaccines-12-01345"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vakili</surname><given-names>B.</given-names></name><name name-style="western"><surname>Karami-Darehnaranji</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mirzaei</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nezafat</surname><given-names>N.</given-names></name></person-group><article-title>Graphene oxide as novel vaccine adjuvant</article-title><source>Int. Immunopharmacol.</source><year>2023</year><volume>125</volume><fpage>111062</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2023.111062</pub-id><pub-id pub-id-type="pmid">37866317</pub-id></element-citation></ref><ref id="B241-vaccines-12-01345"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Arm</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eiser</surname><given-names>N.M.</given-names></name></person-group><article-title>Pulmonary epithelial permeability in bronchiectasis</article-title><source>Br. J. Dis. Chest</source><year>1988</year><volume>82</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/0007-0971(88)90008-3</pub-id><pub-id pub-id-type="pmid">3166919</pub-id></element-citation></ref><ref id="B242-vaccines-12-01345"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Oro</surname><given-names>U.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name></person-group><article-title>The scientific journey of a novel adjuvant (AS37) from bench to bedside</article-title><source>NPJ Vaccines</source><year>2024</year><volume>9</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-00810-6</pub-id><pub-id pub-id-type="pmid">38332005</pub-id><pub-id pub-id-type="pmcid">PMC10853242</pub-id></element-citation></ref><ref id="B243-vaccines-12-01345"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darling</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Harastani</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bricker</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Soudani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Seehra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Boon</surname><given-names>A.C.M.</given-names></name></person-group><article-title>Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters</article-title><source>Sci. Adv.</source><year>2024</year><volume>10</volume><fpage>eadp1290</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adp1290</pub-id><pub-id pub-id-type="pmid">39083604</pub-id><pub-id pub-id-type="pmcid">PMC11290484</pub-id></element-citation></ref><ref id="B244-vaccines-12-01345"><label>244.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>National Institutes of Health</collab></person-group><article-title>NIH-Sponsored Trial of Nasal COVID-19 Vaccine Opens</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nih.gov/news-events/news-releases/nih-sponsored-trial-nasal-covid-19-vaccine-opens" ext-link-type="uri">https://www.nih.gov/news-events/news-releases/nih-sponsored-trial-nasal-covid-19-vaccine-opens</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-27">(accessed on 27 September 2024)</date-in-citation></element-citation></ref><ref id="B245-vaccines-12-01345"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreier</surname><given-names>F.</given-names></name></person-group><article-title>Combined COVID-flu vaccines are coming: Moderna jab clears major test</article-title><source>Nature</source><year>2024</year><comment><italic toggle="yes">ahead of print</italic></comment><pub-id pub-id-type="doi">10.1038/d41586-024-02121-1</pub-id><pub-id pub-id-type="pmid">38942974</pub-id></element-citation></ref><ref id="B246-vaccines-12-01345"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Germain</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Van Allen</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Trynka</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Grun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kiemen</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pugh Bernard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>G.P.</given-names></name></person-group><article-title>AI and immunology</article-title><source>Immunity</source><year>2024</year><volume>57</volume><fpage>1177</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.05.016</pub-id><pub-id pub-id-type="pmid">38865960</pub-id></element-citation></ref><ref id="B247-vaccines-12-01345"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabaan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bakhrebah</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alotaibi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Natto</surname><given-names>Z.S.</given-names></name><name name-style="western"><surname>Alkhaibari</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Alawad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alshammari</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Alwarthan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alhajri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Almogbel</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Unleashing the power of artificial intelligence for diagnosing and treating infectious diseases: A comprehensive review</article-title><source>J. Infect. Public Health</source><year>2023</year><volume>16</volume><fpage>1837</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2023.08.021</pub-id><pub-id pub-id-type="pmid">37769584</pub-id></element-citation></ref><ref id="B248-vaccines-12-01345"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farzan</surname><given-names>R.</given-names></name></person-group><article-title>Artificial intelligence in Immuno-genetics</article-title><source>Bioinformation</source><year>2024</year><volume>20</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.6026/973206300200029</pub-id><pub-id pub-id-type="pmid">38352901</pub-id><pub-id pub-id-type="pmcid">PMC10859949</pub-id></element-citation></ref><ref id="B249-vaccines-12-01345"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>D.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Hibberd</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Campino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>T.G.</given-names></name></person-group><article-title>An integrated in silico immuno-genetic analytical platform provides insights into COVID-19 serological and vaccine targets</article-title><source>Genome Med.</source><year>2021</year><volume>13</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s13073-020-00822-6</pub-id><pub-id pub-id-type="pmid">33413610</pub-id><pub-id pub-id-type="pmcid">PMC7790334</pub-id></element-citation></ref><ref id="B250-vaccines-12-01345"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bricken</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Viard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carrington</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gifford</surname><given-names>D.K.</given-names></name></person-group><article-title>Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions</article-title><source>Cell Syst.</source><year>2020</year><volume>11</volume><fpage>131</fpage><lpage>144.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2020.06.009</pub-id><pub-id pub-id-type="pmid">32721383</pub-id><pub-id pub-id-type="pmcid">PMC7384425</pub-id></element-citation></ref><ref id="B251-vaccines-12-01345"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gifford</surname><given-names>D.K.</given-names></name></person-group><article-title>Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets</article-title><source>Cell Syst.</source><year>2021</year><volume>12</volume><fpage>102</fpage><lpage>107.e4</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2020.11.010</pub-id><pub-id pub-id-type="pmid">33321075</pub-id><pub-id pub-id-type="pmcid">PMC7691134</pub-id></element-citation></ref><ref id="B252-vaccines-12-01345"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>Y.</given-names></name></person-group><article-title>Improving random forest predictions in small datasets from two-phase sampling designs</article-title><source>BMC Med. Inform. Decis. Mak.</source><year>2021</year><volume>21</volume><fpage>322</fpage><pub-id pub-id-type="doi">10.1186/s12911-021-01688-3</pub-id><pub-id pub-id-type="pmid">34809631</pub-id><pub-id pub-id-type="pmcid">PMC8607560</pub-id></element-citation></ref><ref id="B253-vaccines-12-01345"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name></person-group><article-title>AI-based spectroscopic monitoring of real-time interactions between SARS-CoV-2 and human ACE2</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2025879118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2025879118</pub-id><pub-id pub-id-type="pmid">34185681</pub-id><pub-id pub-id-type="pmcid">PMC8256048</pub-id></element-citation></ref><ref id="B254-vaccines-12-01345"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tataje-Lavanda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Malaga</surname><given-names>E.</given-names></name><name name-style="western"><surname>Verastegui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mayta Huatuco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Icochea</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fernandez-Diaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zimic</surname><given-names>M.</given-names></name></person-group><article-title>Identification and evaluation in-vitro of conserved peptides with high affinity to MHC-I as potential protective epitopes for Newcastle disease virus vaccines</article-title><source>BMC Vet. Res.</source><year>2023</year><volume>19</volume><fpage>196</fpage><pub-id pub-id-type="doi">10.1186/s12917-023-03726-w</pub-id><pub-id pub-id-type="pmid">37805566</pub-id><pub-id pub-id-type="pmcid">PMC10559636</pub-id></element-citation></ref><ref id="B255-vaccines-12-01345"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Dutt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kelvin</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name></person-group><article-title>PoxiPred: An Artificial-Intelligence-Based Method for the Prediction of Potential Antigens and Epitopes to Accelerate Vaccine Development Efforts against Poxviruses</article-title><source>Biology</source><year>2024</year><volume>13</volume><elocation-id>125</elocation-id><pub-id pub-id-type="doi">10.3390/biology13020125</pub-id><pub-id pub-id-type="pmid">38392343</pub-id><pub-id pub-id-type="pmcid">PMC10887159</pub-id></element-citation></ref><ref id="B256-vaccines-12-01345"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Persson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Restori</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Emdrup</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Schussek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klausen</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Nicol</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Katkere</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rono</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kirimanjeswara</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>A.B.</given-names></name></person-group><article-title>DNA immunization with in silico predicted T-cell epitopes protects against lethal SARS-CoV-2 infection in K18-hACE2 mice</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1166546</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1166546</pub-id><pub-id pub-id-type="pmid">37114047</pub-id><pub-id pub-id-type="pmcid">PMC10126292</pub-id></element-citation></ref><ref id="B257-vaccines-12-01345"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rowntree</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thuesen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Littler</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Raji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.H.O.</given-names></name><etal/></person-group><article-title>Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>7547</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-51959-6</pub-id><pub-id pub-id-type="pmid">39214998</pub-id><pub-id pub-id-type="pmcid">PMC11364864</pub-id></element-citation></ref><ref id="B258-vaccines-12-01345"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keusch</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Amuasi</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Daszak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Eckerle</surname><given-names>I.</given-names></name><name name-style="western"><surname>Field</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koopmans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Das Neves</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2022</year><volume>119</volume><fpage>e2202871119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2202871119</pub-id><pub-id pub-id-type="pmid">36215506</pub-id><pub-id pub-id-type="pmcid">PMC9586299</pub-id></element-citation></ref><ref id="B259-vaccines-12-01345"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meeusen</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pastoret</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Jungersen</surname><given-names>G.</given-names></name></person-group><article-title>Current status of veterinary vaccines</article-title><source>Clin. Microbiol. Rev.</source><year>2007</year><volume>20</volume><fpage>489</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1128/CMR.00005-07</pub-id><pub-id pub-id-type="pmid">17630337</pub-id><pub-id pub-id-type="pmcid">PMC1932753</pub-id></element-citation></ref><ref id="B260-vaccines-12-01345"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carpenter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Waltenburg</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kile</surname><given-names>J.</given-names></name><name name-style="western"><surname>Killerby</surname><given-names>M.</given-names></name><name name-style="western"><surname>Knust</surname><given-names>B.</given-names></name><name name-style="western"><surname>Negron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Behravesh</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Vaccine Preventable Zoonotic Diseases: Challenges and Opportunities for Public Health Progress</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>993</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10070993</pub-id><pub-id pub-id-type="pmid">35891157</pub-id><pub-id pub-id-type="pmcid">PMC9319643</pub-id></element-citation></ref><ref id="B261-vaccines-12-01345"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Msemburi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Gaythorpe</surname><given-names>K.A.M.</given-names></name><name name-style="western"><surname>Lambach</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lindstrand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hutubessy</surname><given-names>R.</given-names></name></person-group><article-title>Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><issue>(Suppl. 1)</issue><fpage>S28</fpage><lpage>S37</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.07.033</pub-id><pub-id pub-id-type="pmid">37537094</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01345-f001" orientation="portrait"><label>Figure 1</label><caption><p>Schematic representation of traditional vaccines. (<bold>A</bold>) Inactivated vaccines are prepared by inactivating viruses with chemicals, heat-treatment, or UV radiation. (<bold>B</bold>) Live-attenuated vaccines are prepared using a weakened form of the virus, which is attenuated through methods such as non-human cell culturing, genetic modification, or repeated passaging. In contrast, inactivated vaccines contain killed or inactivated forms of the virus. After administration, inactivated vaccine antigens are taken up by antigen-presenting cells (APCs) via endocytosis. Inside APCs, these exogenous antigens are processed and displayed on MHC Class II molecules. The antigen&#8211;MHC-II complexes are presented on the surface of APCs, where they are recognized by T cell receptors (TCRs) on CD4+ T helper cells. This recognition triggers the activation of CD4+ T cells, which play a critical role in humoral immunity by assisting B cells in antibody production. Exogenous antigens can also be cross-presented to MHC-I. In comparison, live-attenuated vaccines infect host cells, including APCs and other host cells, but with limited replication, mimicking a natural infection. After infection, the antigens derived from the pathogens are processed internally by APCs, broken into smaller fragments, and presented on MHC Class I molecules. These MHC-I-antigen complexes are recognized by CD8+ cytotoxic T cells. This interaction activates CD8+ T cells, leading to their proliferation and enabling them to target and destroy infected host cells directly. Endogenous antigens can also be degraded and accessed to MHC-II molecules via autophagy and non-autophagic pathways [<xref rid="B70-vaccines-12-01345" ref-type="bibr">70</xref>]. * Note: Live attenuated vaccines are capable of infecting other host cells, mimicking natural infection processes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-12-01345-g001.jpg"/></fig><fig position="float" id="vaccines-12-01345-f002" orientation="portrait"><label>Figure 2</label><caption><p>Schematic representation of modern vaccines. (<bold>A</bold>) Viral vector vaccines, which carry antigen-encoding DNA, attach to the host cell, undergo endocytosis, and release genetic material upon escaping endosomes. (<bold>B</bold>) Similarly, bacterial vector vaccines release their DNA cargoes into the host cell following attachment and endocytosis. (<bold>C</bold>) DNA vaccines encapsulated in lipid nanoparticles (LNPs) enter the cell and release the DNA into the cytoplasm. The DNA from viral vector, bacterial vector, or LNP-DNA vaccines subsequently enters the nucleus, wherein it is transcribed to mRNA. (<bold>D</bold>) mRNA vaccines directly deliver mRNA into the cytoplasm via membrane fusion, wherein ribosomes translate this to yield antigenic proteins. (<bold>E</bold>) Subunit vaccines and (<bold>F</bold>) phage-like particle vaccines deliver pre-formed antigenic proteins to host cells. (<bold>G</bold>) LNP vaccines containing antigenic proteins are taken up by cells. In all platforms, the produced antigenic proteins are processed by the endoplasmic reticulum (ER) and proteasomes to generate peptides, which bind to MHC-I or MHC-II molecules. These MHC&#8211;peptide complexes are presented on the cell surface, activating CD8+ and CD4+ T cells, thus leading to a virus-specific immune response.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-12-01345-g002.jpg"/></fig><table-wrap position="float" id="vaccines-12-01345-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-01345-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary table for selected RNA virus.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Peculiarities</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Challenges</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Causes COVID-19 with symptoms ranging from mild to severe</p></list-item><list-item><p>High transmissibility</p></list-item><list-item><p>RNA virus with rapid mutation (notably in spike protein)</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Several vaccines developed:<break/>mRNA (Pfizer, Moderna),<break/>viral vector (AstraZeneca, J&amp;J), inactivated (Sinovac)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Variants reducing vaccine efficacy</p></list-item><list-item><p>Need for booster shots</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Seasonal epidemics; segmented RNA genome enabling antigenic drift and shift</p></list-item><list-item><p>Broad host range</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Annual vaccines available: inactivated, live-attenuated, recombinant types</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Mismatch in strain prediction</p></list-item><list-item><p>Antigenic variation reduces long-term efficacy</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dengue</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Four distinct serotypes (DENV-1 to DENV-4); reinfection with a different serotype can cause severe disease</p></list-item><list-item><p>Spread by <italic toggle="yes">Aedes</italic> mosquitoes</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live-attenuated (Dengvaxia) approved for seropositive individuals in some regions,<break/>Tetravalent chimeric LAV (Qdenga)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Risk of antibody-dependent enhancement (ADE) in seronegative individuals</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zika</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Linked to congenital Zika syndrome (microcephaly in infants)</p></list-item><list-item><p>Transmitted by <italic toggle="yes">Aedes</italic> mosquitoes and sexually</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No licensed vaccines available</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Balancing immune response to avoid potential ADE (shared risk with Dengue)</p></list-item><list-item><p>Difficult to conduct clinical trails</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enterovirus (EV-A71)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Includes polioviruses and EV-A71, causing polio, hand-foot-and-mouth disease, and encephalitis</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral (OPV) and inactivated (IPV) vaccines effective for polio<break/>EV-A71 vaccines available in limited regions</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Lack of globally available EVA71 vaccines</p></list-item><list-item><p>Regional disparities in access to existing vaccines</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nipah</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Zoonotic virus with high fatality rate</p></list-item><list-item><p>Spread by fruit bats and through human-to-human transmission</p></list-item><list-item><p>Neurological symptoms common</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No licensed vaccines available (both viral vector vaccine and mRNA vaccine are undergoing clinical trials)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Sporadic outbreaks hinder largescale trials</p></list-item><list-item><p>High-risk, small population targets complicate development</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn><p>This table provides an overview of selected RNA viruses, highlighting their distinctive features and challenges in vaccine development. For each virus, the table includes a brief description of the vaccines currently available on the market, as well as specific obstacles encountered during vaccine development.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01345-t002" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-01345-t002_Table 2</object-id><label>Table 2</label><caption><p>Summarizes the main features, similarities, and differences in the approaches to vaccination for different classes of RNA viruses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Platform</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Key Features/<break/>Approaches</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Challenges</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Similarities</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Differences</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SARS-CoV-2 (COVID-19)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA (Pfizer Inc. New York, NY, USA/BioNTech SE. Mainz, Germany, Moderna Inc. Cambridge, MA, USA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA vaccines use LNPs to deliver spike protein encoding.</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Rapid development and high efficacy.<break/>Need for ultra-cold storage for some vaccines</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Induce strong immune responses.</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Genetic material (mRNA, DNA, protein directly).</p></list-item><list-item><p>Delivery mechanism (LNP, viral-vector, LNP).</p></list-item><list-item><p>Antigen design.</p></list-item><list-item><p>Rare side effects (myocarditis, VITT).</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral Vector (AstraZeneca plc Cambridge, UK, J&amp;J Inc. New Brunswick, NJ, USA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral vector vaccines use adenoviruses as vectors.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-antigen LNP Vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome (stimulator of INF gene, spike protein, nucleocapsid protein), intranasal.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Manufacturing and scale-up, coldchain requirements.</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Annual updates to match circulating strains.</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">High mutation rates requiring frequent updates; development of broad-spectrum vaccines, cold chain requirements.</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Both require frequent updates due to mutation rates, scalability.</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Antigen (strain-specific antigen, targeting three strains, broadly conserved antigens).</p></list-item><list-item><p>Protection (strain-specific, strain2-specific, broad protection).</p></list-item><list-item><p>Antigen coverage.</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant subunits Vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Seasonal (trivalent).</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA-based Universal Vaccines</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Development of universal vaccines targeting multiple influenza strains.</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dengue</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live-attenuated (Dengvaxia by Sanofi, Paris, France)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mimics natural infection.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rick of serotype imbalance, antibody-dependent enhancement.</td><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Risk of antibody-dependent enhancement (ADE); multiple serotypes complicate vaccine design.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Requires prior infection for safe vaccination</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein Subunit</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein delivered with adjuvants.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primarily humoral immunity, durability.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primarily humoral immune response</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNP deliver mRNA encoding dengue antigens.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA design against different serotypes.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safer, fast development</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenovector</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenovirus carrying dengue antigen infects cells.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-existing immunity.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Balanced humoral and cellular immunity</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chimeric Live-attenuated (Qdenga by Takeda Pharmaceuticals, Osaka, Japan)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live-attenuated virus using a DENV-2 backbone.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk of replication, production complexity.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong humoral and cellular immunity, DENV-2 backbone</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Zika</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA encoding Zika virus antigens.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ultra-cold storage limiting distribution, high cost.</td><td rowspan="7" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Most platforms focus on envelop protein or prM protein, avoidance of components that could lead to antibody-dependent enhancement (ADE), vaccines are designed for pregnant women who are high-risk of Zika infection.</td><td rowspan="7" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Focus on pregnant women and long-lasting immunity; Zika cases are rare, limiting trial opportunities.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA plasmids encoding Zika antigens.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limit immunogenicity.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral Vector</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral vector to deliver Zika antigen.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-existing immunity to the vector.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus-like Particle</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-assembled viral proteins mimicking Zika infection.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Production complexity, adjuvant requirement.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated Virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-replicative Zika virus.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Requires multiple doses/boosters.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide-based</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Short synthetic peptides representing Zika epitopes.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited T cell activation.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant Protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Envelope or prM for use as antigen.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Requires potent adjuvants/high production cost.</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Enterovirus A71 (EV-A71)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated vaccine (EnVAX-A71 by Sinovac Biotech, Beijing, China)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uses chemically or heat-inactivated whole enterovirus particles.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Requires large-scale virus cultivation, limited cellular immunity.</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Non-replicative design, both require adjuvant.</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Focus on infant and young children vaccination; different virus strain considerations (C4 vs. B4 genogroups).</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLP Production</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Composed of self-assembled structural proteins mimicking the virus without genetic material and adjuvant improvements.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">May lack certain non-structural viral proteins, limiting T-cell responses.</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Nipah Virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant Vesicular Stomatitis Virus (rVSV)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rVSV is engineered to express Nipah virus antigens (e.g., glycoprotein G) on its surface.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Potential side effects due to replication in certain hosts, slow development.</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Nipah virus-targeting antigens, glycoprotein (G), or fusion protein (F), non-replicative in humans, scalable, single-antigen design which reduces risk of ADE.</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Dosing requirements, safety considerations, speed of development, viral vector might have pre-existing immunity.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA (Moderna)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delivers mRNA encoding Nipah virus glycoproteins.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No approved vaccines; high mortality rate, requiring urgent vaccine development.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral Vector (ChAdOx1 NiVB by University of Oxford, Oxford, UK.)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1 vector encoding Nipah virus antigens.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-existing immunity.</td></tr></tbody></table><table-wrap-foot><fn><p>Summarization is based on the case studies presented in <xref rid="sec4-vaccines-12-01345" ref-type="sec">Section 4</xref>. This comparison will provide insights into the strategies employed for each virus, the technologies involved, and the key challenges associated with developing effective and safe vaccines.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>